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Exosomes originate as the internal vesicles of multivesicular bodies (MVBs) in cells.  
These small vesicles (40-100 nm) have been shown to be secreted by most cell types 
throughout the body.  In the kidney, urinary exosomes are released to the urine by fusion 
of the outer membrane of the MVBs with the apical plasma membrane of renal tubular 
epithelia.  Exosomes contain apical membrane and cytosolic proteins and can be isolated 
using differential centrifugation.  The analysis of urinary exosomes provides a non-
invasive means of acquiring information about the physiological or pathophysiological 
state of renal cells.  The overall objective of this research was to develop methods and 
knowledge infrastructure for urinary proteomics.  We proposed to conduct a proteomic 
analysis of human urinary exosomes.  The first objective was to profile the proteome of 
human urinary exosomes using liquid chromatography-tandem spectrometry (LC-
MS/MS) and specialized software for identification of peptide sequences from 
fragmentation spectra.  We unambiguously identified 1132 proteins.  In addition, the 
phosphoproteome of human urinary exosomes was profiled using the neutral loss 
scanning acquisition mode of LC-MS/MS.  The phosphoproteomic profiling identified 19 
phosphorylation sites corresponding to 14 phosphoproteins.  The second objective was to 
 
 
analyze urinary exosomes samples isolated from patients with genetic mutations.  
Polyclonal antibodies were generated to recognize epitopes on the gene products of these 
genetic mutations, NKCC2 and MRP4.  The potential usefulness of urinary exosome 
analysis was demonstrated using the well-defined renal tubulopathy, Bartter syndrome 
type I and using the single nucleotide polymorphism in the ABCC4 gene.  The third 
objective was to study the normal variability between proteomes of female and male 
urinary exosomes, and to implement a normalization method to analyze urinary exosome 
samples.  Only 19 proteins had a 2-fold change representing 4.9% of the total number of 
proteins identified which shows that there is high concordance between proteomes of 
urinary exosomes isolated from males and females.  The normalization method, timed 
urine collection did not correlate as expected with the intensity signal of MVB markers, 
TSG101 and Alix.  This research shows that the proteomic analysis of human urinary 
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1 Introduction  
The sequencing of the human genome had a great impact in biomedical research 
because access was gained to large amounts of data to expand the analysis of genes, gene 
products and their function [1].  Proteins are the products of genes and are composed of a 
sequence of amino acids.  Proteins are the functional components of eukaryotic cells.   
The majority of human protein sequences are known and this information can be used for 
proteomic studies, i.e. the “systematic analysis of proteins for their identity, quantity and 
function” [2].  As such, the development of proteomic technology in renal physiology 
and pathophysiology has the potential to greatly impact clinical medicine [3].  In order to 
implement proteomic technology in clinical medicine, it is important to develop: methods 
infrastructure, cost-effective, and non-invasive techniques for disease biomarker 
identification and quantification in body fluids such as urine that will allow early disease 
detection.   
 




The kidneys are organs located in the posterior part of the abdomen on each side 
of the vertebral column [4].  These organs maintain the water and sodium balance of the 
human body [5].  Each kidney surrounded by a fibrous capsule has a renal artery and 
renal vein [4].  As shown in Figure 1.1, two major regions can be identified in the 
bisected kidney, the cortex and the medulla.  The medulla can further be divided into the 
outer and the inner medulla.  The outer medulla divides into an inner and an outer stripe. 
 
Figure 1.2 Diagram of the nephron [10]. 
The functional unit of the kidney is the nephron and there are approximately 1 
million nephrons in each human kidney. The nephron shown in Figure 1.2 is composed of 
the glomerulus, proximal tubule, Loop of Henle, the distal convoluted tubule, and the 




cortex, the outer medulla and the inner medulla as shown in the figure.  The proximal 
tubule is further divided into the proximal convoluted tubule (PCT) and the proximal 
straight tubule (PST).  The loop of Henle is composed of the thin limb (TL) and thick 
ascending limb (TAL).  There are two regions of the collecting duct, the outer medullary 
collecting duct (OMCD) and the inner medullar collecting duct (IMCD) [4].  Kidney 
diseases result from damage to the nephrons and/or by genetics.  Some of these renal 
disease processes are glomerular diseases such as nephritic syndrome and renal tubular 
disorders such as polycystic kidney disease, Gitelman syndrome, Bartter syndrome, 
nephrogenic diabetes insipidus, and familial magnesium wasting syndrome [6]. 
In developing non-invasive approaches to identify disease processes internal to 
the kidney, it is ideal to use an easily collected biological sample, such as urine.   The 
urine proteome is very complex and therefore it is important to focus on an isolated sub-
proteome.  This sub-proteome is found in isolated urinary exosomes, which constitutes 
3% of the total excreted in the urine [7, 8].  Urinary exosomes arise as internal vesicles of 
multivesicular bodies (MVBs) that are delivered to the urinary space by fusion of the 
outer membrane of MVBs with the apical plasma membrane of renal tubule epithelial 
cells [6].  Exosomes derive from every epithelial cell type facing the urinary space, 
glomerular podocytes, and cells lining the renal pelvis, ureters and bladder.  
The overall objective of this research is to develop methods and knowledge 
infrastructure for urinary proteomics.  The central focus of the proposed work is on 
urinary exosome analysis by protein mass spectrometry.  The analysis of urinary 




biomarker studies consist of three phases: discovery, validation and implementation [9].  
The specific objectives proposed for this research are: 
1. Large-scale proteomic and phosphoprotoemic analysis of human urinary 
exosomes 
2. Application of human urinary exosome analysis using polyclonal antibodies 







2.1 Human urinary exosomes 
2.1.1 Introduction 
Exosomes originate as the internal vesicles of multivesicular bodies (MVBs) in 
cells (Figure 2.1).  They were first described as products of circulating blood cells [11], 
such as erythrocytes and lymphocytes, and have been shown to be secreted by most cell 
types throughout the body.  These include B cells, T cells, dendritic cells, reticulocytes, 
mastocytes, enterocytes and platelets [9].  In the kidney, exosomes are released to the 
urine by fusion of the outer membrane of the MVBs with the apical plasma membrane 
(Figure 2.2). 
 
Figure 2.1 Electron micrograph (EM) of human urinary exosomes.  
Exosomes were isolated from normal human urine and attached to EM 





Figure 2.2 Diagram of membrane trafficking process [31].  The 
mRNA of a transporter (dots) is translated in the rough endoplasmic 
reticulum (ER) and resulting protein is processed in the Golgi apparatus.  
Vesicles budding from the cis-Golgi are believed to be delivered to the 
apical plasma membrane via the endosomal system, by vesicle-mediated 
translocation to recycling endosomes (RE).  The protein in the apical 
plasma membrane undergoes regulated endocytosis via clathrin-coated 
vesicles, which deliver it to early endosomes and subsequently to late 
endosomes (LE) or multivesicular bodies (MBV).  The transporter protein 
accumulates inside MVBs as a component of the internal MVB vesicles.  
The MVBs can become lysosomes or the membrane of MVBs can fuse 
with the apical plasma membrane delivering the internal vesicles to the 
urine. 
 
Multivesicular bodies (MVBs) or late endosomes are part of the endocytic pathway.  
The endocytic pathway works through the process known as endocytosis.  Endocytosis is 
a cellular process by which eukaryotic cells internalize fluid, molecules and particles 
through an internal membrane system [12].  These molecules include proteins, 
carbohydrates and lipids; they are delivered to the cell exterior via the biosynthetic-




The endocytic pathway is composed of endocytic vesicles, early endosomes, late 
endosomes (MVBs) and lysosomes [13].  Molecules are endocytosed into the cell by the 
invagination of chlathrin-coated pits on the plasma membrane.  These chlathrin-coated 
pits pinch off into chlathrin-coated vesicles inside the cell.  The chlathrin coat is shed and 
the endocytic vesicles fuse with early endosomes.  The early endosomes mature into 
multivesicular bodies by accumulating internal vesicles [14, 15].  These internal vesicles 
contain protein and lipids [13].  The multivesicular bodies have three distinct fates: (1) to 
target protein and lipids for degradation by fusing with lysosomes, (2) to serve as 
temporal storage compartments and (3) to release their internal vesicles as exosomes 
through exocytosis [13].   
2.1.2 Urinary exosome biogenesis 
Urinary exosomes are delivered to the urine from all renal epithelial cell types.  These 
small extracellular vesicles have a size of 40 to 100nm and contain membrane and 
cytosolic proteins.  The biogenesis of urinary exosomes is coupled to the formation of 
multivesicular bodies.  The biogenesis and sorting of cargo protein of multivesicular 
body (MVB) depends on the endosomal sorting complexes required for transport 
(ESCRT) [15, 16, 17].  The mammalian ESCRT machinery is composed of four 
complexes which are ESCRT-0, ESCRT-I, ESCRT-II, and ESCRT-III [16, 17].   
The biogenesis of exosomes starts when plasma membrane proteins are 
monoubiquitinated to be sorted as cargo by the ESCRT machinery [17].  Ubiquitin is a 
protein that can be covalently conjugated to cargo proteins by their lysine residues [16, 
17].  Initial recognition of monoubiquitinated proteins occurs by ESCRT-0 which is 




signal transducing adaptor molecules (STAM1 and STAM2) [16, 17].  The cargo is 
transferred to ESCRT-I, composed of TSG101, VPS28, VPS37A, VPS37B, VPS37C and 
VPS37D [16].  The transfer occurs through the binding of the proline-serine-alanine-
proline (PSAP) motif of HRS by TSG101 [17].  The cargo is transferred to the ESCRT-II 
complex composed of VPS22, VPS25 and VPS36.  The TSG101 protein of the ESCRT-I 
complex is bound by the VPS36 protein of the ESCRT-II complex.  There is evidence 
that the ESCRT-II complex can be bypassed in mammalian cells if the ESCRT-accessory 
protein, ALIX, connects ESCRT-I and ESCRT-III [16, 17].  Once the cargo reaches the 
ESCRT-III complex it is deubiquitinated, sorted and concentrated in maturing 
endosomes.  The ESCRT-III complex is composed of seven chromatin modifying 
proteins (CHMP 1-7) [17].  The cargo is dissociated from the ESCRT complex by the 
AAA+ATPase proteins and accessory proteins.  The VPS4 protein, an AAA+ATPase, 
disassembles the chlathrin coats of the cargo and initiates the formation of the internal 
vesicles of MVBs [16].  Ubiquitination of a protein is not necessary for sorting into the 
formation of MVBs [13] as shown by the presence of tetraspanins (CD9, CD63, CD81 
and CD82) in exosomes.  Tetraspanins inwardly bud into MVBs because they are 
localized in lipid rafts [13]. 
2.1.3 Summary 
 Urinary exosomes are the internal vesicles of multivesicular bodies (MVBs) and 
are released into the urine from renal epithelial cells, including glomerular podocytes, 
renal tubule cells and cells lining the urinary drainage system.  Biogenesis of 
multivesicular bodies (MVBs) is important in the generation of urinary exosomes.  






Proteomics is the large-scale study of proteins and it can further characterize protein 
function, protein interactions and protein sub-cellular distribution [18].  There are two 
aspects of proteomics to be considered in developing new methods and knowledge 
infrastructure for urinary exosome proteomics.  As MacBeath points out these aspects are 
‘discovery-oriented proteomics’ and ‘systems-oriented proteomics’.  Discovery-oriented 
proteomics is the “unbiased approach” to discovering unknown proteins in a biological 
sample.  Systems-oriented proteomics is conducted by analyzing a defined subset of 
proteins in a biological sample [19].  
The discovery-oriented proteomics approach is fundamental to identify potential 
biomarkers in the proteome of human urinary exosomes.  Mass spectrometry (MS) is an 
analytical technique that measures the masses of molecules and atoms [20].  A mass 
spectrometer measures the mass-to-charge ratio of charged molecular ions.   
2.2.2 Tandem Mass Spectrometry 
Mass spectrometry analysis starts by converting molecules into gas-phase 
molecular ions [19].  A mass analyzer separates the gas-phase molecular ions according 
to the mass-to-charge ratios (m/z).  A detector measures the ion current of mass-separated 
molecular ions.  And a data system records these measurements and displays them as a 





The development of electrospray ionization (ESI) was important because it 
opened mass spectrometry to the “identification of proteins and peptides [21].”  
Electrospray ionization is a technique for the generation of gas-phase ions from 
electrically charged liquid droplets [22, 23]. This technique is particularly useful with 
complex molecules because it features the formation of a series of multiply charge ions.  
In order to analyze complex samples, these should be separated by chromatography 
before ionization.  The separation method best suited for complex samples is reverse-
phase high-performance liquid chromatography (RP-HPLC) [24].  Separation with RP-
HPLC depends on the hydrophobic interaction between the nonpolar matrix of the 
stationary phase and the hydrophobic group of the sample [24].  The coupling of the 
separation method, ionization method and mass spectrometry is known as LC-MS.   
The LC-MS approach is coupled to another mass spectrometer in the LC-MS/MS 
approach for protein identification.  The LC-MS/MS approach, is known as tandem mass 
spectrometry and provides “enhanced sensitivity, selectivity and speed of analysis” of 
complex mixtures [25].  Tandem mass spectrometry involves mass selection of parent 
peptide ions (MS1), fragmentation of parent peptides and mass analysis of these peptides 
(MS2).  Fragmentation of peptide ions is accomplished by collision-induced dissociation 
(CID). 
Proteomic analysis is accomplished through the digestion of complex protein 
mixtures using trypsin, an enzyme that cuts peptide bonds following arginine or lysine.  
These tryptic peptides are separated using RP-HPLC and then are delivered to the 
electrospray for ionization.  The peptide ions are delivered to the first mass spectrometer 




CID that yields complementary b- and y- ions.  The m/z of complementary ions are 
analyzed in the second mass spectrometer (MS2) and recorded.  The m/z data from MS1 
and MS2 constitute the experimental spectra and peptides are identified by comparison of 
experimental spectra to a database of theoretical spectra.  Various approaches have been 
developed to analyze large-scale data generated by tandem mass spectrometry studies 
such as SEQUEST [26, 27], target-decoy [28] and InsPecT [29].   
2.2.3 Analysis of tandem mass spectrometry data 
SEQUEST is a program based on a “mechanistic prediction” of peptide 
fragmentation that is quantified to “determine the quality of the match” between the 
theoretical and the experimental spectrum [27].  The SEQUEST program accomplishes 
this in four steps: (1) reduction of data, (2) identification of amino acid sequences in 
peptide database to match experimental mass spectral data, (3) comparison of predicted 
fragment ions from the peptide database to the experimental mass spectral data and (4) 
correlation-based analysis of predicted fragment ions from peptide database and 
experimental mass spectral data [26].   
The target-decoy database search strategy provides an estimate of false-discovery 
rate (FDR) for large data sets.  A composite database is created with the normal (target) 
and reversed (decoy) peptide sequences of the theoretical spectra.  The experimental 
spectra is compared with the composite database and “by definition, 100% of correctly 
assigned spectra should come from the target database” and “incorrectly assigned spectra 
should have an equal chance of coming from either the target or decoy database [28]”. 
The entire data set is filtered by the SEQUEST parameters and the false-discovery rate 




InsPecT uses de novo sequencing to reconstruct peptides from experimental mass 
spectra and theoretical peptide database search [29].  The program generates sequence 
information in the form of tag filters from the experimental data.  These tag filters are 
used to search the peptide database and identify peptide sequences that match the 
experimental data.  The identifications are scored by calculating the P-value by 
comparing match quality score to the distribution of quality scores for incorrect matches 
[29]. 
2.2.4 Summary 
Proteomics is the large-scale study of proteins.  A mass spectrometer measures 
the mass-to-charge ratio (m/z) of molecular ions.  Tandem mass spectrometry coupled to 
liquid chromatography is the technique widely used to identify proteins in complex 
samples.  There are many programs used to analyze large data sets generated by tandem 
mass spectrometry and these use two well-known approaches:  theoretical database 
comparison and de novo sequencing.   
2.3 Development of urinary clinical proteomics 
Clinical proteomics connects scientific and clinical expertise for the purpose of 
understanding and treating disease [30].  The proteomic analysis of urinary exosomes has 
the potential of being useful in clinical proteomics.  Clinical proteomics will require the 
completion of three stages to impact the early diagnosis of disease, the classification of 
disease with regard to therapeutic responses, in assessment of prognosis and in 
monitoring response to therapy.  These three stages are: (1) discovery of potential 
biomarkers, (2) validation of potential biomarkers and (3) implementation of biomarker 




The discovery of potential biomarkers is a hypothesis generation step.  It should 
be done on samples from a relatively small number of extremely well-characterized 
patients and appropriately chosen control subjects.  The tandem mass spectrometry 
approach can be used to profile the entire proteome of the isolated urinary exosomes from 
these patients.  Quantitative mass spectrometry approaches should be implemented to 
compare patients with controls and determine combination of potential protein 
biomarkers.  The protein biomarkers discovered in the first stage can be tested in the 
validation stage to determine their specificity and sensitivity.  Validation of protein 
biomarkers should be done in large clinical data sets with proper adjustment for risk 
factor distribution [31].  The possible assays used for validation are mass spectrometry, 
and antibody-based quantification [9].  These assays used for validation should also be 
used for the final stage, implementation. Implementation of biomarkers assays will be 




3 Large Scale Proteomic Analysis of Human Urinary Exosomes * 
3.1 Introduction 
Urinary exosomes are small extracellular vesicles (<100 nm in diameter) that 
originate from the internal vesicles of multivesicular bodies (MVB) in renal epithelial 
cells, including glomerular podocytes, renal tubule cells, and the cells lining the urinary 
drainage system [6].  Exosomes are released into the urine when the outer membrane of 
the MVB fuses with the apical plasma membrane of the epithelial cell. Exosomes can be 
recovered from the urine by differential centrifugation as a low-density membrane 
fraction.  Exosome isolation can result in marked enrichment of low-abundance urinary 
proteins that have potential pathophysiologic significance.  As a consequence, we and 
others have been working to define optimal conditions for their isolation and purification 
as a prelude to their use in biomarker discovery studies [6-7, 33]. 
In addition, we used a neutral loss scanning approach [34]
 
to investigate the 
phosphoproteome of human urinary exosomes.  Protein phosphorylation is one of the 
most common posttranslational modifications and it plays an important role in cellular 
processes.   
The purpose of this study was to thoroughly expand the known proteome of human 
urinary exosomes by using a highly sensitive LC-MS/MS system, improved software for 
identification of peptide ions and a more elaborate data analysis strategy than in our 
previous study.  
 
 
* This chapter was published in part as: Gonzales PA, Pisitkun T, Hoffert JD, Tchapyjnikov D, Star RA, 
Kleta R, Wang NS, Knepper MA:  Large-scale proteomics and phosphoproteomics of urinary exosomes.  J 





3.2 Methods  
3.2.1 Large-scale proteomic analysis 
3.2.1.1 Urinary Exosome Isolation  
Urine was collected from eight healthy humans: Four men (aged 22 to 33) and four 
women (aged 24 to 35) (National Institute of Diabetes and Digestive and Kidney 
Diseases Clinical Research Protocol 00-DK-0107).  Fifty milliliters per subject was 
collected and mixed together.  The urinary exosome isolation procedure is shown below 
in Figure 3.1.  Protease inhibitors were added (1.67 ml of 100 mM NaN3, 2.5 ml of 11.5 
mM 4-[2-aminoethyl] benzenesulfonyl fluoride, and 50 ml of 1 mM leupeptin).  The 
mixed sample was centrifuged at 17,000 x g for 10 min at 4°C. The 17,000 x g 
supernatant was ultracentrifuged at 200,000 x g for 1 h at 25°C.  The ultracentrifugation 
step was repeated 3 additional times, adding new 17,000 x g supernatant volume each 
time to each of the 12 tubes. Each of the 12 pellets was suspended with 50 ml of 
“isolation solution” (10mM triethanolamine and 250 mM sucrose).  The suspensions 
were pooled together.  
The abundant urinary protein uromodulin or Tamm-Horsfall protein forms very high 
molecular weight complexes through disulfide linkages.  These complexes sediment in 
the 200,000 x g spin unless denatured.  To denature the zona pellucida domains in the 
Tamm-Horsfall protein, we mixed the resuspended pellet with 200 mg/ml dithiothreitol 
(DTT) at 95°C for 2 min.  The resuspended pellet was added to an ultracentrifuge tube, 
and isolation solution was added to increase the volume to 8 ml.  The sample was 
centrifuged at 200,000 x g for 1h at 25°C.  The pellet was suspended in 50 ml of isolation 





Figure 3.1 Differential centrifugation procedure for the isolation of 





3.2.1.2 In-Gel Trypsin Digestion  
The protein concentration was determined using the Bradford Assay.  This sample 
was solubilized in Laemmli sample buffer (1.5% SDS, 6% glycerol/10 mM Tris HCl, and 
60 mg/ml DTT).  Proteins in the exosome sample were separated by 1D SDS-PAGE 
using a Bio-Rad Ready Gel 4 to 15% polyacrylamide gradient gel with 125 μg distributed 
among two lanes.  The gel was stained with Colloidal Coomassie Blue (GelCode Blue 
Stain Reagent; Pierce, Rockford IL) for 10 min and destained using ddH2O (2 x 30 min). 
The gel was divided from top to bottom into 40 1-mm strips over the entire molecular 
weight range of the gel.  Each strip was diced into small pieces (1 mm
3
) and placed into 
labeled centrifuge tubes.  
The gels pieces were destained by adding 100 μl of 25 mM ammonium 
bicarbonate (NH4HCO3)/50% acetonitrile (ACN) for 10 min and were dried using a 
SpeedVac.  The samples were reduced in a solution of 10 mM DTT and 25 mM 
NH4HCO3 at 56°C for 1 h.  The samples were alkylated in a solution containing 55 mM 
iodoacetamide and 25 mM NH4HCO3in the dark at room temperature for 45 min.  The 
gel pieces were washed with 25 mM NH4HCO3 and dehydrated in a solution containing 
25 mM NH4HCO3 and 50% ACN.  The samples were dried using the SpeedVac.  The 
samples were rehydrated in a solution containing 12.5 ng/μl trypsin (V5113; Promega, 
Madison, WI) in 25 mM NH4HCO3 and digested overnight at 37°C. Peptides were 
extracted using 50% ACN/0.1% formic acid (FA).  The extracted samples were dried 
using the SpeedVac to remove ACN and then reconstituted with 0.1% FA.  All 40 
peptide samples were desalted using C18 ZipTips (Millipore, Billerica, MA) before 




3.2.1.3 Nanospray LC-MS/MS 
A high-sensitivity linear ion trap mass spectrometer, LTQ (Thermo Electron 
Corp.) equipped with a nanoelectrospray ion source was used to acquire m/z ratios in both 
precursor ions (MS1) and fragmented ions (MS2) scans.  To reduce further the sample 
complexity before mass analysis, we injected the tryptic peptides extracted from each gel 
slice using an Agilent 1100 nanoflow system (Agilent Technologies, Palo Alto, CA) into 
a reversed-phase liquid chromatographic column (PicoFrit, Biobasic C18; New Objective, 
Woodburn, MA).  This LC-MS/MS method allows the acquisition of raw data files that 
are the MS/MS scans of the five highest intensity peaks after fragmentation with 
collision-induced dissociation in the LTQ mass analyzer. 
3.2.1.4 Analysis of Data  
The raw data files were searched against the NCBI Reference Sequences (RefSeq) 
human protein database by using BIOWORKS software (Thermo Finnigan). 
BIOWORKS utilizes SEQUEST, which is a program that “finds database candidate 
sequences whose theoretical spectra are compared with the experimental spectrum [28].”
 
To identify thoroughly peptide sequences, we searched the raw data files using the target-
decoy approach and InsPecT.  
In addition, we analyzed the data in a two-step process.  The first step was to 
assess and minimize false-discovery peptide identifications using the target-decoy 
approach, manual inspection of spectra, and InsPecT.  The second step was to assess and 
eliminate ambiguous protein identifications.  
3.2.1.5 Target-Decoy  




Proteomics Core Facility in-house software to create a composite database containing the 
forward and reverse sequences of the non-redundant NCBI Reference Sequences 
(RefSeq) human protein database released on January 26, 2007.  We used the forward 
sequences as the target database and the reversed sequences as the decoy database.  We 
searched the raw data files against this composite database.  After the search, we assessed 
the false discovery rate (FDR) by the number of peptides matched from the reversed 
sequences.  The parameters that determine the stringency of the filtering criteria include 
XCorr, Sp rank, and delta Cn.  These parameters were incrementally adjusted, thereby re-
ducing the false-discovery identifications until a target FDR was achieved. In our case, 
the data were filtered to a target of 2% FDR, and the actual FDR was 1.91%.  The filter 
settings used were min Xcorr rank 1, min Sp rank 10, min delta Cn 0.08, charge +1 min 
Xcorr 2.37, charge +2 min Xcorr 2.87, and charge +3 min Xcorr 3.37.  
3.2.1.6 InsPecT  
We performed an additional analysis of the tandem mass spectrometry data using 
the InsPecT tool [29].  InsPecT uses de novo sequencing to generate sequence 
information (tag filters) from the experimental data.  The tag filters are used to search the 
human protein database, non-redundant NCBI Reference Sequences (RefSeq) human 
protein database released on January 26, 2007, and identify peptide sequences that match 
with the experimental data.  The size of the tag filters are three peptides in length on 
average.  As shown in Figure 3.2, the tag filter generated for the protein CHMP1A 
matches the experimental data accurately.  The peptide sequences identified using the tag 
filters are then scored to estimate that the top match is correct [29].  The score procedure 




the distribution of quality scores for incorrect matches.” For these data, we accept only 
peptide matches with P ≤ 0.05. 
 
Figure 3.2 Spectrum generated by InsPecT for CHMP1A protein 
(NP_00279).  The peptide sequence is RVYAENAIRK.  The tag region 
for the b-ions and the y-ions are shown by the black solid lines. 
 
3.2.1.7 Minimizing False-Discovery Peptide Identifications 
In addition to the target-decoy approach, the InsPecT analysis, we validated the 
quality of proteins identified by manually checking the spectra of those proteins with one 
unique peptide.  We filtered out the proteins that did not have the expected molecular 
weight that matched to the corresponding regions in the 1-D SDS PAGE.  
3.2.1.8 Elimination of Ambiguous Protein Identifications  
Once proteins were identified using the approaches described, we needed to 




“ambiguous identification” is defined as an identification for which the peptide sequence 
that is used to determine the protein identity is found in multiple proteins that are not 
splice variants of the same gene (Figure 3.3).   
 
Figure 3.3 Criteria to disambiguate data set.  (A) An unambiguous 
identification when the sequence was a 100% match without gaps to one 
and only one protein.  (B) An unambiguous identification when the 
sequence was a 100% match without gaps to more than one protein but 
these proteins are splice-variant products of one unique gene.  (C) An 
ambiguous identification when a peptide sequence was a 100% match 
without gaps to more than one protein deriving from more than one gene, 
and the identification was based only on that single peptide.   
 
To disambiguate the data set, we generated software that automates the comparison of 
each peptide sequence to the protein sequences in the RefSeq Human Protein Database 
using the BLAST algorithm.  An identification was considered unambiguous when the 
sequence was a 100% match without gaps to one and only one protein (Figure 3.3A).  An 




without gaps to more than one protein but these proteins are splice-variant products of 
one unique gene (Figure 3.3B). An identification was considered ambiguous when a 
peptide sequence was a 100% match without gaps to more than one protein deriving from 
more than one gene and the identification was based only on that single peptide (Figure 
3.3C). The proteins identified from at least one unambiguous peptide were considered 
unambiguous proteins. The proteins that contained only ambiguous peptides were 
considered ambiguous proteins.  
3.2.2 Phosphoproteomic Analysis 
3.2.2.1 Phosphopeptide Enrichment 
We collected urine specimens (200 ml) from six healthy humans, three men and three 
women. We processed the specimens 400 ml/d for 3 d and pooled them. The exosome 
isolation was as described previously except that phosphatase inhibitors 10 mM NaF 
(Sigma, St. Louis, MO), 20 mM β-glycerol phosphate (Fluka, St. Louis, MO), and 1 mM 
sodium orthovanadate (Sigma) were added. The pellet was resuspended in 6 M guanidine 
HCl/50 mM NH4HCO3.  
The sample was concentrated using a Centricon tube at 13,500 x g, with a starting 
volume of 420 μl and a final volume of 55 μl. The sample was reduced with 50 mM 
DTTfor 1 h at 56°C. The sample was alkylated by addition of 100 mM iodoacetamide for 
1 h (dark) at room temperature and was digested with trypsin overnight at 37°C. The 
sample was centrifuged at 16,000 x g for 20 min. The supernatant was kept, and 100% 
FA was added to inactivate the trypsin. The sample was desalted on a 1-ml HLB column 
(Waters Oasis, Milford, MA) by positive displacement via a syringe with a luer adapter. 




and 0.1% FA, and elution buffer 2 contained 90% ACN and 0.1% FA. The eluents, 50 
and 90%, were dried using the SpeedVac.  
Phosphopeptides were enriched from the samples using the Pierce Phosphopeptide 
Isolation Kit (cat. no. 89853) according to the manufacturer’s protocol. Phosphopeptide 
samples were desalted using C18 ZipTips (Millipore) before analysis by mass 
spectrometry.  
Phosphopeptide samples were analyzed on an Agilent 1100 nanoflow system (Agilent 
Technologies) LC connection to a Finnigan LTQ FT mass spectrometer (Thermo 
Electron) equipped with a nanoelectrospray ion source as described previously [34].  The 
five most intense ions were sequentially isolated and fragmented (MS2) in the linear ion 
trap using collision-induced dissociation.  The data-dependent neutral loss algorithm in 
XCALIBUR software was used to trigger an MS3 scan when a neutral loss of 98.0, 49.0, 
or 32.7 Da was detected among the two most intense fragment ions in a given MS2 
spectrum.  
3.2.2.2 Analysis of Phosphopeptide Data Sets 
We searched MS raw data files against a composite database containing the 
forward and reversed peptide sequence of the Human RefSeq Database from January 26, 
2007.  Putative phosphopeptides were selected and filtered to produce MS2 and MS3 data 
sets with target FDR of 2% (high stringency) and 20% (low stringency) via the 
PhosphoPIC program [33].  This software was also used to merge MS2 and MS3 data 
sets into a single file to facilitate subsequent data analysis. Phosphopeptides identified in 
MS2 spectra were submitted for automated phosphorylation site assignment using the 




was considered to be unambiguously assigned.  Phosphopeptides present only in MS3 
spectra were checked manually.  We used Scansite to determine the phosphorylation 
motif for the identified sites (http://scansite.mit.edu/motifscan_seq.phtml).  We searched 
the PhosphoSite database (http://www.phosphosite.org), which is a curated database 
containing identification of phosphorylation sites from peer-review journals, to determine 
whether the sites were novel or previously identified.   
3.3 Results 
3.3.1 Large-Scale Proteomic Profiling of Human Urinary Exosomes  
In this study, we carried out proteomic profiling of a low-density membrane fraction 
from human urine consisting chiefly of exosomes, using a highly sensitive LC-MS/MS 
system, based on an ion trap mass spectrometer (LTQ; Thermo-Finnigan; Thermo 
Electron, San Jose, CA).  We unambiguously identified 1132 proteins including 205 
proteins seen in our previous study and 927 proteins not seen in our previous study of 
human urinary exosomes [6].  The full list (ambiguous and unambiguous identifications) 
contains 1412 proteins and can be viewed in Supplemental Table 1 (Appendix B), and the 
list of proteins that were unambiguously identified in both studies can be viewed at 
http://dir.nhlbi.nih.gov/papers/lkem/exosome/.  The expanded list of exosomal proteins 
includes 177 proteins that are disease related, on the basis of their presence in the OMIM 
database (Table 3.1).  
Predictably, a large number of proteins that were identified were integral membrane 
proteins involved in solute and water transport (Table 3.2).  As seen in our previous study 
[6], these proteins predominantly represent apical transporters present in every renal 




glucose co-transporter 1 and 2, and aquaporin-1 [AQP1]), the thick ascending limb 
(sodium-potassium-chloride co-transporter 2 [NKCC2]), the distal convoluted tubule 
(thiazide-sensitive Na-Cl co-transporter [NCC]), and connecting tubule/collecting duct 
(AQP2, rhesus blood group C glycoprotein [RhCG, an ammonia channel], B1 subunit of 
vacuolar H+-ATPase, and pendrin).  Note that both polycystin-1 and polycystin-2 were 
detected in human urinary exosomes.  
Exosomes derive from MVB and are delivered to the urine when the outer 
membranes of MVB fuse with the apical plasma membrane.  Interestingly, 22 of the 
proteins identified in this study are recognized as components of the apparatus 
responsible for the formation of MVB (Table 3.3).  These 22 proteins account for 
approximately 75% of the proteins that constitute the ESCRT-0, ESCRT-I, ESCRT-II, 
and ESCRT-III complexes involved in multivesicular body formation [16].
 
 
In addition, 17 proteins identified in this study are subunits of the human vacuolar 
H+-ATPase (Table 3.4).  Vacuolar H+ATPases are ATP-dependent proton pumps for 
proton transport into intracellular organelles [36].  These proteins also mediate proton 
transport across the apical plasma membrane of type A intercalated cells and across the 
basolateral plasma membrane of type B intercalated cells [37].  
 
The B1 subunit is 
selectively expressed in intercalated cells and its detection in urinary exosomes establish 
that intercalated cells secrete exosomes as do other types of epithelial cells lining the 
renal tubule.  These proteins constitute 78% of the subunits of the V0 and V1 domains of 
the vacuolar H+-ATPase [38]. 
3.3.2 Phosphoproteomic Analysis of Human Urinary Exosomes  




Recently, technical approaches that allow phosphoproteomic profiling on a large scale 
have been introduced [26, 34, 35, 39].  We used neutral loss scanning with high-
stringency target-decoy analysis to identify phosphorylation sites present in exosomal 
proteins from human urine samples. 
Nineteen phosphorylation sites corresponding to 14 phosphoproteins were 
identified (Table 3.5).  These included both newly identified phosphorylation sites and 
sites that had been previously identified. Two orphan G-protein–coupled receptors are 
included in the former group, viz. GPRC5B and GPRC5C. In GPRC5B, we identified one 
new phosphorylation site, T389, and, in GPRC5C, we identified three new 
phosphorylation sites, T435, S395, and Y426.  These proteins are also known as retinoic 
acid-induced gene 2 (GPRC5B) and retinoic acid–induced gene 3 (GPRC5C).  
A new phosphorylation site was also identified in the COOH-terminal tail of the 
thiazide-sensitive co-transporter (NCC) at S811 (Figure 3.4).  This site is distinct from 
the N-terminal site previously identified [40]
 
and may play a role in regulation of 
transport.  This amino acid is conserved in humans, chimpanzees, rhesus monkeys, and 
horses but not in mice and rats.  Simon et al [41]
 
showed that in rat, the amino acid 





Figure 3.4 A novel phosphorylation site in the NCC protein.  The 
serine-811 on the NCC protein is phosphorylated.  (A)  The 
phosphorylation site on the peptide is denoted by an asterisk (*).  (B)  The 
neutral loss peak (NL) from the +2 mass spectrum and the site-
determining ions, b5, b6, y7 and y8.  
 
Novel phosphorylation sites were also identified in RRAS2 (TC21), VPS4B (an 
ESCRT component), cytochrome b reductase, proteasome-3 subunit, and mucin 1.  This 
study also revealed previously identified phosphorylation sites in AQP2 (S256) [42],
 







(S192, S197, and S207) [46].  Phosphorylation of AQP2 at S256 was confirmed by 
immunoblotting human urinary exosomes samples with a phosphospecific antibody for 





Figure 3.5 Detection of AQP2-S256 phosphorylation in urinary 
exosomes.  IMCD, rat inner medullary collecting duct treated with 
dDAVP (V2R-selective vasopressin analog) for 30 min; exo (10 μg) is 




3.4.1 Large-Scale Proteomic Profiling of Human Urinary Exosomes  
One of the objectives of this study was to expand the existing human urinary exosome 
database by using a higher sensitivity LC-MS/MS mass spectrometer and improved 
computational tools for matching spectra to proteins in the human proteome.  The LTQ 
mass analyzer has an increased trapping efficiency, ion capacity, and ion ejection rate 
compared with the LCQ mass analyzer [6] used in our previous study.  We identified the 
peptide sequences using the SEQUEST program and analyzed them using the target-
decoy database search strategy and the InsPecT tool.  The target-decoy database search 
strategy allows adjustment of SEQUEST search parameters to ensure a given false-
discovery rate (FDR) [28].  The InsPecT tool uses de novo sequencing to generate tag 




the tag [29].”  The data have been made available to the general public and can be 
downloaded from our laboratory’s web-site 
(http://dir.nhlbi.nih.gov/papers/lkem/exosome/).  In addition, the database can be 
searched using the BLAST algorithm.  
3.4.2 Relevance to Renal Biology  
Several of the proteins newly identified in urinary exosomes in this study may 
have considerable relevance to renal biology and the mechanism of renal disease. Our 
previous study [6] identified proteins that were characteristic of most of the cell types 
facing the urinary space from podocytes through transitional epithelial cells of the urinary 
drainage system. In this study, we identified markers of two additional cell types, type A 
and B intercalated cells.  Specifically, the B1 subunit of the H
+
-ATPase is apically 
located in type A intercalated cells [47], and the anion transporter pendrin is present in 
type B intercalated cells [48].  Previously, we showed that urinary exosomes are derived 
from the apical endosomal pathway so that, although the B1 subunit of the H
+
-ATPase is 
also expressed in type B intercalated cells, its basolateral location probably precludes 
delivery to urinary exosomes.  Overall, we identified 17 different vacuolar H
+
-ATPase 
subunits in urinary exosomes, 78% of the whole V0–V1 complex [36].
 
 
We identified all of the subunits of the four ESCRT complexes (ESCRT-0 
through ESCRT-III) in urinary exosomes in this study.  The ESCRT complexes play a 
central role in the formation of MVB and the secretion of exosomes [38].
 
 
Four different orphan G-protein–coupled receptors were identified in urinary 
exosomes in this study, namely GPR98, GPRC5A, GPRC5B, and GPRC5C. These 




known as very large G-protein–coupled receptor 1 or Neurepin) has more than 6000 
amino acids.  The three GPRC5 proteins are members of the metabotropic glutamate 
family, but their natural ligands are unknown.  It will be of interest in future studies to 
discover the role of these proteins in renal development and regulation. 
3.4.3 Phosphoproteomic Analysis of Human Urinary Exosomes  
Posttranslational modifications (PTM) of proteins play an important role in 
protein function.  Among the most important phosphorylation sites identified included six 
that were previously identified in peer-review journals and eight that had not been 
previously identified.  Among the novel sites was serine-811 in the NCC protein.  This 
amino acid is conserved in humans, chimpanzees, rhesus monkeys, and horses but not in 
mice and rats.  The amino acid sequence surrounding this site is absent in rodents owing 
to a difference in exon splicing [41].  Finally, AQP2 phosphorylated at serine-256 was 
readily detectable in urinary exosomes.  Because this phosphorylation event is increased 
by vasopressin-stimulated activation of adenylyl cyclase [42], measurements of the 
amount of serine 256–phosphorylated AQP2 in urine may provide an improved means of 
assessing the state of vasopressin activation using phospho-specific antibodies.  
3.5 Conclusion 
We used a highly sensitive LC-MS/MS system, based on an ion trap mass 
spectrometer (LTQ; Thermo-Finnigan; Thermo Electron, San Jose, CA) to analyze the 
human urinary exosomes proteome.  We unambiguously identified 1132 proteins 
including 205 proteins seen in our previous study and 927 proteins not seen in our 
previous study of human urinary exosomes [6].  The data is available to the general 




(http://dir.nhlbi.nih.gov/papers/lkem/exosome/).  In addition, the database can be 
searched using the BLAST algorithm.  The expanded list of exosomal proteins includes 
177 proteins that are disease related and are potential targets for further biomarkers 
studies. 
Protein phosphorylation regulates cellular signaling processes and may determine 
protein structure, function, and sub-cellular localization [39].  The ability to detect PTM, 
such as phosphorylation, in urinary exosomes may provide an additional level of 
information that could aid in diagnosis and treatment of a variety of renal disorders.  Fur-
thermore, discovery of PTM in urinary exosomes can provide clues about physiologic 
and pathophysiologic mechanism.  In this study, we identified 14 phosphoproteins.  The 
specific phosphorylation sites identified included six that were previously identified and 
eight that had not been previously identified.  Among the novel sites was serine-811 in 
the NCC protein.  This amino acid is conserved in humans, chimpanzees, rhesus 
monkeys, and horses but not in mice and rats.  The amino acid sequence surrounding this 
site is absent in rodents owing to a difference in exon splicing [39].  In addition, AQP2 
phosphorylated at serine-256 was readily detectable in urinary exosomes. 
Table 3.1.  Disease Related Proteins in Human Urinary Exosomes
kidney diseases are presented in italics.  
Gene Protein Name Pep ID Related to Disease (OMIM)
ABCB1 ATP-binding cassette sub-family B member 1 23 61
Colchicine Resistance [MIM : 120080]
Crohn Disease [MIM:266600]
ABCC9
ATP-binding cassette, sub-family C, 
member 9 isoform SUR2A-delta-14 1 2 Cardiomyopahty [MIM: 608569]
ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 1 3 Cholestasis, Progressive Familial Intrahepatic 2 [MIM:601847]
Cholestasis, Benign Recurrent Intrahepatic 2 [MIM:605479]
ACAT1 acetyl-Coenzyme A acetyltransferase 1 precursor 1 2 Alpha-methylacetoacetic Aciduria [MIM:203750]
ACE angiotensin I converting enzyme isoform 1 precursor 23 96 Hypertension [MIM:106180]
ACE angiotensin I convertin enzyme isoform 2 precursor 12 61 Renal Tubular Dysgenesis [267430]
ACE2 angiotensin I converting enzyme 2 precursor 8 17 Hypertension [MIM:300335]
ACOT7 acyl-CoA thioesterase 7 isoform hBACHd 1 1 Mesial temporal lobe epilepsy [MIM:608096]
ACSL4 acyl-CoA synthetase long-chain family member 4 isoform 2 1 2 Mental Retardation, X-linked 63, MRX 63 [MIM:300387]
ACY1 aminoacylase 1 15 43 Amimoacylase 1 Deficiency [MIM:609924]
AHCY S-adenosylhomocysteine hydrolase 10 28 Hypermethioninemia [MIM:180960]
AK1 adenylate kinase 1 4 4 Hemolytic Anemia due to AK1  Deficiency [MIM:103000]
ALAD delta-aminolevulinic acid dehydratase isoform a 1 1 Acute Hepatic Porphyria [MIM:125270]





ALDOA aldolase A 7 14
Aldolase Deficiency  of Red Cells
Myopathy and Hemolytic Anemia [MIM:103850]
ALPL tissue non-specific alkaline phosphatase precursor 3 4 Hypophostasia [MIM:241500]
AMN amnionless protein precursor 1 1 Megaloblastic Anemia 1 [MIM: 261100]
ANPEP membrane alanine aminopeptidase precursor 69 412 Hypertension [MIM:151530]
APOA1 apolipoprotein A-I preproprotein 6 17 Primary Hypoalphalipoproteinemia [MIM:604091]
APOA2 apolipoprotein A-II preproprotein 1 1
Apolipoprotein A-II Deficiency, Familial
Hypercholesterolemia, Familial [MIM:143890]
APRT adenine phosphoribosyltransferase isoform a 2 2 2,8-Dihydroxyadenine urolithiasis [MIM:102600]
APRT adenine phosphoribosyltransferase isoform b 3 10 2,8-Dihydroxyadenine urolithiasis [MIM:102600]
AQP1 aquaporin 1 3 35 Aquaporin 1 Deficiency, Colton-Null [MIM:110450]
AQP2 aquaporin 2 7 36
Autosomal recessive nephrogenic 
diabetes insipidus, type 1 [MIM:222000]
Autosomal dominant nephrogenic 
diabetes insipidus, type 1 [MIM:125800]
ARL6 ADP-ribosylation factor-like 6 4 7 Bardet-Biedl Syndrome 3 [MIM:209900]
ARSE arylsulfatase E precursor 1 2
Chondrodysplasia Punctata 1, 
X-linked Recessive [MIM:302950]
ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1 preproprotein isoform a 7 16 Farber Disease [MIM:228000]
ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1 isoform b 9 34 Farber Disease [MIM:228000]
ASL argininosuccinate lyase isoform 3 1 1 Argoninosuccinic Aciduria [MIM:207900]
ASS1 argininosuccinate synthetase 1 20 59 Citrullinemia [MIM:215700]
ATIC 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase 1 1 Aica-ribosiduria due to Atic Deficiency [MIM:608688]
ATP6V0A4 ATPase, H+ transporting, lysosomal V0 subunit a4 1 2
Renal Tubular Acidosis, Distal, 
Autosomal Recessive [MIM:602722]
ATP6V1B1 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 8 17
Renal Tubular Acidosis, Distal, with 
Progressive Deafness [MIM:267300]
B2M beta-2-microglobulin precursor 1 1 Hypercatabolic Hypoproteinemia [MIM:241600]
Information for each protein include "Gene" name, "Protein Name", "Pep" refers to the number of unique 
peptides identified in LC-MS/MS, "ID" refers to the number of spectra and "Related to Disease [OMIM]" 
refers to the disease with which the protein is related according to OMIM. The 34 proteins associated with 
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Table 3.1 Continued
Gene Protein Name Pep ID Related to Disease (OMIM)
B4GALT1 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase 1, membrane-bound form 1 1
Congenital Disorder of 
Glycosylation Type Iid [MIM:607091]
CA2 carbonic anhydrase II 9 25
Autosomal recessive syndrome of 
osteopetrosis with renal tubular acidosis 
[MIM:259730]
CA4 carbonic anhydrase IV precursor 2 2 Proximal renal tubular acidosis [MIM:114760]
CC2D1A coiled-coil and C2 domain containing 1A 6 6
Mental Retardation Autosomal Recessive 3 
[MIM:608443]
CD2AP CD2-associated protein 14 21
Focal Segmental Glomerulosclerosis FSGS3 
[MIM:607832]
CETP cholesteryl ester transfer protein, plasma precursor 7 14
Cholesterol Ester Transfer Protein Deficiency 
[MIM:607322]
CFH complement factor H isoform b precursor 
1 1
Hemolytic Uremic Syndrome, Atypical 
[MIM: 235400]
CFI complement factor I 1 1 Complement Factor I Deficiency [MIM: 610984]
CHMP2B chromatin modifying protein 2B 4 15
Frontotemporal Dementia, Chromosome 3-linked 
[MIM:6000795]
CLTC clathrin heavy chain 1 12 24 Renal Cell Carcinoma [MIM:118955]
COL18A1 alpha 1 type XVIII collagen isoform 1 precursor 1 1 Knobloch Syndrome [MIM:267750]
COL6A1 collagen, type VI, alpha 1 precursor 6 21
Bethlem Myopathy [MIM:158810]
Ullrich Congenital Muscular Dystrophy, 
Autosomal Dominant [MIM:254090]
COL6A3 alpha 3 type VI collagen isoform 5 precursor 
1 2
Ullrich Congenital Muscular Dystrophy 
[MIM: 254090]
CP ceruloplasmin precursor 6 15 Aceruloplasminemia [MIM:604290]
CRYAB crystallin, alpha B 7 12 Alpha-B Crystallinopathy [MIM:608810]
CRYM crystallin, mu isoform 1 1 3
Autosomal Dominant Nonsyndromic Deafness 
[MIM:123740]
CST3 cystatin C precursor 1 3
Icelandic-type cerebroarterial amyloidosis 
[MIM:105150]
CSTB cystatin B 2 10
Myoclonic Epilepsy of Unverricht and Lundborg 
[MIM:254800]
CTSC cathepsin C isoform b precursor 1 1 Papillo-LeFevre Syndrome [MIM: 245000]
CTH cystathionase isoform 2 1 1 Cystathioniruria [MIM:219500]
CTSA cathepsin A precursor 3 15 Galactosialidosis [MIM:256540]
CTSC cathepsin C isoform a preproprotein 1 2 Papillon-Lefevre Syndrome [MIM:245000]
CTSD cathepsin D preproprotein 1 2 Neuronal Ceroid Lipofuscinosis [MIM:610127]
CTNS cystinosis, nephropathic isoform 1 1 3 Nephropathic Cystinosis [MIM: 219800]
CUBN cubilin 104 672 Megaloblastic Anemia 1, Finnish Type [MIM:261100]
CUL4B cullin 4B 1 1
Cabezas Syndrome [MIM:300354]
Mental Retardation-Hypotonic Facies Syndrome
 [MIM:300639]
DDAH1 dimethylarginine dimethylaminohydrolase 1 1 5 Hypertension [MIM: 604743]
DDC dopa decarboxylase (aromatic L-amino acid decarboxylase) 11 31
Aromatic L-Amino Acid 
Decarboxylase Deficiency [MIM:608643]
DNM2 dynamin 2 isoform 3 1 1
Charcot-Marie-Tooth Disease, 
Dominant Intermediate B [MIM:606482]
DNM2 dynamin 2 isoform 4 
1 1
Charcot-Marie-Tooth Neuropathy, 
Dominant Intermediate B [MIM: 606482]
DYSF dysferlin 1 1 Miyoshi Myopathy [MIM: 254130]
DPYS dihydropyrimidinase 5 6 Dihydropyrimidinuria [MIM:222748]
DSC2 desmocollin 2 isoform Dsc2b preproprotein 1 3
Arrhythmogenic right ventricular 
dysplasia-11 [MIM:610476]
DSP desmoplakin isoform II 10 16
Keratosis Palmoplantaris Striata II 
Dilated Cardiomyopathy 
With Woolly Hair and Keratoderma [MIM:605676]
ECE1 endothelin converting enzyme 1 1 1 Hirschsprung Disease [MIM: 142623]
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Table 3.1 Continued
Gene Protein Name Pep ID Related to Disease (OMIM)
EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1 precursor 
1 3
Doyne Honeycomb Retinal Dystrophy 
[MIM: 126600]
ELA2 elastase 2, neutrophil preproprotein 1 1 Cyclic Hematopoiseis [MIM:162800]
ENPEP glutamyl aminopeptidase (aminopeptidase A) 25 100 Hypertension [MIM:138297]
FAH fumarylacetoacetate hydrolase (fumarylacetoacetase) 2 2 Tyrosinemia Type I [MIM:276700]
FLNB filamin B, beta (actin binding protein 278) 
1 1
Spondylocapotarsal Synostosis Syndrome 
[MIM: 272460]
FBP1 fructose-1,6-bisphosphatase 1 7 16
Fructose-1,6-Bisphosphatase Deficiency 
[MIM:229700]
FGA fibrinogen, alpha polypeptide isoform alpha-E preproprotein 5 17
Renal Amyloidosis [MIM:105200]
Dysfibrinogenemia [MIM:134820]
FGG fibrinogen, gamma chain isoform gamma-A precursor 1 1 Dysfibrinogenemia[MIM:134850]
FTCD formiminotransferase cyclodeaminase 
4 7
Glutamate Formiminotransferase Deficiency 
[MIM: 229100]
FTH1 ferritin, heavy polypeptide 1 1 7 Iron Overload, Autosomal Dominant [MIM:134770]
FTL ferritin, light polypeptide 5 14 Hyperferritinemia-Cataract Syndrome [MIM:600886]
FUCA1 fucosidase, alpha-L-1, tissue 1 1 Fucosidosis [MIM:230000]
FXYD2 FXYD domain-containing ion transport regulator 2 isoform 1 1 7 Hypomagnesemia 2, Renal [MIM:154020]
G6PD glucose-6-phosphate dehydrogenase isoform a 1 1
Nonspherocytic Hemolytic Anemia due to 
G6PD Deficiency [MIM:305900]
GAA acid alpha-glucosidase preproprotein 4 8
Infantile-onset Glycogen Storage 
Disease Type II [MIM:232300]
GALK1 galactokinase 1 1 1 Galactokinase Deficiency [MIM: 230200]
GBE1 glucan (1,4-alpha-), branching enzyme 1 1 2 Type IV Glycogen Storage Disease [MIM:232500]
GCS1 mannosyl-oligosaccharide glucosidase 1 1 Congenital Disorder of Glycosylation [MIM: 606056]
GK glycerol kinase isoform a 1 1 Glycerol Kinase Deficiency [MIM: 307030]
GLB1 galactosidase, beta 1 isoform a 16 70 Gangliosidosis GM1 [MIM:230500]
GLUL glutamine synthetase 2 2 Congenital Glutamine Deficiency [MIM:610015]
GM2A GM2 ganglioside activator precursor 2 3
Gangliosidosis GM2 AB Variant 
Tay-Sachs Disease [MIM:272750]
GPI glucose phosphate isomerase 9 19
Chronic Hemolytic Anemia Duet to 
GPI Deficiency [MIM:172400]
GPR98 G protein-coupled receptor 98 precursor 1 1
Familial Febrile Seizures [MIM:604352]
Usher Syndrome Type IIC [MIM:605472]
GSN gelsolin isoform b 10 21 Finnish Type Familial Amyloidosis [MIM:105120]
GSS glutathione synthetase 1 3 Glutathione Synthetase Deficiency [MIM:266130]
HNMT histamine N-methyltransferase isoform 1 1 1 Susceptibility to Asthma [MIM:600807]
HPD 4-hydroxyphenylpyruvate dioxygenase 1 1 Tyrosinemia Type III [MIM:276710]
HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) 6 21 Hypertension [MIM:601688]
HSPB1 heat shock 27kDa protein 1 8 30
Charcot-Marie-Tooth Disease, Type 2F [MIM:606595]
Distal Hereditary Motor Neuropathy IIB [MIM:608634]
ICAM1 intercellular adhesion molecule 1 precursor 1 1 Graves Disease [MIM: 275000]
IL1RN interleukin 1 receptor antagonist isoform 1 precursor 2 2 Gastic Cancer Risk [MIM:137215]
IRF6 interferon regulatory factor 6 1 1
Van der Woude Syndrome [MIM:119300]
Popliteal Pterygium Syndrom [MIM:119500]
ITM2B integral membrane protein 2B 5 21 Familial Dementia [MIM:176500]
JUP junction plakoglobin 9 15 Naxos Disease [MIM:601214]
KALRN kalirin, RhoGEF kinase isoform 3 1 1 Coronary Heart Disease [MIM:608901]
KHK ketohexokinase isoform a 2 4 Essential Fructosuria [MIM:229800]
KL klotho 
1 1
Hyperphosphatemic Tumoral Calcinosis 
[MIM: 211900]
KLK1 kallikrein 1 preproprotein 1 1 Decreased Urinary Activity of Kallikrein [MIM:147910]
LGALS3 galectin 3 
1 1
Lymphocyte Function-Associated 
Antigen 1 [MIM: 116920]
LAMP2 lysosomal-associated membrane protein 2 precursor 4 26 Danon Disease [MIM:300257]
LRRK2 leucine-rich repeat kinase 2 4 5 Parkinson Disease [MIM:607060]
LYZ lysozyme precursor 1 3 Familal Visceral Amyloidosis  [MIM:105200]
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Table 3.1 Continued
Gene Protein Name Pep ID Related to Disease (OMIM)
MIF
macrophage migration inhibitory factor 
(glycosylation-inhibiting factor) 1 6 Rheumatoid Arthritis [MIM: 604302]
MME membrane metallo-endopeptidase Neprilysin 48 311
Hypertension
Important cell surface marker in the diagnostic of 
human acute lymphocytic leukemia [MIM:120520]
MPO myeloperoxidase 7 32 Myeloperoxidase Deficiency [MIM:254600]
MTHFD1 methylenetetrahydrofolate dehydrogenase 1 4 5 Spina Bifida [MIM:601634]
MYH14 myosin, heavy chain 14 isoform 1 
1 1
Autosomal Dominant Nonsyndromic 
Sensorineural Deafness [MIM: 600652]
MYH14 myosin, heavy chain 14 isoform 2 8 17
Autosomal Dominant nonsyndromic 
sensorineural hearing loss [MIM:600652]
MYH3 myosin, heavy chain 3, skeletal muscle, embryonic 1 1 Freeman-Sheldon Syndrome [MIM:193700]
MYH9 myosin, heavy polypeptide 9, non-muscle 19 51
Fechtner syndrome [MIM:153640]
Epstein syndrome [MIM:153650]
MYO15A myosin XV 1 3 Recessive Congenital Deafness [MIM:600316]
MYO6 myosin VI 7 21
Autosomal Recessive Congenital Sensorineural Deafness 
[MIM:607821]
Autosomal Dominant Nonsyndromic Sensorineural Deafness 
[MIM:606346]
NAGLU alpha-N-acetylglucosaminidase precursor 21 63 Mucopolysaccharidosis Type IIIB [MIM:252920]
NDRG1 N-myc downstream regulated gene 1 2 5 Charcot-Marie-Tooth Disease Type 4D [MIM:601455]
NEB nebulin 2 4 Nemaline Myopathy [MIM:256030]
NPHS2 podocin 6 9
Autosomal recessive steroid-resistant 
nephrotic syndrome [MIM:600995]
PAFAH1B1 platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit (45kD) 1 1 Miller-Dieker Lissencephaly Syndrome [MIM:607432]
PARK7 DJ-1 protein 1 1 Parkison Disease 7, Autosomal Recessive [MIM: 606324]
PCBD1 pterin-4 alpha-carbinolamine dehydratase precursor 1 1 Hyperphenylalaninemic [MIM:264070]
PDCD10 programmed cell death 10 2 3 Cerebral Cavernous Malformations [MIM:603285]
PHGDH phosphoglycerate dehydrogenase 2 2
Phosphoglycerate Dehydrogenase Deficiency 
[MIM:601815]
PKD1 polycystin 1 1 1 Polycystic Kidney Disease, adult, type I [MIM:601313]
PKD2 polycystin 2 1 2 Polycistic kidney disease, adult, type II [MIM:173910]
PKHD1 polyductin isoform 2 6 9
Autosomal Recessive Polycystic 
Kidney Disease [MIM:263200]
PKLR pyruvate kinase, liver and RBC isoform 1 1 1 Pyruvate Kinase Deficiency [MIM:266200]
PLOD1 lysyl hydroxylase precursor 1 1 Ehlers-Danlos Syndrome, Type VIA [MIM:225400]
PRKCH protein kinase C, eta 1 2 Cerebral Infarction [MIM:601367]
PROM1 prominin 1 23 174 Autosomal Recessive Retinal Degeneration [MIM:604365]
PRNP prion protein preproprotein 1 1 Creutzfeldt-Jakob Disease [MIM: 123400]
PSAP prosaposin isoform a preproprotein 3 6
Metachromatic Leukodystrophy 
Due to SAP1 Deficiency [MIM:249900]
Gaucher Disease, Atypical 
Due to SAP2 Deficiency [MIM:610539]
PSAP prosaposin isoform c preproprotein 1 4 Metachromatic Leukodystrophy [MIM: 249900]
PSAT1 phosphoserine aminotransferase isoform 1 
2 4 Phosphoserine Aminotransferase Deficiency [MIM: 610992]
PTPRJ protein tyrosine phosphatase, receptor type, J precursor 1 1 Somatic Colon Cancer [MIM:114500]




RBP4 retinol-binding protein 4, plasma precursor 2 3 Retinol-Binding Protein Deficiency [MIM:180250]
RDX radixin 16 23 Autosomal Recessive Deafness 24 [MIM:611022]
ROBO2 roundabout, axon guidance receptor, homolog 2 1 1 Vesicoureteral Reflux 2 [MIM:610878]
RP2 XRP2 protein 3 5 X-Linked Retinitis Pigmentosa 2 [MIM:312600]
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Table 3.1 Continued
RYR1 skeletal muscle ryanodine receptor isoform 1 1 1
Malignant Hyperthermia [MIM:145600]
Central Core Disease [MIM:117000]
Minicore Myopathy with External 
Ophthalmoplegia [MIM:255320]
Gene Protein Name Pep ID Related to Disease (OMIM)
SERPING1 complement component 1 inhibitor precursor 7 14 Hereditary Angioedema Type I [MIM:106100]
SLC3A1 solute carrier family 3, member 1 14 25 Cystinuria [MIM:220100]
SLC4A1 solute carrier family 4, anion exchanger, member 1 [kAE1] 2 2
Defective kidney acid secretion leading 
to distal renal tubular acidosis [MIM:179800]
SLC4A4 solute carrier family 4, sodium bicarbonate cotransporter, member 4 [NBC1] 2 3
Renal Tubular Acidosis, Proximal, 
With Ocular Abnormalities [MIM:604278]
SLC5A1 solute carrier family 5 (sodium/glucose cotransporter), member 1 [SGLT1] 2 3 Glucose/Galactose Malabsorption [MIM:606824]
SLC5A2 solute carrier family 5 (sodium/glucose cotransporter), member 2 [SGLT2] 4 9 Renal Glucosuria [MIM:233100]
SLC6A19 solute carrier family 6, member 19 4 8 Hartnup Disorder [MIM:234500]
SLC12A1 sodium potassium chloride cotransporter 2 [NKCC2] 25 94 Bartter Syndrome, Antenatal, Type 1 [MIM:601678]
SLC12A3 solute carrier family 12 (sodium/chloride transporters), member 3 [NCC] 28 102 Gitelman Syndrome [MIM:263800]
SLC22A12 urate anion exchanger 1 isoform a [URAT1] 1 2 Renal Hypouricemia [MIM:220150]
SLC25A3 solute carrier family 25 member 3 isoform b precursor 1 5 Mitochondrial Phosphate Carrier Deficiency [MIM:610773]
SLC26A4 pendrin 2 4
Pendred Syndrome [MIM:274600]
Deafness, Autosomal Recessive 4 [MIM:600791]
SLC44A4 NG22 protein isoform 1 6 59 Sialidosis 1 [MIM:606107]
SPR sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase) 1 2
Dystonia, Dopa-Responsive, Due To 
Sepiapterin Reductase Deficiency [MIM:251120]
SQSTM1 sequestosome 1 1 2 Paget Disease of Bone [MIM:602080]
SUCLA2 succinate-CoA ligase, ADP-forming, beta subunit 1 1 Mitochondrial DNA Depletion Syndrome [MIM: 609560]
TECTA tectorin alpha precursor 1 1
Autosomal Dominant nonsyndromic 
sensorineural hearing loss [MIM:601842]
TF transferrin 12 20 Alzheimer Disease [MIM:104300]
TPP1 tripeptidyl-peptidase I preproprotein 8 42 Ceroid Lipofuscinosis Neuronal 2 [MIM:204500]
TSG101 tumor susceptibility gene 101 17 66 Breast Cancer [MIM:176960]
TTN titin isoform novex-1 4 5 Cardiomyopathy [MIM:188840]
UMOD uromodulin precursor 35 1278 Medullary cystic kidney disease-2 (MCKD2) [MIM:603860] 
Familial juvenile hyperuricemic nephropathy (FJHN) [MIM:16200]
VCP valosin-containing protein 2 2
Inclusion Body Myopathy with Early Onset 
Paget Disease and Frontotemporal Dementia 
[MIM:167320]
VAMP7 vesicle-associated membrane protein 7 1 1 Beta-Ureidopropionase Deficiency [MIM: 606673]
VCL vinculin isoform meta-VCL 3 5 Cardiomyopathy, Dilated [MIM: 611407]
VWF von Willebrand factor preproprotein 1 4 Von Willebrand Disease [MIM: 193400]
ZMPSTE24 zinc metalloproteinase STE24 1 1 Madibuloacral Dysplasia [MIM: 608612]
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Table 3.2.  Solute and water transporters
Table contains all of the proteins that are solute and water transporters.
Ref Seq Gene Protein Name Pep ID
NP_000918 ABCB1 ATP-binding cassette sub-family B member 1 23 61
NP_003733 ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 1 3
NP_005680 ABCB6 ATP-binding cassette, sub-family B, member 6 1 1
NP_064694 ABCC9 ATP-binding cassette, sub-family C, member 9 isoform SUR2A-delta-14 1 2
NP_149163 ABCC11 ATP-binding cassette, sub-family C, member 11 isoform a 1 1
NP_932766 AQP1 aquaporin 1 3 35
NP_000477 AQP2 aquaporin 2 7 36
NP_000692 ATP1A1 Na+/K+ -ATPase alpha 1 subunit isoform a proprotein 19 57
NP_001001787 ATP1B1 Na+/K+ -ATPase beta 1 subunit isoform b 1 1
NP_001001937 ATP5A1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit precursor 3 5
NP_001677 ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta subunit precursor 4 5
NP_001174 ATP6AP1 ATPase, H+ transporting, lysosomal accessory protein 1 precursor 1 1
NP_001685 ATP6V0C ATPase, H+ transporting, lysosomal, V0 subunit c 1 9
NP_005168 ATP6V0A1 ATPase, H+ transporting, lysosomal V0 subunit a isoform 1 1 1
NP_065683 ATP6V0A4 ATPase, H+ transporting, lysosomal V0 subunit a4 1 2
NP_004682 ATP6V0D1 ATPase, H+ transporting, lysosomal, V0 subunit d1 1 1
NP_689778 ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit D2 2 4
NP_001681 ATP6V1A ATPase, H+ transporting, lysosomal 70kD, V1 subunit A, isoform 1 22 49
NP_001683 ATP6V1B1 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 8 17
NP_001684 ATP6V1B2 vacuolar H+ATPase B2 12 27
NP_001686 ATP6V1C1 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C1 isoform A 1 1
NP_001034451 ATP6V1C2 vacuolar H+ ATPase C2 isoform a 1 1
NP_057078 ATP6V1D H(+)-transporting two-sector ATPase 2 3
NP_001687 ATP6V1E1 vacuolar H+ ATPase E1 isoform a 2 2
NP_001034456 ATP6V1E1 vacuolar H+ ATPase E1 isoform c 1 1
NP_001034455 ATP6V1E1 vacuolar H+ ATPase E1 isoform b 1 1
NP_004222 ATP6V1F ATPase, H+ transporting, lysosomal 14kD, V1 subunit F 1 1
NP_004879 ATP6V1G1 vacuolar H+ ATPase G1 1 2
NP_998784 ATP6V1H ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H isoform 1 8 34
NP_036415 KCNG2 potassium voltage-gated channel, subfamily G, member 2 1 2
NP_853514 PKD1L3 polycystin 1-like 3 1 1
NP_001009944 PKD1 polycystin 1 isoform 1 precursor 1 1
NP_000288 PKD2 polycystin 2 1 2
NP_057405 RHCG Rhesus blood group, C glycoprotein 5 8
NP_000531 RYR1 skeletal muscle ryanodine receptor isoform 1 1 1
NP_006505 SCN10A sodium channel, voltage-gated, type X, alpha 1 11
NP_054858 SCN11A sodium channel, voltage-gated, type XI, alpha 1 1
NP_000329 SLC12A1 sodium potassium chloride cotransporter 2 25 94
NP_000330 SLC12A3 solute carrier family 12 (sodium/chloride transporters), member 3 28 102
NP_064631 SLC12A9 solute carrier family 12 (potassium/chloride transporters), member 9 1 1
NP_003975 SLC13A2 solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2 5 10
NP_073740 SLC13A3 solute carrier family 13 member 3 isoform a 2 2
NP_001011554 SLC13A3 solute carrier family 13 member 3 isoform b 1 3
NP_004161 SLC1A1 solute carrier family 1, member 1 3 6
NP_066568 SLC15A2 solute carrier family 15 (H+/peptide transporter), member 2 1 1
NP_060954 SLC22A11 solute carrier family 22 member 11 2 9
NP_653186 SLC22A12 urate anion exchanger 1 isoform a 1 2
NP_003049 SLC22A2 solute carrier family 22 member 2 isoform a 2 3
NP_003051 SLC22A5 solute carrier family 22 member 5 1 1
NP_004781 SLC22A6 solute carrier family 22 member 6 isoform a 1 3
NP_695010 SLC22A6 solute carrier family 22 member 6 isoform d 1 1
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Table 3.2 Continued
Ref Seq Gene Protein Name Pep ID
NP_004245 SLC22A8 solute carrier family 22 member 8 1 2
NP_005838 SLC23A1 solute carrier family 23 (nucleobase transporters), member 1 isoform a 4 6
NP_689898 SLC23A1 solute carrier family 23 (nucleobase transporters), member 1 isoform b 6 10
NP_005975 SLC25A1 solute carrier family 25 (mitochondrial carrier; citrate transporter), member 1 1 1
NP_998776 SLC25A3 solute carrier family 25 member 3 isoform b precursor 1 5
NP_775897 SLC26A11 solute carrier family 26, member 11 1 1
NP_000432 SLC26A4 pendrin 2 4
NP_003030 SLC2A5 solute carrier family 2 (facilitated glucose/fructose transporter), member 5 12 22
NP_775867 SLC39A5 solute carrier family 39 (metal ion transporter), member 5 1 1
NP_000332 SLC3A1 solute carrier family 3, member 1 14 25
NP_001012679 SLC3A2
solute carrier family 3 (activators of dibasic and neutral amino acid transport), 
member 2 isoform a 10 18
NP_002385 SLC3A2
solute carrier family 3 (activators of dibasic and neutral amino acid transport), 
member 2 isoform c 3 5
NP_536856 SLC44A1 CDW92 antigen 1 1
NP_065161 SLC44A2 CTL2 protein 18 70
NP_000333 SLC4A1 solute carrier family 4, anion exchanger, member 1 2 2
NP_003750 SLC4A4 solute carrier family 4, sodium bicarbonate cotransporter, member 4 2 3
NP_000334 SLC5A1 solute carrier family 5 (sodium/glucose cotransporter), member 1 2 3
NP_689564 SLC5A10 solute carrier family 5 (sodium/glucose cotransporter), member 10 isoform 1 2 2
NP_001035915 SLC5A10 solute carrier family 5 (sodium/glucose cotransporter), member 10 isoform 2 1 3
NP_848593 SLC5A12 solute carrier family 5 (sodium/glucose cotransporter), member 12 isoform 2 2 4
NP_003032 SLC5A2 solute carrier family 5 (sodium/glucose cotransporter), member 2 4 9
NP_666018 SLC5A8 solute carrier family 5 (iodide transporter), member 8 1 1
NP_001011547 SLC5A9 solute carrier family 5 (sodium/glucose cotransporter), member 9 1 3
NP_057699 SLC6A13 solute carrier family 6 (neurotransmitter transporter, GABA), member 13 1 1
NP_001003841 SLC6A19 solute carrier family 6, member 19 4 8
NP_004165 SLC9A3 solute carrier family 9 (sodium/hydrogen exchanger), isoform 3 2 3
NP_004776 SLC9A3R2 solute carrier family 9 isoform 3 regulator 2 1 1
NP_851322 SLCO4C1 solute carrier organic anion transporter family, member 4C1 2 2
NP_003365 VDAC1 voltage-dependent anion channel 1 6 43
NP_005653 VDAC3 voltage-dependent anion channel 3 1 1
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Table 3.3.  Proteins of the ESCRT Complex
Table contains all of the proteins that are members of the ESCRT Complex:
ESCRT 0 ESCRT I ESCRT II ESCRT III ATPase complex and accessory
Gene Protein Pep ID Ref Seq ESCRT
HGS Hepatocyte growth factor-regulated tyrosine kinase substrate 1 1 NP_004703 ESCRT-0
TSG101 Tumor susceptibility gene 101 15 47 NP_006283 ESCRT-I
VPS28 Vacuolar protein sorting 28 isoform 1 5 8 NP_057292 ESCRT-I
VPS28 Vacuolar protein sorting 28 isoform 2 2 8 NP_898880 ESCRT-I
VPS37B Vacuolar protein sorting 37B 4 10 NP 078943 ESCRT-I
- , - , - , - ,    .
_
VPS37C Vacuolar protein sorting 37C 1 1 NP_060436 ESCRT-I
VPS25 EAP25 4 15 NP_115729 ESCRT-II
VPS36 EAP45 2 3 NP_057159 ESCRT-II
SNF8 EAP30 1 1 NP_009172 ESCRT-II
CHMP2A CHMP2A 6 40 NP_055268 ESCRT-III
CHMP2B CHMP2B 3 11 NP_054762 ESCRT-III
VPS24 CHMP3 1 3 NP_057163 ESCRT-III
VPS24 CHMP3 1 4 NP 001005753 ESCRT III_ -
CHMP4B CHMP4B 2 6 NP_789782 ESCRT-III
CHMP5 CHMP5 2 7 NP_057494 ESCRT-III
CHMP1A CHMP1A 1 3 NP_002759 ESCRT-III
CHMP1B CHMP1B 1 2 NP_065145 ESCRT-III
CHMP6 CHMP6 2 3 NP_078867 ESCRT-III
VPS4A Vacuolar protein sorting factor 4A 11 25 NP_037377 ATPase Complex
VPS4B Vacuolar protein sorting factor 4B 11 32 NP 004860 ATPase Complex    _  
PDCD6IP ALIX 27 104 NP_037506 Accessory
C1orf58 Hypothetical protein LOC148362 11 34 NP_653296 Accessory
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Table 3.4.  Vacuolar H-ATPase subunits in human urinary exosomes
Table contains proteins that are found in human urinary exosomes and are subunits of the human 
vacuolar H+-ATPase.
Ref Seq Gene Protein Name Pep ID
NP_005168 ATP6V0A1 ATPase, H+ transporting, lysosomal V0 subunit a isoform 1 1 1
NP_065683 ATP6V0A4 ATPase, H+ transporting, lysosomal V0 subunit a4 1 2
NP_001685 ATP6V0C ATPase, H+ transporting, lysosomal, V0 subunit c 1 1
NP_004682 ATP6V0D1 ATPase, H+ transporting, lysosomal, V0 subunit d1 1 1
NP_689778 ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit D2 2 4
NP_001681 ATP6V1A ATPase, H+ transporting, lysosomal 70kD, V1 subunit A, isoform 1 22 49
NP_001683 ATP6V1B1 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 8 17
NP_001684 ATP6V1B2 vacuolar H+ATPase B2 12 27
NP_001686 ATP6V1C1 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C1 isoform A 1 1
NP_001034451 ATP6V1C2 vacuolar H+ ATPase C2 isoform a 1 1
NP_057078 ATP6V1D H(+)-transporting two-sector ATPase 2 3
NP_001687 ATP6V1E1 vacuolar H+ ATPase E1 isoform a 2 2
NP_001034455 ATP6V1E1 vacuolar H+ ATPase E1 isoform b 1 1
NP_001034456 ATP6V1E1 vacuolar H+ ATPase E1 isoform c 1 1
NP_004222 ATP6V1F ATPase, H+ transporting, lysosomal 14kD, V1 subunit F 1 1
NP_004879 ATP6V1G1 vacuolar H+ ATPase G1 1 2
NP_998784 ATP6V1H ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H isoform 1 8 34
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Table 3.5.  Human urinary exosomes phosphopeptides
Table contains phosphopeptides found in urinary exosomes.  MSn refers to spectra for phosphorylation site identification.  
Motif refers to phosphorylation motif site and GO Function.
Ref Seq Protein Name, Sequence Site Gene Novel Site MSn Motif GO Function
NP_061123 
G protein-coupled receptor family C, group 5, 
member C isoform b GPRC5C
R.AEDMYSAQSHQAA(T*)PPKDGK.N T435 Yes MS2, MS3 proline-directed
K.VP(S*)EGAYDIILPR.A S395 Yes MS2, MS3 acidophilic
R.AEDM(Y*)SAQSHQAATPPKDGK.N Y426 Yes MS2 tyrosine kinase
NP_001035149 Secreted phosphoprotein 1 isoform c SPP1
K.AIPVAQDLNAPSDWD(S*)R.G S192 No MS2 Miscellanous
R.GKD(S*)YETSQLDDQSAETHSHK.Q S197 MS2, MS3 Miscellanous
R.GKDSYETSQLDDQ(S*)AETHSHK.Q S207 MS2, MS3 acidophilic
NP_057319 
G protein-coupled receptor, family C, group 5, 
member B precursor GPRC5B
R.SNVYQPTEMAVVLNGG(T*)IPTAPPSHTGR.H T389 Yes MS2 basophilic
NP_000477 Aquaporin 2 AQP2
R.RQ(S*)VELHSPQSLPR.G S256 No MS2,MS3
NP_004860 Vacuolar protein sorting factor 4B VPS4B
K.EGQPSPADEKGND(S*)DGEGESDDPEKKK.L S102 Yes MS2 acidophilic
NP_054762 Chromatin modifying protein 2B CHMP2B
K.ATI(S*)DEEIER.Q S199 No MS2, MS3 (unfiltered) basophilic
NP_687033 Proteasome alpha 3 subunit isoform 2 PSAM3
K.ESLKEEDE(S*)DDDNM S243 No MS2, MS3 acidophilic
NP_036382 Related RAS viral (r-ras) oncogene homolog 2 RRAS2
R.KFQEQECPP(S*)PEPTRK.E S186 Yes MS2, MS3 DNA damage kinase
NP_031381 Heat shock 90kDa protein 1, beta HSP90AB1




























Ref Seq Protein Name, Sequence Site Gene Novel Site MSn Motif GO Function
NP_612433 Kinesin family member 12 KIF12
R.VTTRPQAPK(S*)PVAK.Q S236 Yes MS2, MS3 proline-directed
NP_079119 Cytochrome b reductase 1 CYBRD1
R.NLALDEAGQRS(T*)M. T285 Yes MS2 acidophilic
NP_001037857 Mucin 1 isoform 7 precursor MUC1
R.DTYHPMSEYPTYH(T*)HGR.Y T118 Yes MS2, MS3 (unfiltered) N/A
NP_000330
Solute carrier family 12 (sodium/chloride transporters), 
member 3 SLC12A3
R.GARP(S*)VSGALDPK.A S811 Yes MS2 basophilic
NP_000329 Sodium potassium chloride cotransporter 2 SLC12A1
K.IEYYRN(T*)GSISGPK.V T118 No MS2, MS3 N/A

























4 Application of urinary exosomes analysis using polyclonal antibodies  
4.1 Introduction 
4.1.1 Bartter syndrome type I * 
The potential clinical usefulness of urinary exosomes was demonstrated using the 
well-defined renal tubulopathy, Bartter syndrome type I, as an example. Patients with 
Bartter syndrome type I, have mutations in the SLC12A1 gene, which encodes for the 
NKCC2  sodium potassium chloride cotransporter 2 protein. The NKCC2 protein is 
expressed on the apical membrane of the thick ascending limb of Henle (TAL) [48].  It is 
the main cotransporter of sodium and chloride in the TAL [49]. 
 Patients with Bartter syndrome type I become apparent already in utero or later in 
infancy [50].  Clinical features of Bartter syndrome type I include dehydration with low 
blood pressure, seizures, tetany (involuntary contraction of muscles), muscular weakness, 
paresthesias (feeling of numbness of the hands and feet) and joint pain due to 
chondrocalcinosis (calcification within tissues) [51].  Physiologic features include 
hypercalciuria, which results in nephrocalcinosis, deposition of calcium in the kidney, 
and renal failure [50, 51].  The mutation in the NKCC2 cotransporter leads to loss of 
function, resulting in salt wasting in the thick ascending limb and volume contraction 
which also affects the absorption of calcium and magnesium, resulting in 
hypermagnesiuria and hypercalciuria [50]. 
Patients with Bartter syndrome type I should not receive a treatment with thiazides 
 
* This portion of the chapter was published as: Gonzales PA, Pisitkun T, Hoffert JD, Tchapyjnikov D, Star 
RA, Kleta R, Wang NS, Knepper MA.  Large-scale proteomics and phosphoproteomics of urinary 




because it would block the salt reabsorption in the distal convoluted tubule (DCT), which 
will deprive the kidney of the compensatory mechanism that works through the thiazide-
sensitive cotransporter (NCC) protein [50].  The NCC protein is functionally expressed 
on the apical membrane of the distal convoluted tubule of the kidney [49, 52].  It 
reabsorbs sodium and chloride and it is “essential for sodium chloride conservation in the 
kidney” [52].  The purpose of this part of the research is to use the anti-NKCC2 and anti-
NCC polyclonal antibodies to qualitatively analyze samples obtained from patients 
clinically diagnosed with Bartter syndrome type I. 
4.1.2 Mutation of ABCC4 gene 
In addition, we generated a polyclonal antibody by designing a synthetic peptide 
corresponding to the sequence of the multidrug resistance protein 4, MRP4.  The gene 
coding the MRP4 protein, ABCC4, is located in chromosome 13 and its product has a 
length of 1,325 amino acids.  The multidrug resistance protein 4 is a member of the C 
subfamily ATP-binding cassette (ABC) transporters.  The main characteristics of the 
ABCC transporters are the ability to bind and to hydrolyze ATP to drive translocation of 
their substrates across membranes against a diffusion gradient [53].  The protein contains 
two membrane-spanning domains and each consists of six transmembrane helices with 
two cytosolic ATP-binding domains [53].  It is an organic anion transporter localized in 
the apical proximal tubule of the kidney. 
The ABCC4 gene contains 31 exons and it is highly polymorphic with at least 25 
non-synonymous SNPs [53].  In general, a person’s genome contains unique SNPs that 
are not responsible for a disease state but have the potential to be disease biomarkers.  




gene product.  The specific non-synonymous polymorphism on the ABCC4 gene has the 
potential to affect the protein expression.  One type of mutation in the gene is due to the 
single nucleotide polymorphism (SNP) of thymine (T) to cytosine (C) located in exon 2, 
IVS2-5T>C.  This SNP causes the deletion of 121 base pairs and results in a short gene 
product (67 amino acids) and a normal gene product (1,325 amino acids).  Thus, the 
patients that have this homozygous splice site mutation in the ABCC4 gene abnormally 
express a short-form of protein in addition to a normal protein.  The purpose of the 
collaboration was to develop an affinity-purified antibody that would recognize the short 
and normal gene products and to qualitatively analyze the isolated urinary exosomes from 
these patients. 
4.1.3 Designing anti-human polyclonal antibodies 
The implementation of proteomic studies in urinary exosomes requires the use of 
suitable antibodies.  These antibodies can be monoclonal and polyclonal.  Polyclonal 
antibodies are produced against synthetic peptides (20-25 amino acids in length) 
corresponding to the protein of interest which are called immunizing peptides.  The 
characteristics used to select candidates for immunizing peptides are immunogenicity, 
specificity and the lack of post-translational modifications [54]. 
The immunogenicity of a peptide sequence in a protein is determined by the 
content of charged amino acids, which are aspartic acid (D), arginine, glutamic acid (R), 
lysine (K) and histidine (H) and polar amino acids which are serine (S), threonine (T), 
tyrosine (Y), asparagines (N), and glutamine (Q).  In general it is preferable to have the 
least number of non-polar amino acids; alanine (A), valine (V),  leucine (L), isoleucine 




proline (P) moiety is helpful because the peptide sequence is less likely to have secondary 
structures, α-helices and β-sheets, that would be obstructive.  We used programs such as 
Emboss Lite (http://helixweb.nih.gov/emboss-lite/protein.hrml) to aid in the design of 
these synthetic peptides. 
The Kyte-Doolittle hydropathy index measures the hydrophilicity and 
hydrophobicity of the amino acids in the protein sequence.  Hydrophilic amino acids, 
charged or polar amino acids, are most likely to be found on the exterior of the protein 
and most likely to be immunogenic.  Hydrophobic amino acids, which are non-polar, are 
most likely to be found in the interior of the proteins or in the transmembrane region of 
the cell and less likely to be immunogenic. 
The specificity of the antibody is determined by the level of recognition of the 
intended target protein.  A BLAST analysis (National Center for Biotechnology 
Information, www.ncbi.nlm.nih.gov/BLAST/) is used to determine if the peptide 
sequence is specific for the intended target protein.  The peptide sequence of the protein 
is searched for motifs that would indicate possible post-translational modifications near 
or on the site of the epitope. 
We proposed to qualitatively assess patients’ samples by generating a polyclonal 
antibody to bind to an epitope in the amino-terminal of the human MRP4 protein; and to 
use previously generated polyclonal antibodies for NKCC2 and NCC.  The purpose of 
producing polyclonal antibodies to recognize epitopes in human proteins is for the future 
use in proteomic studies involving immunoblotting.  Our hypothesis is that the affinity-




urinary exosomes samples obtained from the patients; and that the Bartter syndrome type 
I patient samples will show the absence of the NKCC2 protein band. 
4.2 Methods and Materials 
4.2.1 Patients with Bartter Syndrome Type I  
We collected spot urine samples from two patients with clinically diagnosed 
Bartter syndrome type I.  The patients were enrolled in the institutional review board–
approved protocol 76-HG-0238.  We obtained written informed consent from the parents 
and/or patient.  We collected urine samples from healthy humans and used them as 
controls.  We processed all samples using the differential centrifugation method to isolate 
human urinary exosomes described already.  Each sample was prepared for 
immunoblotting by solubilizing in Laemmli buffer (1.5% SDS, 6% glycerol, 10 mM Tris 
HCl, and 60 mg/ml DTT).  The samples, patient 1 and patient 2, and the control samples, 
control 1 and control 2, were loaded onto a 1-D SDS-PAGE gel on the basis of time as 
measured by creatinine excretion.  The proteins were transferred to Immobilon-P 
(Millipore) membranes, blocked, and probed with antigen-specific NKCC2 [55] and 
NCC primary antibodies. We incubated the blots with species-specific fluorescence 
secondary antibodies (Alexa 688) and visualized them using the Odyssey Infrared 
Imaging System (LiCor, Lincoln, NE). 
4.2.2 Patients with mutation in ABCC4 gene 
We collected spot urine samples (100 to 180 ml) from two patients with a splice 
site variation in the ABCC4 gene.  We obtained written informed consent from the 
patients.  We collected urine samples from healthy humans and used them as controls.  




urinary exosomes described already.  Each sample was prepared for immunoblotting by 
solubilizing in Laemmli buffer (1.5% SDS, 6% glycerol, 10 mM Tris HCl, and 60 mg/ml 
DTT).  
The samples, patient 3 and the control, were loaded onto a 1-D SDS-PAGE gel 
and the samples, patient 4, and the control, were loaded onto another 1-D SDS-PAGE gel 
on the basis of time as measured by creatinine excretion.  The proteins were transferred to 
Immobilon-P (Millipore) membranes, blocked, and probed with a commercially available 
antigen-specific MRP4 primary antibody (Abcam).  We incubated the blots with species-
specific fluorescence secondary antibodies (Alexa 688) and visualized them using the 
Odyssey Infrared Imaging System (LiCor, Lincoln, NE). The commercially available 
MRP4 antibody is a rat monoclonal antibody corresponding to amino acids 372-431 of 
human MRP4. 
 The samples, patient 3, the control, patient 4, and the control were loaded onto a 
1-D SDS-PAGE gel on the basis of time as measured by creatinine excretion.  The 
proteins were transferred to nitrocellulose membranes, blocked and probed with the 
antigen-specific polyclonal MRP4 primary antibody.  We incubated the blot with species-
specific fluorescence secondary antibody (Alexa 688) and visualized it using the Odyssey 
Infrared Imaging System (LiCor, Lincoln, NE). 
4.2.3 Polyclonal antibodies 
4.2.3.1 Multidrug resistant protein 4 
The MRP-4 protein contains 1,325 amino acids, and we designed two synthetic 
peptides with epitopes in the first 67 amino acids of the protein.  The synthetic peptide 1 




LPVYQEVKPNPLQDANLC.  The synthetic peptide 2 starts at position 32 and ends at 
position 53.  The sequence is KIGHKRRLEEDDMYSVLPEDRS.   
The online software program Emboss Lite (http://helixweb.nih.gov/emboss-lite, 
previously known as GCG-Lite) was used to determine the hydropathy (hydrophylicity 
and hydrophobicity) parameters.  We used the ‘pepPlot’ program to output the 
hydropathy parameters.  We used the ‘Motifs’ program to determine the most common 
post-translational motifs found in the sequence of the protein.  We used the protein 
BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) analysis to determine whether these 
peptide sequences are unique to the MRP4 protein.   
The peptides were synthesized and purified by high performance liquid 
chromatography at Lofstrand Labs Limited (Gaithersburg, MD).  A cysteine residue was 
added to the carboxyl terminal which enabled the peptide to be covalently attached to the 
resin for affinity purification of the antibody.  The cysteine residue enables the peptide to 
be conjugated to the carrier protein, keyhole limpet haemocyanin (KLH), for the 
immunizing injection.  The immunization of the rabbits was done at Antibodies 
Incorporated (Davis, CA).  The rabbits were immunized using Freund’s complete 
adjuvant and the serum was collected as bleeds for affinity-purification of the polyclonal 
antibody. 
4.2.3.2 Thiazide-sensitive co-transporter 
The thiazide-sensitive co-transporter, NCC, protein is located in the distal 
convoluted tubule of the nephron in the kidney.  The protein expressed in humans 




found in the human protein.  The sequence starts at position 76 and ends at position 97, 
and it is PGEPRKVRPTLADLHSFLKQEG. 
4.2.3.3 Sodium potassium chloride co-transporter 2 
 The sodium potassium chloride co-transporter 2, NKCC2, protein is located in the 
thick ascending limb of the nephron in the kidney.  The protein expressed in humans 
contains 1,099 amino acids. The synthetic peptide for the polyclonal antibody, L320, was 
designed against the NKCC2 protein expressed in rats which contains 1,095 amino acids 
[52].  The sequence starts at position 33 and it ends at position 55.  The sequence is 
SDSTDPPHYEETSFGDEAQNRLK. 
4.2.4 Affinity purification of polyclonal antibodies 
 The synthetic peptides which contain terminal cysteine residues are immobilized 
permanently on a column resin prior to purification of polyclonal antibody from serum.  
The resin is a custom-made affinity resin for purification of antibodies.  The resin is 
porous, crosslinked and it contains 6% beaded agarose activated with iodoacetyl groups. 
These iodoacetyl groups react with the exposed sulfhydryls (-SH) on the cysteine 
residues of the synthetic peptides to form covalent and irreversible thioether bonds.  
 We prepared the peptide columns using 2 mg of the synthetic peptide and 
followed the protocol of the SulfoLink Kit® (Pierce).  Rabbit 316 was immunized with 
synthetic peptide 1 and rabbit 319 was immunized with synthetic peptide 2.  The rabbit 
serum bleed was diluted in an equal volume of PBS, and were added to the peptide 
column in 2 ml aliquots.  The sample was left in the column for at least 15 minutes 




entire sample is added to the column, then the column is washed to get rid of unbound 
sample.  The purified antibody is eluted from the column in 1mL fractions, with an acidic 
elution buffer, 0.1M glycine-HCl at pH 2.5-3.0.  The eluted sample is collected in tubes 
containing 200 μl Tris buffer (pH 8, 1M) to neutralize elution.  We collected seven 
fractions and monitored by measuring the optical density at 280 nm.  We expect the 
optical density to be the highest for fractions 3, 4 and 5.  Once the optical density was 
measured and we added 15 μl of 100 mM sodium azide to preserve the purified antibody.  
4.2.5 Characterization of polyclonal antibody 
 The MRP4 antibody was characterized by immunoblotting where we expect to 
see a predominant band in the tissue in which it is shown to be expected.  We obtained 
tissue sample from the human kidney cortex and outer medulla, and a predominant band 
is expected at the glycosylated molecular weight of 170 kD.  The molecular weight 
without glycosylation is 146 kD.  The predominant band is expected in the membrane 
fractions and not in cytosol of the human kidney cortex and outer medulla.  The 
predominant band is not expected in the tissue sample when the antibody was pre-
absorbed with the immunizing peptide. 
4.3 Results 
4.3.1 Bartter syndrome type I 
An example of the utility of exosome analysis is shown in Figure 4.1, describing 
immunoblotting in patients with Bartter syndrome type I, associated with mutations in the 
SLC12A1 gene, which encodes for the NKCC2 sodium-potassium-chloride cotransporter 
protein [51].  Urine samples were obtained from two patients (patients 1 and 2) with 





Figure 4.1 Disease-related protein NKCC2 and Bartter syndrome Type 
1.  (A) Details of clinical phenotype for patients with Bartter syndrome 
type I, patient 1 and patient 2.  (B) Ultrasound images showing calcium 
deposits (white arrowheads) in the kidneys of patients 1 and 2.   
(C) Immunoblot of urinary exosomes samples from patient 1, patient 2, 
control 1 and control 2 using polyclonal rabbit anit-NKCC2 and NCC. 
 




by the ultrasound images showing deposits of calcium in the kidney also known as 
nephrocalcinosis [50, 51]
 
(Figure 4.1B) and other typical laboratory findings.  The two 
urinary exosome samples obtained from the patients with Bartter syndrome type I were 
analyzed by immunoblotting for the presence of the NKCC2 protein (Figure 4.1C). 
Compared with the respective control samples, patients 1 and 2 showed an absence of the 
NKCC2 protein bands, expected at 160 kD for monomeric NKCC2 and 320kD for 
dimeric NKCC2.  In addition, the samples (patients 1 and 2) were probed for the thiazide-
sensitive co-transporter (NCC) protein to ensure that urinary exosomes were successfully 
isolated and loaded properly.  Strong NCC bands were obtained in samples from both 
patients with Bartter syndrome type I and control samples.  
 The polyclonal antibodies used for the immunoblotting of the patient samples 
were generated against synthetic peptide sequences in the NKCC2 and NCC proteins. 
The anti-NKCC2 polyclonal antibody was generated against a 23-amino acid synthetic 
peptide at the amino-terminal of the protein in the rat proteome. This antibody was 
previously characterized in kidney tissue samples obtained from rats [55].  The synthetic 
peptide sequence was analyzed using the BLAST analysis tool to determine if the 
polyclonal antibody would recognize the epitope in the human protein.  The peptide 
sequence matches 19 amino acids out of 21 amino acids found in the human NKCC2 
protein.  The anti-NCC polyclonal antibody was generated against a 22-amino acid 
synthetic peptide of the protein in the human proteome.  The sequence matches the NCC 
protein in human, horse, rat, cow, chimpanzee, rhesus monkey and dogs.   The anti-NCC 




4.3.2 Mutation of ABCC4 gene 
Urinary exosomes samples from two patients with a mutation of the ABCC4 
gene, which produces a short-form and normal MRP4 protein, were analyzed by 
immunoblotting.  A commercially-available monoclonal antibody against MRP4 was 
used to detect expression changes in MRP4 protein (Figure 4.2).  The commercial 
monoclonal antibody, anti-MRP4, was generated to recognize an epitope in the carboxyl-
terminal of the protein, amino acids 372-431.  We generated a polyclonal antibody to 
bind to an epitope in the amino-terminal of the MRP4 protein.  Synthetic peptide 1 targets 
amino acids 2 to 19 and synthetic peptide 2 targets amino acids 32 to 53 of the MRP4 
protein. 
 
Figure 4.2 Genetic mutation of ABCC4 results in short-form and 
normal MRP4 protein.  Patient samples (patient 3 and patient 4) and 
control samples (control 3 and control 4) were probed with commercial 
monoclonal anti-MRP4 antibody.  Expected molecular weight for normal 
protein is 170 kD and for the short protein is between 15 and 20 kD. 
 
The synthetic peptide 1 has 6 amino acids that are either charged or polar. Also, it 
contains three prolines, which are helpful in preventing free rotation and there is less 




either charged or polar. It contains one proline and there are only four non-polar amino 
acids.  The software program, Emboss Lite, uses the Kyte-Doolittle method for 
calculating the hydropathy index, hydrophilic and hydrophobic tendencies, evaluated 
systematically for each amino acid in the sequence [56].  The hydropathy index was 
calculated for the first 60 amino acids which includes the sequence for the epitopes, 
amino acids 2 to 19 (synthetic peptide 1) and amino acids 32-53 (synthetic peptide 2).  
Both sequences target epitopes that are hydrophilic and likely to be immunogenic (Table 
4.1).  
Both peptide sequences were analyzed using the BLAST tool to determine their 
specificity for the MRP4 protein.  The results from this analysis show that synthetic 
peptide 1 highly matches the MRP4 protein in humans, chimpanzee, and rhesus monkey 
as defined by the parameters used in the BLAST search.  Synthetic peptide 2 highly 
matches the MRP4 protein in humans, cows, chimpanzee, rhesus monkey and dogs.  In 
addition, the MRP4 protein sequence was analyzed for post-translational modifications 
that could potentially mask the epitope site using the Emboss Lite program.  A tyrosine 
phosphorylation site is predicted between amino acids 37 to 45, which are found in the 
epitope for synthetic peptide 2.  
The antibody fraction purified from rabbit serum 316 has a concentration of μg/μl 
and the antibody fraction purified from rabbit serum 319 has a concentration of μg/μl.  
The antibodies generated with synthetic peptide 1 and 2, were characterized in kidney 
tissue samples where the MRP4 protein is expected to be expressed.  The MRP4 protein 
is expected in the kidney cortex and outer medulla, which contain the proximal tubule. 




expected molecular weight is 146 kD.  As shown in Figure 4.3, antibody 316 fractions 4 
and 5 do not show the expected band; antibody 316 fraction 3 shows the expected band 
very faintly at 170 kD.  Antibody 319 fraction 5 (319-5) shows a strong band at the 
expected molecular weight (Figure 4.4A).   
 
Figure 4.3 Characterization of rabbit polyclonal anti-MRP4 antibody 
(316) generated with synthetic peptide 1 (LPVYQEVKPNPLQDANLC).  
Three fractions (316-3, -4, and-5) were used to probe kidney tissue 
samples from human cortex (Hctx), rat cortex (Rctx), mouse cortex (Mctx) 
and human urinary exosomes (H UExo).   
 
Antibody 319 fraction 5 was characterized in the membrane and cytosol fractions 
of human cortex and medulla.  The membrane fractions of the tissue sample show strong 
bands at the expected molecular weight and the cytosol fractions do not (Figure 4.4B).  
The antibody 319-5 was pre-absorbed with synthetic peptide 2; the membrane and 
cytosol fractions were incubated with this pre-absorbed antibody and the expected bands 





Figure 4.4 Characterization of rabbit polyclonal anti-MRP4 antibody 
(319) generated with synthetic peptide 2 
(KIGHKRRLEEDDMYSVLPEDRS).  (A) Fraction 4 was used to probe 
kidney tissue samples from human cortex (Hctx), rat cortex (Rctx), mouse 
cortex (Mctx) and human urinary exosomes (H UExo).  Expected 
molecular weight is 170 kD.  (B)  Fraction 4 was used to probe kidney 
tissue membrane (Mem Hctx) and cytosolic (Cyt Hctx) samples.   
(C) Fraction 4 was incubated with synthetic peptide 2 and membrane and 




The samples from patient 4, patient 5, control 4 and control 5 were incubated with 
polyclonal antibody 319-5.  Patient 4 and patient have a mutation in the ABCC4 gene 
which causes the expression of a normal protein (1,325 amino acids) and a short-form 
protein (67 amino acids).  The immunoblotting (Figure 4.5) shows the expected band for 
the MRP4 protein at 170 kD in the control samples and the patient samples.  In addition, 
there are bands between 15 and 20 kD (with glycosylation) present in patient 4 and 
patient 5 but missing in control 4 and control 5. 
 
Figure 4.5 Genetic mutation of ABCC4 results in production of short-
form and normal MRP4 protein.  Patient samples (patient 3 and patient 4) 
and control samples (control 3 and control 4) were probed with rabbit 
polyclonal anti-MRP4 antibody (319 fraction 4).  Expected molecular 
weight for the normal protein is 170 kD and for the short-form protein is 





4.4.1 Bartter syndrome type I 
As illustrated in Figure 4.1, analysis of human urinary exosomes by mass 
spectrometry (Chapter 3) and immunoblotting can provide information with regard to 
genetic diseases involving apical membrane proteins as shown by the qualitative 
assessment of urinary exosome samples from patients with Bartter syndrome type I.  
Mutations in the SLC12A1 gene cause Bartter syndrome type I [49].  Many such 
mutations presumably result in misfolding of the NKCC2 protein, preventing the apical 
delivery of the protein and therefore preventing incorporation into urinary exosomes.  
The anti-NKCC2 and anti-NCC polyclonal antibodies generated against synthetic 
peptides were used in the immunoblotting technique to complete the qualitative 
assessment.  The anti-NKCC2 polyclonal antibody was generated against a 23-amino 
acid synthetic peptide that matches the protein in the human proteome [53].  The anti-
NCC polyclonal antibody was generated against a 22-amino acid synthetic peptide that 
matches the protein in the human proteome.  Immunoblotting analysis of the urinary 
exosome samples from Bartter syndrome type I patients showed a complete absence of 
the NKCC2 protein.  As a loading control, the patient samples showed the presence of the 
NCC protein, found in the distal convoluted tubule of the kidney and was identified in the 
proteome of the urinary exosomes. 
4.4.2 Mutation in ABCC4 gene 
The urinary exosomes samples from two genotyped patients with a mutation of 
the ABCC4 gene, producing a short and normal MRP4 protein, were analyzed by 




the renal proximal tubule [57].  There are 98 single nucleotide polymorphisms (SNPs) in 
the ABCC4 gene and there is little evidence of a complete loss of function of the MRP4 
protein [58].  The single nucleotide polymorphism in the intron region between exon 2 
and 3, IVS2-5T>C, results in the production of a truncated protein, 67 amino acids in 
length, and a normal protein, 1,325 amino acids in length.  This mutation of the ABCC4 
gene could have an effect on the organic anion transport in and it might be involved in 
drug resistance.  We wanted to conduct an initial qualitative analysis of urinary exosomes 
samples from patients with this mutation. 
The immunoblotting analysis was done with a commercially-available 
monoclonal antibody against MRP4 (Figure 4.2).  The commercial monoclonal antibody, 
anti-MRP4, recognizes an epitope in the carboxyl-terminal of the protein, amino acids 
372-431.  We generated a polyclonal antibody targeted to an epitope in the amino-
terminal of the MRP4 protein.  The polyclonal antibody generated was raised against a 
synthetic peptide that was designed to be immunogenic, unique and lacks-post 
translational modifications.  The synthetic peptide was determined to be highly 
hydrophilic and as result expected to be immunogenic.  The immunogenicity was 
determined using the hydropathy index using the Kyte-Doolittle method for calculating 
hydrophobicity and hydrophilicity of peptide regions in a protein.  A hydrophobic region 
is more likely to span across the membrane and less likely to be immunogenic.  A 
hydrophilic region is more likely to be exposed on the surface of the protein and more 
likely to be immunogenic.  A hydrophobic amino acid has a positive index value and a 




The polyclonal antibody (319-5) was characterized in kidney tissue samples 
(Figure 4.4).  The patient samples were analyzed by immunoblotting using this 
polyclonal antibody.  The patient samples (Figure 4.5) showed a band at the expected 
molecular weight of the normal MRP4 protein, 170 kD and a fainter band at the expected 
molecular weight for the short-form protein, between 15 and 20 kD.  The band for the 
short-form protein was missing from the control samples.  
4.5 Conclusion 
Urinary exosome analysis has the potential of usefulness in genetic mutation 
analysis.  This potential application was demonstrated to be feasible using immuno-
assays such as immunoblotting with highly specific antibodies.   
As examples of the usefulness of the urinary exosomes analysis in genetic 
mutation analysis, we qualitatively analyzed samples from patients clinically diagnosed 
with the well-defined renal tubulopathy, Bartter syndrome type I, and samples from 
patients with a single nucleotide polymorphism (SNP) in the ABCC4 gene.  The anti-
NKCC2 polyclonal antibody was used to probe the urinary exosomes patient samples 
(patient 1 and patient 2) and these showed an absence of the NKCC2 protein band.  The 
anti-MRP4 polyclonal antibody was generated to probe urinary exosomes patient samples 
(patient 3 and patient 4) and showed a strong band for the normal MRP4 protein and faint 
band for the short-form MRP4 protein.  Genetic mutation analysis of well-characterized 
patient samples is the first step in application of urinary exosomes analysis in large-scale 
biomarker discovery.
Table 4.1.Kyte-Doolittle Hydropathy Index for MRP4 protein
The hydropathy values are shown for amino acids 1 to 60 (out of 1,325)
Position Residue Result Position Residue Result
1 M 0.000 31 F 0.256
2 L 0.000 32 K -0.600
3 P 0.000 33 I -0.711
4 V 0.000 34 G -1.033
5 Y 0.033 35 H -1.033
6 Q -0.356 36 K -1.733
7 E -1.167 37 R -1.689
8 V -1.167 38 R -2.578
9 K -1.211 39 L -2.922
10 P -1.456 40 E -2.356
11 N -1.456 41 E -2.067
12 P -0.867 42 D -1.656
13 L -1.722 43 D -0.689
14 Q -0.867 44 M -0.689
15 D -0.411 45 Y -0.478
16 A -0.111 46 S -0.478
17 N -0.433 47 V -0.478
18 L -0.389 48 L -0.589
19 C 0.311 49 P -0.889
20 S 1.011 50 E -1.133
21 R 0.711 51 D -1.400
22 V 1.000 52 R -1.444
23 F 1.000 53 S -1.911
24 F 0.333 54 Q -2.122
25 W 0.244 55 H -2.122
26 W 1.167 56 L -1.311
27 L 1.011 57 G -1.200
28 N 0.267 58 E -1.156
29 P 0.456 59 E -0.456





5 Normal variability and normalization of urinary exosomes: Gender 
Proteomics 
5.1 Introduction 
Urinary exosomes analysis provides a non-invasive window to cell processes in 
the kidney and a potential means of enrichment of disease biomarkers. Future biomarker 
studies using tandem mass spectrometry (LC-MS/MS) and immunoblotting require 
knowledge of normal variability among human populations and development of 
normalization techniques. The qualitative approach used to identify proteins in a sample 
as shown in Chapter 3 is not sufficient when developing strategies for biomarker studies. 
For this we propose to use a quantitative approach in addition to a qualitative approach.  
The quantification of expressed proteins using tandem mass spectrometry in a sample can 
be accomplished by a label-free approach [21, 60].  The quantification of protein-fold 
change using the immunoblotting technique can be accomplished by normalizing the 
loading of samples based on equal time. 
The two types of approaches commonly used for quantification of protein 
expression using tandem mass spectrometry are label-based and label-free.  Label-based 
approaches generally use chemical labels “to discriminate between a peptide in one 
sample and the same peptide in another sample” [21].  The difference in the masses is 
detected by the mass analyzer providing quantitative data. There are currently many 
methods that are considered label-base approaches such ICAT, IVICAT [61], SILAC and 




Label-free approaches use direct comparison of peptide peak intensities.  An 
important factor in this approach is the mass accuracy of the analyzer in the first stage of 
mass spectrometry.  The major advantages of this approach in future biomarker studies 
are that there is no added cost for use of labeling reagents and its application is not 
limited by the number of samples as some label-based approaches. 
We proposed to study the normal variability between proteomes of female and 
male urinary exosomes.  In the process, we developed valuable knowledge and tools to 
quantitatively analyze proteomic data.  The quantification of the tandem mass 
spectrometry data is a relative quantification and was done using a label-free approach. 
The relative quantification of protein abundance between these two samples is 
accomplished by plotting the intensity of the signal as the peptide is eluted from the 
chromatographic column [18].  The area under the curve of this plot is the extracted ion 
current (XIC) as defined by Ong and Mann.  The XIC of the peptide is linearly related to 
the amount of the peptide and can be compared when the same peptide is identified in 
two different chromatographic runs.  In our case the two chromatographic runs are the 
two samples of isolated urinary exosomes from males and females. 
Our hypothesis for the quantitative study of tandem mass spectrometry data is that 
there should be a high concordance between proteomes of urinary exosomes isolated 
from males and females.  We define high concordance as a change of less than 5% of the 
total number of proteins between the proteomes of males and females.  In addition, any 





In collaboration with Dr. Jeffrey Kopp from the National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK), we extended our study to analyze the proteins 
that have a 2-fold increase/decrease by the immunoblotting technique.  The 
immunoblotting technique will be normalized by loading isolated urinary exosomes 
samples based on timed urine collection.  In this study we plan to enroll three female and 
three male volunteers. 
Implementing a normalization method to analyze isolated urinary exosomes 
samples using the immunoblotting assay is an important quantitative approach. In our 
research we propose to use timed urine collection.  We hypothesize that time will linearly 
correlate with urinary exosomes excretion which will be quantified by signal intensity of 
multivesicular body (MVB) markers, TSG-101 and Alix [7]. 
5.2 Methods and Materials 
5.2.1 Tandem mass spectrometry study 
Urine was collected from eight healthy humans: Four men (aged 22 to 33) and 
four women (aged 24 to 35) (National Institute of Diabetes and Digestive and Kidney 
Diseases Clinical Research Protocol 00-DK-0107).  Fifty milliliters per subject was 
collected.  Protease inhibitors were added (1.67 ml of 100 mM NaN3, 2.5 ml of 11.5 mM 
4-[2-aminoethyl] benzenesulfonyl fluoride, and 50 ml of 1 mM leupeptin).  The samples 
from men were mixed and the samples from women were mixed.  The two mixed 
samples were centrifuged at 17,000 x g for 10 min at 4°C.  The 17,000 x g supernatant 
was ultracentrifuged at 200,000 x g for 1 h at 25°C.  The ultracentrifugation step was 
repeated 3 additional times, adding new 17,000 x g supernatant volume each time to each 




of the 12 pellets was suspended with 50 μl of “isolation solution” (10mM triethanolamine 
and 250 mM sucrose).  The suspensions were pooled together. 
To denature the zona pellucida domains in the Tamm-Horsfall protein, we mixed 
the re-suspended pellets with 200 mg/ml dithiothreitol (DTT) at 95°C for 2 min.  The re-
suspended pellets were added to ultracentrifuge tubes, and isolation solution was added to 
increase the volume to 8 ml.  The samples were ultracentrifuged at 200,000 x g for 1h at 
25°C. The pellets were suspended in 50 μl of isolation solution and frozen at -80°C. 
5.2.1.1 In-Gel Trypsin Digestion  
The protein concentration was determined using the Bradford Assay.  The male 
sample had a concentration of 0.76 mg/ml and the female sample had a concentration of 
0.85 mg/ml.  The male mixed sample and the female mixed sample were solubilized in 
Laemmli sample buffer (1.5% SDS, 6% glycerol/10 mM Tris HCl, and 60 mg/ml DTT). 
Proteins in the exosome samples were separated by 1D SDS-PAGE using a Bio-Rad 
Ready Gel 4 to 15% polyacrylamide gradient gel with 36 μg in each lane.  The gel was 
stained with Colloidal Coomassie Blue (GelCode Blue Stain Reagent; Pierce, Rockford 
IL) for 10 min and destained using ddH2O (2 x 30 min).  The gel was divided from top to 
bottom into 20 1-mm strips over the entire molecular weight range of the gel.  Each strip 
was diced into small pieces (1 mm
3
) and placed into labeled centrifuge tubes. 
The gels pieces were destained by adding 100 μl of 25 mM ammonium 
bicarbonate (NH4HCO3)/50% acetonitrile (ACN) for 10 min and were dried using a 
SpeedVac.  The samples were reduced in a solution of 10 mM DTT and 25 mM 
NH4HCO3 at 56°C for 1 h.  The samples were alkylated in a solution containing 55 mM 




gel pieces were washed with 25 mM NH4HCO3 and dehydrated in a solution containing 
25 mM NH4HCO3 and 50% ACN.  The samples were dried using the SpeedVac.  The 
samples were rehydrated in a solution containing 12.5 ng/μl trypsin (V5113; Promega, 
Madison, WI) in 25 mM NH4HCO3 and digested overnight at 37°C.  Peptides were 
extracted using 50% ACN/0.1% formic acid (FA).  The extracted samples were dried 
using the SpeedVac to remove ACN and then reconstituted with 0.1% FA.  All 40 
peptide samples (20 peptide sample from male and 20 peptide samples from female) were 
desalted using C18 Zip Tips (Millipore,Billerica, MA) before analysis by mass 
spectrometry. 
5.2.1.2 Nanospray LC-MS/MS 
A high-accuracy Fourier transform mass spectrometer, FT-ICR (Thermo Electron 
Corp.) equipped with a nano-electrospray ion source was used to acquire m/z ratios in 
precursor ions (MS1).  And high-sensitivity linear ion trap mass analyzer, LTQ (Thermo 
Electron Corp.) was used to acquire m/z ratios in fragmented ions (MS2) scans.  To 
reduce further the sample complexity before mass analysis, we injected the tryptic 
peptides extracted from each gel slice using an Agilent 1100 nanoflow system (Agilent 
Technologies, Palo Alto, CA) into a reversed-phase liquid chromatographic column 
(PicoFrit, Biobasic C18; New Objective, Woodburn, MA).  This LC-MS/MS method 
allows the acquisition of raw data files that are the MS/MS scans of the top three highest 
intensity peaks after fragmentation with collision-induced dissociation in the FT-ICR 
mass analyzer. 
5.2.2 Analysis of Data  




human protein database by using the BIOWORKS software (Thermo Finnigan). 
BIOWORKS utilizes SEQUEST, and to identify all peptide sequences, we searched the 
raw data files using the target-decoy approach. 
To apply the target-decoy database searching strategy, we used the NHLBI 
Proteomics Core Facility in-house software to create a composite database containing the 
forward and reverse sequences of the non-redundant NCBI Reference Sequences 
(RefSeq) human protein database released on January 26, 2007.  We searched separately, 
the raw data files for the female and male samples against this composite database. After 
the search, we assessed the False-Discovery Rate (FDR) by the number of peptides 
matched from the reversed sequences. 
The parameters that determine the stringency of the filtering criteria include 
XCorr, Sp rank, and delta Cn.  These parameters were incrementally adjusted, thereby re-
ducing the false-discovery identifications until a FDR target was achieved.  In our case, 
the data were filtered to a target of 2% FDR, and the actual FDR was 1.59% for the 
female sample, and 1.71% for the male sample.  The filter settings used for the male 
sample were max Xcorr rank 1, min Sp rank 1, min delta Cn 0.1, charge +1 min Xcorr 
1.91, charge +2 min Xcorr 0, and charge +3 min Xcorr 0. 
5.2.3 Label-free quantification 
The quantification of the male and female samples was carried out using the 
custom computer program, QUOIL (Quantification without Isotope Labeling), developed 
by the NHLBI Proteomic Core Facility [60].  The program requires that one of the 
samples be chosen as the reference sample, this choice has no effect on the final outcome 




containing the chromatographic data were read by the QUOIL program and ion 
chromatograms were reconstructed.  Intensities are counted when these meet pre-defined 
mass tolerance and threshold as well as signal-to-noise ratios.  We pre-defined the 
precursor mass tolerance (m/z) to 0.05 daltons and the minimum signal-to-noise ratio to 
1.5.  These reconstructed ion chromatograms contain peak areas of peptides identified in 
both proteomes [60].  The peak area is calculated by integration using the trapezoidal 
approximation within a defined window around the peak center as shown in Figure 6.x. 
The defined window is determined by the retention time and the peak center is defined by 
the highest peak within that window [60]. 
The ratio of peak areas is calculated (female/male) for all peptides identified per 
protein and were manually inspected.  The ratio of peak areas were log-transformed (log 
base 2) and the median of the log-transformed ratios was determined.  The criteria to 
consider proteins as potential candidates of variability between these two proteomes 
were: (1) Proteins with two or more peptides with a peak area ratio less than 1 or greater 
than 1; (2) Reconstructed chromatograms of peak areas pass manual inspection; (3) The 
median of the log-transformed peak area ratios for the protein’s peptides was 2 or greater. 
5.2.3 Immunoblotting study 
5.2.3.1 Urine collection 
Six volunteers were enrolled in the study, three males and three females, for six 
days (National Institute of Diabetes and Digestive and Kidney Diseases Clinical Research 
Protocol).  The first three days were the diet adaptation phase (days 1-3) [62] and the last 
three days were the urine collection phase (days 4-6).  Urine is collected at room 




the collection container (1.67 ml of 100 mM NaN3, 2.5 ml of 11.5 mM 4-[2-aminoethyl] 
benzenesulfonyl fluoride, and 50 ml of 1 mM leupeptin).  During the six day admission, 
volunteers had a normal diet and a water intake appropriate for their body weight.  Table 
6.1 shows the volume of urine collected per 12-hour period per volunteer for the three 
days of urine collection. 
5.2.3.2 Urinary exosome isolation 
The urinary exosomes were isolated from all six 12-hour samples collected from 
each volunteer using the procedure described previously (Chapter 3).  Briefly, a fraction 
of the total volume of 12-hour urine sample is centrifuged at 17,000 x g for 10 min at 
37°C. The 17,000 x g pellet is re-suspended in 1mL of isolation solution, 200 mg of DTT 
is added and the sample is heated to 37°C for 5 minutes. The pellet is vortexed for at least 
5 min to dissolve cross-linked Tamm-Horsfall protein. Isolation solution is added to 
make a total volume of 8 mL and the sample is centrifuged at 17,000 x g for 10 minutes 
at 37°C.  The supernatant is added to the previous 17,000 x g supernatant and 
ultracentrifuged at 200,000 x g for 1 h at 37°C.  Pellets are re-suspended in 0.1% SDS. 
5.2.3.3 Immunoblotting 
Protein concentrations for all samples were determined using the Bradford Assay.  
The samples were solubilized in Laemmli sample buffer (1.5% SDS, 6% glycerol/10 mM 
Tris HCl).  The samples were loaded onto a 1-D SDS-PAGE gel on the basis of timed 
urine collection, the time for loading is 0.07 hours.  The samples were loaded as follows: 
Gel 1 has samples from male volunteer M2 and female volunteer F1; Gel 2 has samples 
from male volunteer M3 and female volunteer F2; Gel 3 has samples from male volunteer 




membranes, blocked, and probed with antigen-specific TSG-101 and Alix primary 
antibodies.  We incubated the blots with species-specific fluorescence secondary 
antibodies (Alexa 688) and visualized them using the Odyssey Infrared Imaging System 
(LiCor, Lincoln, NE). 
5.3 Results 
In this study, we used tandem mass spectrometry to determine the normal 
variability among male and female proteomes isolated from urinary exosomes.  We used 
a high accuracy FT-ICR mass spectrometer to analyze these samples.  The protein 
expression in these samples was quantified using a label-free approach with the NHLBI 
Proteomic Core program, QUOIL. 
A total of 388 proteins were identified from both proteomes in male and female 
samples after target/decoy analysis predicting a false positive identification rate of less 
than 2% for both samples as shown in Table 5.1.  Out of the total 388 proteins identified 
from both proteomes, only 27 proteins were not previously identified in the large-scale 
proteomic analysis of urinary exosomes (Chapter 3).  And among all proteins, only 19 
were identified that differ by at least 2-fold as shown in Table 5.2. 
The immunoblots in Figure 5.1 were incubated with Alix and TSG-101 which are 
markers for multivesicular bodies (MVB). The Alix protein has a 100 kDa molecular 
weight and it is the upper band on the immunoblots. The TSG-101 protein has a 47 kDa 
molecular weight and it is the lower band on the immunoblots.  As shown in Figure 5.1A 
all six samples from male volunteer M-2 have bands for Alix and TSG-101.  Only three 





Figure 5.1 Immunoblots of urinary exosomes samples from three male 
healthy volunteers (M2, M3, M4) and three female healthy volunteers (F1, 
F2, F3).  Six samples were collected per volunteer corresponding to 12-
hour urine collections.  Samples were loaded based on time, t=0.07 hours.  
Anti-TSG101 and anti-Alix antibodies were used to probe samples.  




Figure 5.1B shows that all six samples from male volunteer M-3 have bands for 
Alix and TSG-101.  The last two samples for female volunteer F-2 have bands for TSG-
101.  Figure 5.1C shows that only five samples from male volunteer M-4 show bands for 
TSG-101 and Alix.  And only one sample from female volunteer F-3 shows bands for 
TSG-101 and Alix. 
5.4 Discussion 
One of the objectives of this study was to acquire knowledge about the normal 
variability among human populations for future biomarker studies using urinary 
exosomes isolation.  We compared exosomes isolated from pooled samples of urine from 
four normal human females and four human males.  The samples were solubilized in SDS 
and proteins were separated by SDS-PAGE followed by in-gel trypsin digestion of 
contiguous gel slices.  The digests were analyzed by tandem mass spectrometry using the 
FT-ICR mass spectrometer (Thermo-Finnegan LTQ) and we compared the two samples 
quantitatively using a label-free approach with the integration software, QUOIL, 
developed by the NHLBI Proteomic Core.  The relative quantification of protein 
abundance using the QUOIL program was accomplished by plotting the intensity of the 
identified peptide signal as the peptide is eluted from the chromatographic column.  
These reconstructed ion chromatograms contain peak areas of peptides identified in both 
proteomes.  The peak areas were calculated by integration and the ratio of peak areas was 
calculated.  This ratio is log-transformed and the median is used to determine the fold-
change. 
There were 388 proteins identified in both male and female proteomes from 




4.9% of the total number of proteins identified in both proteomes.  This result shows that 
there is high concordance between proteomes of urinary exosomes isolated from males 
and females. 
The second objective of the proposed research was to extend our study to analyze 
the proteins that have a 2-fold change by the immunoblotting technique.  In order to 
quantify protein expression with the immunoblotting technique we proposed to normalize 
samples by loading based on timed urine collection.  We enrolled six healthy volunteers, 
three male and three female for a six-day study.  We collected 12-hour urine samples for 
the last three days of the study.  The urinary exosomes samples were isolated by 
centrifugation and loaded onto SDS-PAGE gels.  The proteins were transferred to 
nitrocellulose membranes and probed with antibodies against MVB markers.  We 
expected a linear correlation of excreted urinary exosomes with timed urine collection, as 
shown by the signal intensity of MVB markers, TSG-101 and ALIX.  The results of the 
normalization did not show a linear correlation of timed urine collection and signal 
intensity of MVB markers. 
5.5 Conclusion 
A total of 388 proteins were identified in the two urine samples after the 
application of high stringency acceptance criteria and target/decoy analysis predicting a 
false positive identification rate of 1%.  Among all proteins, only 19 proteins were 
identified that differ by at least 2-fold between female and male urinary exosomes.   
These include 15 that were lower in female than male samples and 4 that were higher in 
female than male samples.  Therefore, we conclude that there is high concordance 




Finally, the analysis of proteins that differ by at least a 2-fold between female and 
male urinary exosomes depended on implementing a normalization method.  The 
proposed normalization method was to load samples based on timed urine collections.  
The samples were probed with antibodies against MVB markers, TSG101 and Alix.  The 
results did not show correlation between signal intensity of TSG101 and Alix and timed 
urine collection.  A possible explanation is that the excretion of Tamm-Horsfall protein, 
prevent the efficient isolation of urinary exosomes.  Tamm-Horsfall tends to form vast 
aggregates in urine that can entrain the exosomes.   
Table 5.1  Proteins identified in male and female urinary exosomes proteomes










NP_000026 aldolase B, fructose-bisphosphate ALDOB 10 55 11 67
NP_000032 apolipoprotein E precursor APOE 7 23 5 5
NP_000038 arylsulfatase E precursor ARSE 1 1 1 1
NP_000041 argininosuccinate synthetase 1 ASS1 5 13 4 8
NP_000058 carbonic anhydrase II CA2 6 16 6 12
NP_000090 cystatin C precursor CST3 1 4 1 1
NP_000261 purine nucleoside phosphorylase NP 3 4 3 5
NP_000276 Xaa-Pro dipeptidase PEPD 2 6 1 1
NP_000282 phosphoglycerate kinase 1 PGK1 8 19 5 11
NP_000299 cathepsin A precursor CTSA 1 2 1 3
NP_000329 sodium potassium chloride cotransporter 2 SLC12A1 18 99 13 51
NP_000330 solute carrier family 12 (sodium/chloride transporters), member 3 SLC12A3 15 55 5 13
NP_000332 solute carrier family 3, member 1 SLC3A1 6 15 6 13
NP_000334 solute carrier family 5 (sodium/glucose cotransporter), member 1 SLC5A1 2 3 2 4
NP_000356 triosephosphate isomerase 1 TPI1 2 4 2 6
NP_000382 tripeptidyl-peptidase I preproprotein TPP1 2 8 2 6
NP_000395 galactosidase, beta 1 GLB1 10 36 10 52
NP_000434 ATP-binding cassette, subfamily B, member 4 isoform A ABCB4 2 3 3 4
NP_000468 albumin preproprotein ALB 16 42 9 15
NP_000469 tissue non-specific alkaline phosphatase precursor ALPL 3 4 1 4
NP_000477 aquaporin 2 AQP2 2 18 2 12
NP_000498 fructose-1,6-bisphosphatase 1 FBP1 3 4 3 6
NP_000509 beta globin HBB 1 2 1 1
NP_000552 glutathione S-transferase mu 1 isoform 1 GSTM1 3 6 1 2
NP_000615 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 SERPINA5 9 28 6 36
NP_000628 glutathione reductase GSR 1 2 1 1
NP_000657 aminoacylase 1 ACY1 11 19 8 28
NP_000678 S-adenosylhomocysteine hydrolase AHCY 2 4 4 6
NP_000691 annexin I ANXA1 4 9 10 52
NP_000692 Na+/K+ -ATPase alpha 1 subunit isoform a proprotein ATP1A1 21 70 12 26
NP_000704 biliverdin reductase B (flavin reductase (NADPH)) BLVRB 2 4 1 1
NP_000780 angiotensin I converting enzyme isoform 1 precursor ACE 15 51 13 60
NP_000837 glutathione S-transferase A2 GSTA2 3 4 6 14
NP_000840 glutathione S-transferase mu 3 GSTM3 3 4 3 6
NP_000843 glutathione transferase GSTP1 4 12 6 14
NP_000851 hydroxyprostaglandin dehydrogenase 15-(NAD) HPGD 4 8 5 8
NP_000884 kininogen 1 isoform 2 KNG1 6 13 6 22
NP_000918 ATP-binding cassette, subfamily B, member 1 ABCB1 9 37 10 33
NP_001002857 annexin A2 isoform 2 ANXA2 11 31 12 44
NP_001003841 solute carrier family 6, member 19 SLC6A19 1 2 1 8
NP_036344 NADP-dependent leukotriene B4 12-hydroxydehydrogenase PTGR1 2 6 4 8
NP_001005502 carboxypeptidase M precursor CPM 2 5 1 1
NP_001007070 syntenin isoform 3 SDCBP 3 14 3 6
NP_036361 5'-nucleotidase, cytosolic II NT5C2 1 2 1 1
NP_001008741 peptidylprolyl isomerase A-like LOC388817 1 2 1 1
NP_001009881 zinc finger, CCHC domain containing 11 isoform a ZCCHC11 1 25 1 26
NP_001012679
solute carrier family 3 
(activators of dibasic and neutral amino acid transport),
 member 2 isoform a
SLC3A2 5 20 1 7
NP_001014390 heat shock protein HSP 90-beta HSP90AB2P 4 6 2 4
NP_001014436 drebrin-like isoform b DBNL 1 7 1 3
NP_001017421 actin-like protein FKSG30 2 137 2 126
NP_001018017 mucin 1 isoform 3 precursor MUC1 4 30 4 19
NP_001019770 histone cluster 2, H2bf HIST2H2BF 2 4 3 8
NP_003370 ezrin EZR 19 127 10 86
NP_001026888 glycerophosphodiester phosphodiesterase domain containing 3 isoform 1 GDPD3 1 1 1 3
NP_001027467 serine/threonine kinase 24 (STE20 homolog, yeast) isoform b STK24 2 6 2 3
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NP_001027536 gamma-glutamyltransferase 1 precursor GGT1 3 5 1 2
NP_001055 transketolase isoform 1 TKT 1 1 3 4
NP_001060 tubulin, beta 2 TUBB2A 4 7 3 9
NP_060712 solute carrier family 47, member 1 SLC47A1 2 3 3 6
NP_001072 cubilin CUBN 52 238 40 318
NP_074035 smooth muscle myosin heavy chain 11 isoform SM2A MYH11 2 8 1 9
NP_001141 membrane alanine aminopeptidase precursor ANPEP 38 514 31 492
NP_001144 annexin IV ANXA4 12 22 18 40
NP_001145 annexin 5 ANXA5 7 15 3 5
NP_001146 annexin VI isoform 1 ANXA6 14 30 7 18
NP_001166 Rho GDP dissociation inhibitor (GDI) beta ARHGDIB 2 3 2 6
NP_003050 solute carrier family 22 member 4 SLC22A4 1 2 1 2
NP_001227 carbonyl reductase 3 CBR3 1 2 1 3
NP_001279 chloride intracellular channel 1 CLIC1 2 4 1 3
NP_001419 enolase 1 ENO1 17 43 8 48
NP_001485 GDP dissociation inhibitor 2 isoform 1 GDI2 7 17 5 10
NP_001531 heat shock protein beta-1 HSPB1 3 6 6 11
NP_001601 acid phosphatase 2, lysosomal isoform 1 precursor ACP2 4 14 2 7
NP_001604 alpha 2 actin ACTA2 11 133 9 84
NP_001605 actin, gamma 1 propeptide ACTG1 7 117 5 120
NP_001619 aldose reductase AKR1B1 2 11 2 4
NP_001630 serum amyloid P component precursor APCS 4 8 3 6
NP_001638 apolipoprotein D precursor APOD 2 11 8 27
NP_001650 ADP-ribosylation factor 3 ARF3 1 2 1 5
NP_001653 ADP-ribosylation factor 5 ARF5 3 6 3 11
NP_001681 ATPase, H+ transporting, lysosomal V1 subunit A ATP6V1A 12 25 7 13
NP_001683 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 ATP6V1B1 4 9 2 3
NP_001684 vacuolar H+ATPase B2 ATP6V1B2 7 22 4 9
NP_001687 vacuolar H+ ATPase E1 isoform a ATP6V1E1 1 2 2 5
NP_001704 betaine-homocysteine methyltransferase BHMT 4 8 2 4
NP_001738 gelsolin-like capping protein CAPG 7 31 5 15
NP_001748 carbonyl reductase 1 CBR1 3 5 3 8
NP_001760 CD9 antigen CD9 3 19 3 9
NP_001771 CD63 antigen isoform A CD63 3 28 2 30
NP_001782 cell division cycle 42 isoform 1 CDC42 1 2 1 2
NP_001814 brain creatine kinase CKB 6 21 2 3
NP_001879 crystallin, mu isoform 1 CRYM 5 9 4 6
NP_001880 crystallin, zeta isoform a CRYZ 3 3 3 3
NP_071396 kinesin family member 13A KIF13A 1 3 1 2
NP_001926 dipeptidylpeptidase IV DPP4 22 104 20 95
NP_001954 epidermal growth factor (beta-urogastrone) EGF 13 65 11 92
NP_001958 eukaryotic translation initiation factor 4A2 EIF4A2 1 2 1 2
NP_001968 glutamyl aminopeptidase (aminopeptidase A) ENPEP 10 20 10 22
NP_002022 fyn-related kinase FRK 4 6 1 2
NP_002023 ferritin, heavy polypeptide 1 FTH1 1 3 1 1
NP_002037 glyceraldehyde-3-phosphate dehydrogenase GAPDH 5 19 4 10
NP_002049 gamma-glutamyltransferase 2 GGT2 8 53 9 109
NP_002058 guanine nucleotide binding protein (G protein), alpha 11 (Gq class) GNA11 4 9 2 4
NP_002060 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 GNAI1 2 5 1 2
NP_002061 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 GNAI2 5 16 3 8
NP_002063 guanine nucleotide binding protein (G protein), q polypeptide GNAQ 3 11 3 6
NP_002070 aspartate aminotransferase 1 GOT1 6 9 1 2
NP_002077 growth factor receptor-bound protein 2 isoform 1 GRB2 1 1 1 1
NP_002146 heat shock 70kDa protein 6 (HSP70B') HSPA6 2 13 2 6
NP_002188 aconitase 1 ACO1 4 11 3 8
NP_002291 L-lactate dehydrogenase B LDHB 8 33 6 34
NP_002347 myristoylated alanine-rich protein kinase C substrate MARCKS 3 8 2 3
NP_002435 moesin MSN 13 27 11 24
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NP_002515 neuroblastoma RAS viral (v-ras) oncogene homolog NRAS 1 4 1 1
NP_002551 purinergic receptor P2X4 P2RX4 1 6 1 3
NP_002558 prostatic binding protein PEBP1 2 8 2 7
NP_002582 cytosolic phosphoenolpyruvate carboxykinase 1 PCK1 2 3 5 8
NP_002605 PDZ domain containing 1 PDZK1 10 21 5 13
NP_002624 phosphoglucomutase 1 PGM1 6 10 4 6
NP_002635 polymeric immunoglobulin receptor PIGR 6 11 10 20
NP_002645 pyruvate kinase, muscle isoform M2 PKM2 1 3 1 5
NP_002700 protein phosphatase 1, catalytic subunit, beta isoform 1 PPP1CB 1 2 1 2
NP_002785 proteasome beta 2 subunit PSMB2 1 1 1 1
NP_002796 proteasome 26S ATPase subunit 5 PSMC5 1 2 1 5
NP_002859 RAB5B, member RAS oncogene family RAB5B 2 3 1 1
NP_002872 v-ral simian leukemia viral oncogene homolog B RALB 3 7 5 8
NP_002875 RAP1A, member of RAS oncogene family RAP1A 2 10 1 6
NP_002897 radixin RDX 7 11 2 2
NP_003030 solute carrier family 2 (facilitated glucose/fructose transporter), member 5 isoform 1 SLC2A5 4 16 5 10
NP_003032 solute carrier family 5 (sodium/glucose cotransporter), member 2 SLC5A2 4 8 6 11
NP_001883 casein kinase 1, alpha 1 isoform 2 CSNK1A1 1 1 1 2
NP_003051 solute carrier family 22 member 5 SLC22A5 1 2 1 3
NP_003078 synuclein, gamma (breast cancer-specific protein 1) SNCG 2 7 2 6
NP_003095 sorbitol dehydrogenase SORD 2 11 2 4
NP_003121 sorcin isoform a SRI 2 3 1 2
NP_003304 tissue specific transplantation antigen P35B TSTA3 1 1 1 1
NP_003320 thioredoxin TXN 1 6 1 4
NP_003325 ubiquitin-activating enzyme E1 UBA1 3 5 1 1
NP_003339 ubiquitin-conjugating enzyme E2N UBE2N 1 6 1 2
NP_003352 uromodulin precursor UMOD 19 1720 19 1921
NP_003364 vinculin isoform VCL VCL 2 3 2 2
NP_003365 voltage-dependent anion channel 1 VDAC1 2 10 3 11
NP_001003962 calpain, small subunit 1 CAPNS1 2 4 1 4
NP_003390 X-prolyl aminopeptidase 2, membrane-bound XPNPEP2 21 61 16 53
NP_003397 tyrosine 3/tryptophan 5 -monooxygenase activation protein, zeta polypeptide YWHAZ 4 14 5 16
NP_003536 histone cluster 1, H4e HIST1H4E 2 3 4 10
NP_001020527 anoctamin 6 ANO6 1 2 1 5
NP_003680 aldo-keto reductase family 7, member A2 AKR7A2 2 3 2 3
NP_003730 aldo-keto reductase family 1, member C3 AKR1C3 2 4 2 7
NP_003733 ATP-binding cassette, sub-family B (MDR/TAP), member 11 ABCB11 1 5 1 2
NP_003750 solute carrier family 4, sodium bicarbonate cotransporter, member 4 isoform 2 SLC4A4 4 20 1 4
NP_003818 N-ethylmaleimide-sensitive factor attachment protein, alpha NAPA 1 2 1 1
NP_003861 IQ motif containing GTPase activating protein 1 IQGAP1 7 12 8 9
NP_003881 Fc fragment of IgG binding protein FCGBP 5 8 8 11
NP_003900 copine III CPNE3 8 21 7 24
NP_003920 RAB7, member RAS oncogene family-like 1 isoform 1 RAB7L1 2 4 1 4
NP_003962 sperm associated antigen 9 isoform 3 SPAG9 1 1 2 2
NP_003970 G protein-coupled receptor, family C, group 5, member A GPRC5A 1 11 1 6
NP_003975 solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2 SLC13A2 2 3 4 10
NP_003977 gamma-butyrobetaine dioxygenase BBOX1 1 1 4 8
NP_004024 annexin VI isoform 2 ANXA6 1 1 1 1
NP_004025 annexin VII isoform 2 ANXA7 10 28 6 13
NP_004033 arylsulfatase F precursor ARSF 5 10 6 21
NP_004046 calpain 5 CAPN5 4 11 1 2
NP_004090 stomatin isoform a STOM 11 46 8 54
NP_004095 fatty acid synthase FASN 3 3 1 1
NP_004152 RAB1A, member RAS oncogene family isoform 1 RAB1A 1 3 2 7
NP_004153 RAB5A, member RAS oncogene family RAB5A 5 8 4 7
NP_004172 ubiquitin carboxyl-terminal esterase L1 UCHL1 1 1 1 1
NP_004209 RAB11B, member RAS oncogene family RAB11B 5 8 6 12
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NP_004247 organic cation transporter like 3 SLC22A13 3 5 1 1
NP_004288 G alpha 14 GNA14 2 4 2 7
NP_004300 Rho GDP dissociation inhibitor (GDI) alpha ARHGDIA 2 7 2 4
NP_004326 bone marrow stromal cell antigen 2 BST2 1 2 1 1
NP_004404 dipeptidase 1 DPEP1 18 112 12 98
NP_004438 epidermal growth factor receptor pathway substrate 8 EPS8 14 24 3 5
NP_004512 kinesin family member 5B KIF5B 1 2 1 2
NP_004628 RAB7, member RAS oncogene family RAB7A 4 10 3 10
NP_005991 tubulin, alpha 4a TUBA4A 3 6 1 2
NP_004659 maltase-glucoamylase MGAM 20 62 13 29
NP_004682 ATPase, H+ transporting, lysosomal, V0 subunit d1 ATP6V0D1 3 7 1 2
NP_004842 napsin A preproprotein NAPSA 3 47 3 52
NP_004860 vacuolar protein sorting factor 4B VPS4B 13 40 5 17
NP_004896 peroxiredoxin 6 PRDX6 5 6 5 7
NP_004915 actinin, alpha 4 ACTN4 9 14 7 10
NP_004920 calbindin 1 CALB1 4 8 3 5
NP_004921 F-actin capping protein beta subunit CAPZB 3 5 3 4
NP_004990 myosin VI MYO6 3 11 2 5
NP_005013 profilin 1 PFN1 4 5 3 4
NP_005023 plastin 3 PLS3 4 4 1 1
NP_005100 oxidative-stress responsive 1 OXSR1 2 2 1 1
NP_005106 major vault protein MVP 2 3 3 7
NP_005130 annexin A3 ANXA3 2 4 6 13
NP_005168 ATPase, H+ transporting, lysosomal V0 subunit a1 isoform c ATP6V0A1 1 1 1 1
NP_005263 guanine nucleotide binding protein, alpha transducing activity polypeptide 2 GNAT2 1 5 1 3
NP_005264 guanine nucleotide-binding protein, beta-2 subunit GNB2 5 32 4 16
NP_005265 guanine nucleotide binding protein (G protein), gamma 5 GNG5 1 2 1 1
NP_005336 heat shock 70kDa protein 1A HSPA1A 10 40 9 33
NP_005361 mel transforming oncogene RAB8A 4 20 4 16
NP_005388 podocalyxin-like isoform 2 precursor PODXL 6 50 3 41
NP_005393 ras related v-ral simian leukemia viral oncogene homolog A RALA 1 2 2 3
NP_005424 viral oncogene yes-1 homolog 1 YES1 4 7 2 3
NP_005498 cofilin 1 (non-muscle) CFL1 2 3 1 2
NP_005552 lysosomal-associated membrane protein 1 LAMP1 3 12 2 13
NP_005557 L-lactate dehydrogenase A isoform 1 LDHA 4 14 4 12
NP_005558 galectin 3 binding protein LGALS3BP 14 95 12 91
NP_005663 prostate stem cell antigen preproprotein PSCA 1 5 1 9
NP_005718 tetraspan 1 TSPAN1 1 5 1 3
NP_005722 actin related protein 2/3 complex subunit 2 ARPC2 3 3 1 2
NP_005755 PDZK1 interacting protein 1 PDZK1IP1 2 18 2 4
NP_005887 isocitrate dehydrogenase 1 (NADP+), soluble IDH1 9 21 5 7
NP_005908 cytosolic malate dehydrogenase MDH1 6 12 5 14
NP_006000 tubulin, alpha 1a TUBA1A 8 25 5 16
NP_004554 mitochondrial phosphoenolpyruvate carboxykinase 2 isoform 1 precursor PCK2 1 1 1 1
NP_006008 prominin 1 PROM1 15 90 8 30
NP_006026 CDC42-binding protein kinase beta CDC42BPB 1 1 1 1
NP_006057 aldo-keto reductase family 1, member A1 AKR1A1 6 11 6 15
NP_006077 tubulin, beta, 4 TUBB3 4 14 2 6
NP_006079 tubulin, beta, 2 TUBB2C 1 4 1 5
NP_006127 capping protein (actin filament) muscle Z-line, alpha 2 CAPZA2 2 2 1 1
NP_277050 Rho GTPase activating protein 18 ARHGAP18 1 3 1 1
NP_006216 phospholipase C, delta 1 PLCD1 6 13 2 3
NP_006261 related RAS viral (r-ras) oncogene homolog RRAS 1 3 2 3
NP_006279 Thy-1 cell surface antigen preproprotein THY1 2 10 2 11
NP_006283 tumor susceptibility gene 101 TSG101 13 22 5 10
NP_006308 brain abundant, membrane attached signal protein 1 BASP1 6 19 6 10
NP_006364 vesicle amine transport protein 1 VAT1 6 19 6 10
NP_006409 olfactomedin 4 precursor OLFM4 10 41 5 16
NP_006479 ketohexokinase isoform b KHK 1 2 1 3
NP_006487 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 GNAI3 3 8 2 6
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NP_006563 guanine nucleotide binding protein (G protein), alpha 13 GNA13 7 10 2 2
NP_006588 heat shock 70kDa protein 8 isoform 1 HSPA8 10 43 6 27
NP_006601 mannan-binding lectin serine protease 2 isoform 1 precursor MASP2 4 142 3 33
NP_775931 downstream of tyrosine kinase 7 DOK7 1 20 1 24
NP_006624 IQ motif containing GTPase activating protein 2 IQGAP2 2 3 2 2
NP_006751 uroplakin 2 UPK2 3 8 3 5
NP_006752 tyrosine 3/tryptophan 5 -monooxygenase activation protein, epsilon polypeptide YWHAE 8 16 6 23
NP_006786 EH-domain containing 1 EHD1 4 9 4 5
NP_006817 tyrosine 3/tryptophan 5 -monooxygenase activation protein, theta polypeptide YWHAQ 2 6 2 3
NP_006852 RAB35, member RAS oncogene family RAB35 3 7 3 6
NP_008880 syntaxin binding protein 2 STXBP2 5 9 9 13
NP_008883 uroplakin 1B UPK1B 1 2 2 6
NP_008931 uroplakin 1A UPK1A 4 11 5 19
NP_009057 valosin-containing protein VCP 2 5 1 3
NP_009111 trehalase (brush-border membrane glycoprotein) TREH 2 3 2 3
NP_009148 programmed cell death 10 PDCD10 1 3 1 2
NP_009160 protein kinase C and casein kinase substrate in neurons 2 PACSIN2 3 4 1 2
NP_009172 EAP30 subunit of ELL complex SNF8 1 2 1 2
NP_009219 membrane metallo-endopeptidase MME 31 199 27 189
NP_036205 chaperonin containing TCP1, subunit 5 (epsilon) CCT5 1 1 1 3
NP_036226 peroxiredoxin 5 isoform a precursor PRDX5 1 4 1 2
NP_036269 dimethylarginine dimethylaminohydrolase 1 isoform 1 DDAH1 2 5 2 4
NP_036322 aldehyde dehydrogenase 1 family, member L1 ALDH1L1 5 7 4 5
NP_036376 solute carrier family 7 (cationic amino acid transporter, y+ system), member 8 isoform a SLC7A8 2 7 1 1
NP_060784 ubiquitin-conjugating enzyme E2-like isoform b UEVLD 9 25 5 6
NP_065806 serine incorporator 1 SERINC1 1 3 1 1
NP_036382 related RAS viral (r-ras) oncogene homolog 2 isoform a RRAS2 1 3 1 3
NP_036524 penta-EF-hand domain containing 1 PEF1 2 5 2 4
NP_036611
tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein, 
gamma polypeptide
YWHAG 2 6 3 8
NP_037364 programmed cell death 6 PDCD6 4 5 2 2
NP_037377 vacuolar protein sorting factor 4A VPS4A 9 20 2 2
NP_037506 programmed cell death 6 interacting protein PDCD6IP 24 81 17 56
NP_038464 NCK-associated protein 1 isoform 1 NCKAP1 2 4 1 1
NP_039234 chloride intracellular channel 4 CLIC4 3 5 3 7
NP_054701 lysosomal-associated membrane protein 2 isoform B precursor LAMP2 2 12 1 8
NP_054762 chromatin modifying protein 2B CHMP2B 3 5 2 6
NP_055111 calpain 7 CAPN7 19 74 15 44
NP_060691 Mob4B protein MOBK1B 1 1 1 1
NP_055135 heme binding protein 2 HEBP2 1 1 1 1
NP_055179 glyceraldehyde-3-phosphate dehydrogenase, spermatogenic GAPDHS 2 5 1 4
NP_055268 chromatin modifying protein 2A CHMP2A 3 16 2 7
NP_055289 acid sphingomyelinase-like phosphodiesterase 3B isoform 1 SMPDL3B 1 4 1 2
NP_055415 EH-domain containing 3 EHD3 5 10 3 6
NP_055440 podocin NPHS2 5 15 1 2
NP_055535 serine/threonine kinase 2 SLK 5 8 3 3
NP_055576 putative MAPK activating protein PM28 KIAA0174 13 75 11 49
NP_055814 RAB21, member RAS oncogene family RAB21 1 2 2 4
NP_055956 glycerol-3-phosphate dehydrogenase 1-like GPD1L 1 4 1 2
NP_056348 dihydroxyacetone kinase 2 DAK 9 27 9 45
NP_056991 leucine aminopeptidase 3 LAP3 2 3 1 1
NP_057058 lambda-crystallin CRYL1 2 3 2 4
NP_057078 H(+)-transporting two-sector ATPase ATP6V1D 2 3 1 4
NP_057159 vacuolar protein sorting 36 VPS36 2 6 1 1
NP_057163 vacuolar protein sorting 24 isoform 1 VPS24 1 1 2 3
NP_057215 ras-related GTP-binding protein RAB10 RAB10 1 7 2 11
NP_057292 vacuolar protein sorting 28 isoform 1 VPS28 4 4 5 8
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NP_057319 G protein-coupled receptor, family C, group 5, member B precursor GPRC5B 4 21 2 7
NP_057370 dicarbonyl/L-xylulose reductase DCXR 2 5 3 5
NP_057373 calcium binding protein 39 CAB39 4 6 3 4
NP_057406 GTPase Rab14 RAB14 3 4 3 4
NP_057494 chromatin modifying protein 5 CHMP5 5 17 3 8
NP_057569 Vps20-associated 1 homolog VTA1 3 8 6 14
NP_057635 transmembrane 7 superfamily member 3 TM7SF3 3 8 2 5
NP_057699 solute carrier family 6 (neurotransmitter transporter, GABA), member 13 SLC6A13 1 2 1 1
NP_059830 WD repeat-containing protein 1 isoform 1 WDR1 5 8 5 10
NP_055113 quinolinate phosphoribosyltransferase QPRT 1 1 2 3
NP_060187 mu-protocadherin isoform 2 MUCDHL 1 1 1 1
NP_001008274 transgelin 3 TAGLN3 1 2 1 2
NP_060347 hypothetical protein LOC54978 C2orf18 1 4 1 8
NP_060436 vacuolar protein sorting 37C VPS37C 1 3 1 1
NP_001071089 vacuolar protein sorting 37D VPS37D 3 10 3 9
NP_060705 CNDP dipeptidase 2 CNDP2 10 30 8 23
NP_001129975 hypothetical protein LOC284422 LOC284422 3 13 3 7
NP_059996 leptin receptor gene-related protein LEPROT 1 1 1 2
NP_061123 G protein-coupled receptor family C, group 5, member C isoform b GPRC5C 12 194 10 143
NP_061329 G-protein gamma-12 subunit GNG12 2 10 1 2
NP_061330 BAI1-associated protein 2-like 1 BAIAP2L1 3 6 1 2
NP_061485 ras-related C3 botulinum toxin substrate 1 isoform Rac1b RAC1 3 11 3 5
NP_061816 tubulin, alpha 8 TUBA8 1 11 1 4
NP_061907 ras homolog gene family, member F RHOF 1 1 1 1
NP_062547 sushi domain containing 2 SUSD2 2 5 1 2
NP_062815 transient receptor potential cation channel, subfamily V, member 5 TRPV5 1 2 1 1
NP_064424 tubulin, beta polypeptide 4, member Q TUBB4Q 2 5 2 8
NP_064524 3-hydroxybutyrate dehydrogenase, type 2 BDH2 3 4 4 7
NP_065145 chromatin modifying protein 1B CHMP1B 4 9 3 5
NP_065161 solute carrier family 44, member 2 SLC44A2 4 13 3 5
NP_060261 feline leukemia virus subgroup C cellular receptor family, member 2 FLVCR2 1 2 1 4
NP_065842 TAO kinase 1 TAOK1 1 2 1 2
NP_066289 ubiquitin C UBC 4 83 4 78
NP_066299 myosin, light chain 6, alkali, smooth muscle and non-muscle isoform 1 MYL6 1 1 1 1
NP_066361 RAP2A, member of RAS oncogene family RAP2A 3 4 2 3
NP_068576 angiotensin I converting enzyme 2 precursor ACE2 8 16 5 10
NP_068733 cofilin 2 CFL2 1 2 1 3
NP_068814 heat shock 70kDa protein 2 HSPA2 10 28 7 27
NP_068839 integral membrane protein 2B ITM2B 2 10 2 4
NP_071738 GLI pathogenesis-related 2 GLIPR2 1 1 1 2
NP_071399 fidgetin-like 1 FIGNL1 1 10 1 8
NP_071412 MAWD binding protein isoform a PBLD 2 3 2 6
NP_071435 transmembrane BAX inhibitor motif containing 1 TMBIM1 1 6 1 4
NP_001173 antiquitin ALDH7A1 1 2 1 1
NP_073609 epidermal growth factor receptor pathway substrate 8-like protein 2 EPS8L2 5 8 2 2
NP_073740 solute carrier family 13 member 3 isoform a SLC13A3 2 4 2 4
NP_006139 LIM and SH3 protein 1 LASP1 1 1 1 1
NP_078867 chromatin modifying protein 6 CHMP6 2 7 2 2
NP_078943 vacuolar protein sorting 37B VPS37B 4 8 4 9
NP_079119 cytochrome b reductase 1 CYBRD1 2 4 1 2
NP_079526 tweety 3 TTYH3 2 2 1 3
NP_079533 NG22 protein isoform 1 SLC44A4 3 38 3 15
NP_109589 phosphotriesterase related PTER 2 2 2 3
NP_112601 serine carboxypeptidase vitellogenic-like CPVL 2 6 1 2
NP_115729 vacuolar protein sorting 25 VPS25 1 1 1 1
NP_115788 hypothetical protein LOC84418 C5orf32 1 17 1 9
NP_149124 2',3'-cyclic nucleotide 3' phosphodiesterase CNP 8 15 2 3
NP_203693 myosin IC MYO1C 21 54 8 20
NP_003560 syntaxin 7 STX7 1 2 1 1
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NP_443102 sorting nexin associated golgi protein 1 SNAG1 2 4 1 2
NP_542416 protein tyrosine phosphatase, non-receptor type 13 isoform 4 PTPN13 1 2 1 2
NP_612410 family with sequence similarity 125, member A FAM125A 2 6 2 4
NP_612433 kinesin family member 12 KIF12 9 15 4 6
NP_620153 MIT, microtubule interacting and transport, domain containing 1 MITD1 4 13 3 5
NP_620164 carboxymethylenebutenolidase CMBL 2 3 2 3
NP_631900 crumbs 3 isoform a precursor CRB3 1 2 1 2
NP_644670 EH-domain containing 4 EHD4 10 20 10 22
NP_647537 attractin isoform 1 ATRN 2 4 2 3
NP_647539
tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein, 
beta polypeptide
YWHAB 6 14 5 14
NP_653186 urate anion exchanger 1 isoform a SLC22A12 2 4 4 6
NP_653296 hypothetical protein LOC148362 C1orf58 6 30 5 18
NP_653308 prominin 2 PROM2 9 43 6 18
NP_659409 lactate dehydrogenase A-like 6A LDHAL6A 1 3 1 4
NP_665683 glutathione S-transferase alpha 1 GSTA1 1 1 1 1
NP_665875 annexin A11 ANXA11 23 144 19 73
NP_683718 serine hydroxymethyltransferase 1 (soluble) isoform 2 SHMT1 2 4 5 10
NP_689564 solute carrier family 5 (sodium/glucose cotransporter), member 10 SLC5A10 2 3 1 2
NP_689742 G protein-coupled receptor 155 isoform 10 GPR155 1 7 1 5
NP_689898 solute carrier family 23 (nucleobase transporters), member 1 isoform b SLC23A1 2 2 4 7
NP_705898 copine VIII CPNE8 5 16 3 5
NP_006623 solute carrier family 17 (sodium phosphate), member 3 SLC17A3 1 1 1 1
NP_789782 chromatin modifying protein 4B CHMP4B 4 9 1 2
NP_808592 N-acylsphingosine amidohydrolase (acid ceramidase) 1 preproprotein isoform a ASAH1 4 8 2 3
NP_821133 tubulin, beta TUBB 2 6 3 5
NP_857635 peroxiredoxin 5 isoform c precursor PRDX5 1 1 1 2
NP_859047 peroxiredoxin 1 PRDX1 3 5 4 11
NP_859427 peroxiredoxin 2 isoform b PRDX2 2 4 3 4
NP_861441 solute carrier family 36 (proton/amino acid symporter), member 2 SLC36A2 7 17 7 18
NP_872270 pyruvate kinase, muscle isoform M1 PKM2 13 35 10 21
NP_872372 vitelline membrane outer layer 1 isoform 1 VMO1 1 2 2 2
NP_874384 synaptophysin-like 1 isoform b SYPL1 1 8 1 5
NP_908930 fructose-bisphosphate aldolase A ALDOA 4 10 2 6
NP_932766 aquaporin 1 AQP1 2 46 2 51
NP_937895 gelsolin isoform b GSN 8 15 3 5
NP_944492 transmembrane 4 superfamily member 8 isoform 2 TSPAN3 1 16 2 11
NP_955376 SFT2 domain containing 2 SFT2D2 1 2 1 3
NP_958842 RAB5C, member RAS oncogene family isoform a RAB5C 4 9 4 9
NP_974197 regulator of G-protein signalling 19 interacting protein 1 isoform 1 GIPC1 2 4 2 3
NP_976074 CD59 antigen preproprotein CD59 1 11 1 2
XP_060887 PREDICTED: similar to peptidyl-Pro cis trans isomerase LOC128192 1 2 1 2
82
Table 5.2.  Proteins that changed at least 2-fold 
Ref Seq Protein Name Gene
NP_006308brain abundant, membrane attached signal protein 1 BASP1
NP_057494chromatin modifying protein 5 CHMP5
NP_003900copine III CPNE3
NP_005908cytosolic malate dehydrogenase MDH1
NP_004438epidermal growth factor receptor pathway substrate 8 EPS8
NP_000395galactosidase, beta 1 GLB1
NP_00660 mannan-binding lectin serine protease 2 isoform 1 precursor MASP2
NP_000692Na+/K+ -ATPase alpha 1 subunit isoform a proprotein ATP1A1
NP_079533NG22 protein isoform 1 SLC44A4
NP_859047peroxiredoxin 1 PRDX1
NP_653308prominin 2 PROM2
NP_004628RAB7, member RAS oncogene family RAB7A
NP_000330solute carrier family 12 (sodium/chloride transporters), member SLC12A3
NP_006283tumor susceptibility gene 101 TSG101
NP_00388 Fc fragment of IgG binding protein FCGBP
NP_00153 heat shock protein beta-1 HSPB1
NP_620153MIT, microtubule interacting and transport, domain containing 1MITD1






6 Summary and Conclusion 
 Urinary exosomes are small extracellular vesicles that originate from the internal 
vesicles of multivesicular bodies in renal epithelial cells, including glomerular podocytes, 
renal tubule cells and the cells lining the renal pelvis, ureters and bladder.  Exosomes 
contain membrane and cytosolic proteins. The mechanism for exosome formation and 
excretion starts by the endocytosis of apical membrane proteins into the cell via 
chlathrin-coated vesicles.  These vesicles are delivered to early endosomes and 
subsequently fuse with the multivesicular body (MVB).  The apical plasma membrane 
proteins are internalized into the MVB by membrane invagination forming “cytosol-in” 
vesicles.  The outer membrane of the MVB fuses with the apical plasma membrane and 
releases these internal vesicles through exocytosis in the urinary space.  Urinary 
exosomes are isolated by ultracentrifugation and provide a non-invasive means of 
acquiring information about the physiological or pathophysiological state of renal cells. 
 The overall objective of this research was to develop methods and knowledge 
infrastructure for urinary proteomics.  The central focus of the proposed work was on 
urinary exosome analysis by protein mass spectrometry. The first objective had two 
components: (1) to expand the proteome of human urinary exosomes by using a highly 
sensitive LC-MS/MS system, improved software for identification of peptide ions and a 
more elaborate data analysis strategy, and (2) to investigate the phosphoproteome of 
human urinary exosomes using neutral loss scanning.  We unambiguously identified 1132 
proteins including:  177 proteins that are disease related (Table 3.1), 81 proteins involved 
in solute and water transport (Table 3.2), 22 proteins that are recognized components of 




subunits of the human vacuolar H+-ATPase (Table 3.4).  The phosphoproteomic profiling 
identified 19 phosphorylation sites corresponding to 14 phosphoproteins.  The 
phosphorylation sites identified include six previously known and eight previously 
unknown.  These results show that the newly identified proteins in urinary exosomes may 
have considerable relevance to renal biology and the mechanism of renal disease.  The 
detection of phosphorylation, the most important post-translational modification of 
proteins, provides another level of information about physiological and 
pathophysiological state of renal cells. 
 The second objective was to apply urinary exosome analysis using polyclonal 
antibodies.  We proposed to qualitatively assess patients’ samples by generating 
polyclonal antibodies to bind to an epitope in the amino-terminal of the human MRP4 
protein, and to use previously generated polyclonal antibodies to bind to epitopes of the 
NKCC2 and NCC proteins.  The potential usefulness of urinary exosome analysis was 
demonstrated using the well-defined renal tubulopathy, Bartter syndrome type I and using 
the single nucleotide polymorphism in the ABCC4 gene. 
Patients with Bartter syndrome type I have mutations in the SLC12A1 gene which 
encodes for the NKCC2 protein.  NKCC2 is expressed on the apical membrane of the 
thick ascending limb of Henle.  We used a previously generated anti-NKCC2 antibody to 
immunoblot the urinary exosomes samples from two patients with Bartter syndrome type 
I.  The patient samples showed a complete absence of the NKCC2 protein.  In addition, 
we used a previously generated anti-NCC antibody to ensure that urinary exosomes were 




Patients with a single nucleotide polymorphism of the ABCC4 gene which results in 
the expression of a short and normal gene product have evidence of potential loss of 
function of the MRP4 protein.  We generated a polyclonal anti-MRP4 antibody to bind to 
an epitope in the amino-terminal of the protein.  The polyclonal antibody was raised 
against a synthetic peptide that was designed to be highly specific.  The synthetic peptide 
is immunogenic, unique and lacks post-translational modifications.  The anti-MRP4 
antibody was characterized in kidney tissue samples and shown to be highly specific.  
Urinary exosome patient samples were probed with our polyclonal antibody and showed 
a band at the expected molecular weight of the MRP4 protein and a fainter band at the 
expected molecular weight for the short protein.  The results showed that urinary 
exosome analysis can be useful in gaining insight of genetic mutations that cause disease. 
The third objective was to study the normal variability between proteomes of female 
and male urinary exosomes and to implement a normalization method to analyze urinary 
exosome samples.  We compared urinary exosome samples from pooled samples of urine 
from four normal human females and four normal human males. The samples were 
solubilized in SDS and the proteins were separated by SDS-PAGE followed by in-gel 
trypsin digestion of contiguous gel slices.  The digests were analyzed by tandem mass 
spectrometry. The samples were compared quantitatively using a label-free approach 
with the integration software, QUOIL.  There were 388 proteins identified in both male 
and female urinary exosome proteomes.  Only 19 proteins had a 2-fold change 
representing 4.9% of the total number of proteins identified.  Therefore, there is high 
concordance between proteomes of urinary exosomes isolated from males and females.  




quantify the excretion of exosomal proteins.  We collaborated with Dr. Jeffrey Kopp to 
enroll six healthy volunteers, three males and three females, and analyzed their urinary 
exosome samples using immunoblotting.  The results showed that the normalization 
method we implemented did not correlate with the intensity signal of MVB markers, 
TSG101 and Alix.  Further work needs to be completed to implement timed urine 
collection as a normalization method. 
The work completed showed that the analysis of urinary exosomes by protein mass 
spectrometry can be the basis for future biomarker studies as well as physiological 
studies.  We used a highly sensitive LC-MS/MS system to expand the known proteome 
of human urinary exosomes.  We used neutral loss scanning in LC-MS/MS to investigate 
the phosphoproteome of human urinary exosomes.  We applied the analysis of human 
urinary exosomes to gain understanding of genetic mutations and we generated highly-
specific polyclonal antibodies to be used for immunoassays.  And, we studied the normal 
variability among human populations based on gender. 
The analysis of urinary exosomes provides a non-invasive method potentially useful 
in future biomarker discovery studies.  Therefore, in this work we proposed to investigate 
the possible use of analysis of urinary exosomes in clinical proteomics.  The overall 
objective of this research is to develop methods and knowledge infrastructure for urinary 
proteomics.  The central focus was urinary exosome analysis by protein mass 
spectrometry.  From the results found, it is clear that expanding the known proteome of 
human urinary exosomes and investigating the phosphoproteome of human urinary 
exosomes provides a basis for biomarker studies.  Human urinary exosome analysis can 




importance of studying normal variability among human populations as well as 




7 Future Works 
The potential of urinary exosome analysis as a route to biomarker discovery in renal 
diseases still faces many limitations despite our current progress [7, 8, 31].  More work 
needs to be done to standardize protocols to collect, process, and store urine samples in a 
clinical setting.  Our current isolation approach for urinary exosomes includes an 
ultracentrifugation step that needs to be replaced for future clinical studies.   
7.1 Isolation Method 
 The ultracentrifugation step requires expensive instrumentation and long 
processing times would hinder clinical studies.  Filtration methods have been proposed to 
replace the ultracentrifugation step [32] but these tend to retain and concentrate soluble 
proteins in addition to exosomes. The Tamm-Horsfall protein hinders the concentration 
of exosomes using filtration methods. 
7.2 Tamm-Horsfall 
A particular problem is the excretion of Tamm-Horsfall protein, an extraordinary 
abundant urinary protein that interferes with successful mass spectrometry and 
immunoblotting [9].  Tamm-Horsfall protein is an 80 kDa glycoprotein produced 
abundantly by kidney cells [63].  This protein is excreted in varying amounts that hinder 
the quantification of samples.  Current work addressing this problem shows that Tamm-
Horsfall can be depolymerized using a reducing agent, DTT, after the 17,000 x g 
centrifugation step in addition to heat (37 °C).  
7.2 Quantification 
In the long run, the most important technical challenge may be to develop 




biomarker candidates.  Both labeling and non-labeling methods have been developed to 
make protein mass spectrometry quantitative [21].  Use of creatinine as a normalizing 
variable may be inadequate because of high subject-to-subject variability in its rate of 
excretion but may need to be used in combination with other methods of quantification 
[8].  An alternative method is to quantify the excretion of exosomal proteins by counting 
the number of exosomes using negative-stain electron micrograph (EM).  The number of 
exosomes can be correlated to exosomes markers such as TSG-101 and Alix.   
Finally, we have shown that even without quantification, urinary exosome analysis 
can be valuable in situations such as genetic diseases where a protein may be entirely 
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Electron Micrograph Negative Staining Protocol with Uranyl Acetate 
NHLBI EM Core Standard Procedure 
Materials: 
1. Staining Solution:  1% uranyl acetate (w/v) in deionized water.  Stir in dark until 
completely dissolved. Allow any undissolved material to settle.  Store in dark. In 
order to avoid precipitates, do not withdraw solution from bottom of container. 
Solution may be made by dilution of 2% uranyl acetate prepared in the same way. 
Note:  Uranyl acetate is manufactured from depleted uranium but it still gives off a small 
amount of alpha radiation.  Therefore all wet and dry uranyl acetate waste must be 
disposed of in marked containers as radioactive waste.  As it is a heavy metal, uranyl 
acetate is toxic, and should be handled and disposed of as such. 
2. Specimen Grids:  Copper EM grids with formar and carbon film (Electron 
Microscopy Sciences). 
Procedure: 
1. On day that staining is to be done, subject the formvar/carbon grids to glow discharge 
(plasma cleaning) treatment for one minute to make the film hydrophilic. 
2. Holding a grid in a forceps, apply 5µl of the particulate suspension to the grid.  It 
should spread immediately to cover the grid. 
3. After 1 min, remove excess suspension by touching a piece of filter paper to the edge 




4. Immediately wash and stain by quickly running 4 drops of 1% uranyl acetate over the 
grid. 
5. Immediately remove excess uranyl acetate from the grid with filter paper as in step 3. 
6. Allow the grid to air dry at least 5 min before inserting into the electron microscope. 
7. The samples were viewed with a JEM 1200EX electron microscope (JEOL USA) at 
80kV and a magnification of 20,000X.  Images were acquired with an AMT XR60B 
6.8 megapixel digital camera (Advanced Microscope Technologies). 
 
Appendix B: Supplementary Table 1. Complete List of Proteins in Human Urinary Exosomes
Amb Technique Gi Number Ref Seq Gene Protein Name Pep ID GO Component GO Process GO Function Related to Disease [OMIM]
2 21071030 NP_570602 A1BG alpha 1B-glycoprotein 1 1 extracellular region not classified not classified








serine-type endopeptidase inhibitor activity
tumor necrosis factor binding
wide-spectrum protease inhibitor activity
2 74271845 NP_653271 A2ML1 alpha-2-macroglobulin-like 1 1 1 not classified not classified endopeptidase inhibitor activity
2 20357568 NP_056238 AASDHPPT aminoadipate-semialdehyde dehydrogenase1 3

















Colchicine Resistance [MIM : 120080]
Crohn Disease [MIM:266600]
2 21536378 NP_003733 ABCB11 ATP-binding cassette, sub-family B (MDR/TAP)1 3






bile acid-exporting ATPase activity
nucleotide binding
sodium-exporting ATPase activity, 
phosphorylative mechanism
transporter activity
Cholestasis, Progressive Familial 
Intrahepatic 2 [MIM:601847]
Cholestasis, Benign Recurrent 
Intrahepatic 2 [MIM:605479]
Yes 2 4505771 NP_000434 ABCB4 ATP-binding cassette, subfamily B, member 7 20
integral to membrane



























ATPase activity, coupled to transmembrane 
movement of substances
nucleotide binding






ATPase activity, coupled to transmembrane 
movement of substances
nucleotide binding












transporter activity Cardiomyopahty [MIM: 608569]
1,2 14249382 NP_116139 ABHD14B abhydrolase domain containing 14B 6 20 nucleus not classified not classified
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hydrolase activity, acting on glycosyl bonds
metal ion binding
peptidyl-dipeptidase A activity
zinc ion binding Hypertension [MIM:106180]










chloride ion binding 




Renal Tubular Dysgenesis [MIM: 
267430]












zinc ion binding Hypertension [MIM:300335]













2 8659555 NP_002188 ACO1 aconitase 1 6 9
cytoplasm metabolism
tricarboxylic acid cycle






2 22165400 NP_671517 ACOT11 thioesterase, adipose associated isoform BF1 1 cytoplasm
fatty acid metabolism
intracellular signaling cascade













Mesial temporal lobe epilepsy 
[MIM:608096]
2 6005988 NP_009030 ACP1 acid phosphatase 1 isoform b 1 2
cytoplasm
soluble fraction




non-membrane spanning protein tyrosine 
phosphatase activity
protein tyrosine phosphatase activity









1,2 6382064 NP_001090 ACPP prostatic acid phosphatase precursor 8 13
extracellular region




protein tyrosine phosphatase activity






















Mental Retardation, X-linked 63, 
MRX 63 [MIM:300387]
2 115511026 NP_443188 ACSM1 acyl-CoA synthetase medium-chain family m1 1 mitochondrial matrix
benzoate metabolism
butyrate metabolism





















structural constituent of cytoskeleton







structural constituent of cytoskeleton






structural constituent of cytoskeleton































structural constituent of muscle
ZASP binding






positive regulation of cell 
motility
regulation of apoptosis















structural constituent of cytoskeleton





2 5031573 NP_005712 ACTR3 ARP3 actin-related protein 3 homolog 6 13





Yes 2 92373393 NP_001035225ACTR3B actin-related protein 3-beta isoform 2 1 3 cytoskeleton actin filament polymerization
actin filament binding
protein binding










Amimoacylase 1 Deficiency 
[MIM:609924]
2 18087825 NP_542389 ACY3 aspartoacylase (aminocyclase) 3 1 1 not classified metabolism
aspartoacylase activity
hydrolase activity, acting on ester bonds









2 71565154 NP_000662 ADH5 class III alcohol dehydrogenase 5 chi subun 1 2










2 4501939 NP_000663 ADH6 class V alcohol dehydrogenase 6 1 1






2 67551265 NP_056261 AHCTF1 transcription factor ELYS 1 3 nucleus
development
transcription DNA binding
2 9951915 NP_000678 AHCY S-adenosylhomocysteine hydrolase 10 28 cytoplasm one-carbon compound metabolism
adenosylhomocysteinase activity
hydrolase activity Hypermethioninemia [MIM:180960]
2 61743954 NP_001611 AHNAK AHNAK nucleoprotein isoform 1 1 1 nucleus
nervous system 
development protein binding












negative regulation of bone 
mineralization
negative regulation of insulin 
receptor signaling pathway
pinocytosis
positive regulation of 
phagocytosis
regulation of inflammatory 
response
skeletal development
cysteine protease inhibitor activity
kinase inhibitor activity




nucleobase, nucleoside, nucleotide 










2 5174391 NP_006057 AKR1A1 aldo-keto reductase family 1, member A1 7 16
not classified aldehyde metabolism
glucose metabolism





1,2 4502049 NP_001619 AKR1B1 aldo-keto reductase family 1, member B1 3 17


































bile acid transporter activity
chlordecone reductase activity
electron carrier activity
Yes 2 93277124 NP_001035267AKR1CL2 aldo-keto reductase family 1, member C-like 1 1 not classified not classified oxidoreductase activity





2 41152114 NP_036199 AKR7A3 aldo-keto reductase family 7, member A3 2 7 cytosol aldehyde metabolism
aldo-keto reductase activity
electron carrier activity
2 51558759 NP_001003945 ALAD delta-aminolevulinic acid dehydratase isoform a 1 1





Acute Hepatic Porphyria 
[MIM:125270]





cellular response to starvation
hemolysis of host red blood cells
maintenance of mitochondrion 
localization
negative regulation of apoptosis





















2 68163411 NP_001618 ALCAM activated leukocyte cell adhesion molecule 1 1











2 21361176 NP_000680 ALDH1A1 aldehyde dehydrogenase 1A1 10 15
cytoplasm aldehyde metabolism
metabolism
aldehyde dehydrogenase (NAD) activity
androgen binding
oxidoreductase activity
Ras GTPase activator activity
retinal dehydrogenase activity




















aldehyde dehydrogenase (NAD) activity
aldehyde dehydrogenase [NAD(P)+] activity
electron carrier activity






3-chloroallyl aldehyde dehydrogenase 
activity
aldehyde dehydrogenase [NAD(P)+] activity
oxidoreductase activity






3-chloroallyl aldehyde dehydrogenase 
activity
aldehyde dehydrogenase [NAD(P)+] activity
oxidoreductase activity






3-chloroallyl aldehyde dehydrogenase 
activity
aldehyde dehydrogenase [NAD(P)+] activity
oxidoreductase activity
2 12007648 NP_072090 ALDH8A1 aldehyde dehydrogenase 8A1 isoform 1 1 1
intracellular
cell surface














aldehyde dehydrogenase (NAD) activity
aminobutyraldehyde dehydrogenase activity
oxidoreductase activity








Aldolase Deficiency  of Red Cells
Myopathy and Hemolytic Anemia 
[MIM:103850]















2 29029632 NP_004295 ALK anaplastic lymphoma kinase Ki-1 1 1





protein amino acid N-linked 
glycosylation
protein amino acid 
phosphorylation
transmembrane receptor 





receptor signaling protein tyrosine kinase 
activity
transferase activity
transmembrane receptor protein tyrosine 
kinase activity









negative regulation of cell 
volume
oxygen and reactive oxygen 
species metabolism
positive regulation of cell 
adhesion
positive regulation of cell 
growth
positive regulation of cell 
proliferation









potassium channel inhibitor activity









zinc ion binding Hypophostasia [MIM:241500]












negative regulation of immune 
response













2 110611172 NP_112205 AMN amnionless protein precursor 1 1
integral to membrane
membrane development not classified
Megaloblastic Anemia 1 [MIM:
261100]
Yes 2 56549664 NP_001008220AMY1C salivary amylase alpha 1C precursor 5 7 not classified not classified not classified









hydrolase activity, acting on glycosyl bonds
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hydrolase activity, acting on glycosyl bonds
Yes 2 4757752 NP_004664 ANGPTL1 angiopoietin-like 1 precursor 1 1 extracellular space not classified receptor binding
2 6912236 NP_036230 ANGPTL2 angiopoietin-like 2 precursor 1 1 extracellular space development receptor binding
Yes 2 29893555 NP_114123 ANGPTL6 angiopoietin-like 6 1 1 not classified
angiogenesis
cell differentiation not classified












Yes 2 56676397 NP_037407 ANKRD11 ankyrin repeat domain 11 1 1 nucleus not classified not classified
1,2 4502095 NP_001141 ANPEP membrane alanine aminopeptidase precursor 69 412
ER-Golgi intermediate 
compartment









zinc ion binding Hypertension [MIM:151530]



























2 51896029 NP_001003954ANXA13 annexin A13 isoform b 1 2 plasma membrane cell differentiation
calcium ion binding
calcium-dependent phospholipid binding








2 50845388 NP_001002858ANXA2 annexin A2 isoform 1 20 156
plasma membrane











phospholipase A2 inhibitor activity
1,2 4502105 NP_001144 ANXA4 annexin IV 24 84
cytoplasm
anti-apoptosis




















1,2 71773329 NP_001146 ANXA6 annexin VI isoform 1 27 75








2 4809279 NP_004025 ANXA7 annexin VII isoform 2 13 33
not classified not classified
calcium ion binding
calcium-dependent phospholipid binding
voltage-gated calcium channel activity
2 71773480 NP_001150 AOX1 aldehyde oxidase 1 1 1 not classified
electron transport
inflammatory response
oxygen and reactive oxygen 
species metabolism








2 14210504 NP_115882 AP1M1 adaptor-related protein complex 1, mu 1 sub1 1
clathrin vesicle coat
coated pit intracellular protein transport protein binding
Yes 2 4557469 NP_001273 AP2B1 adaptor-related protein complex 2, beta 1 su1 2







Yes 2 71773106 NP_001025177AP2B1 adaptor-related protein complex 2, beta 1 su1 4


























2 4502123 NP_001151 APAF1 apoptotic peptidase activating factor 1 isofor 1 2
cytosol
intracellular








































negative regulation of lipid 
catabolism
negative regulation of lipoprotein 
metabolism
neutrophil activation
positive regulation of interleukin-8 
biosynthesis
regulation of cytokine production









































regulation of axon extension
regulation of ne
antioxidant activity

























transferase activity, transferring hexosyl 
groups







transferase activity, transferring glycosyl groups 2,8-Dihydroxyadenine urolithiasis 
[MIM:102600]






transferase activity, transferring glycosyl groups
2,8-Dihydroxyadenine urolithiasis 
[MIM:102600]
1,2 37694062 NP_932766 AQP1 aquaporin 1 3 35
integral to membrane



















transporter activitywater channel activity
Autosomal recessive nephrogenic 
diabetes insipidus, type 1 
[MIM:222000]
Autosomal dominant nephrogenic 
diabetes insipidus, type 1 
[MIM:125800]
Yes 2 4502187 NP_001161 AQP7 aquaporin 7 1 1
integral to membrane














Yes 1,2 4502203 NP_001650 ARF3 ADP-ribosylation factor 3 4 14
intracellular








Yes 1,2 4502205 NP_001651 ARF4 ADP-ribosylation factor 4 2 4
intracellular










Yes 1,2 4502209 NP_001653 ARF5 ADP-ribosylation factor 5 9 27
intracellular

















cortical actin cytoskeleton 
organization and biogenesis
ER to Golgi vesicle-mediated 
transport
negative regulation of receptor 
mediated endocytosis







Yes 2 51479145 NP_006412 ARFGEF1 brefeldin A-inhibited guanine nucleotide-exc 1 1 intracellular
exocytosis
regulation of ARF protein signal 
transduction
ARF guanyl-nucleotide exchange factor 
activity
binding
2 4757766 NP_004299 ARHGAP1 Rho GTPase activating protein 1 1 1
intracellular
cytoskeleton organization and 
biogenesis




Rho GTPase activator activity
SH3/SH2 adaptor activity





negative regulation of cell 
adhesion
Rho protein signal transduction
GTPase activator activity
protein binding
Rho GDP-dissociation inhibitor activity
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negative regulation of cell 
adhesion
Rho protein signal transduction
GTPase activator activity
Rho GDP-dissociation inhibitor activity
2 7662088 NP_056128 ARHGEF12 Rho guanine nucleotide exchange factor (GE1 3 intracellular




Rho guanyl-nucleotide exchange factor 
activity
2 9506653 NP_061960 ARL15 ADP-ribosylation factor related protein 2 1 1 not classified not classified GTP binding
1,2 4757774 NP_004302 ARL3 ADP-ribosylation factor-like 3 2 4
intracellular
G-protein coupled receptor 
protein signaling pathway
rRNA processing















Bardet-Biedl Syndrome 3 
[MIM:209900]































2 27436879 NP_775104 ARMC3 armadillo repeat containing 3 1 1 not classified not classified binding
2 156151430 NP_079415 ARMC9 armadillo repeat containing 9 1 1 not classified not classified binding
2 22907052 NP_006400 ARPC1A actin related protein 2/3 complex subunit 1A 1 1 not classified not classified not classified








2 5031597 NP_005710 ARPC3 actin related protein 2/3 complex subunit 3 2 3
Arp2/3 protein complex
cell motility











structural constituent of cytoskeleton







structural constituent of cytoskeleton




actin cytoskeleton organization 
and biogenesis
cell motility




2 13569956 NP_112240 ARPC5L actin related protein 2/3 complex, subunit 5- 1 2 cytoskeleton regulation of actin filament polymnot classified
1,2 22748653 NP_689498 ARRDC1 arrestin domain containing 1 5 8 not classified not classified not classified























transferase activity, transferring acyl groups, 
acyl groups converted into alkyl on transfer
Farber Disease [MIM:228000]






transferase activity, transferring acyl groups, acyl 
groups converted into alkyl on transfer Farber Disease [MIM:228000]

































protein binding Citrullinemia [MIM:215700]
2 24497618 NP_054828 ATAD2 two AAA domain containing protein 1 1









nucleobase, nucleoside, nucleotide 






Aica-ribosiduria due to Atic 
Deficiency [MIM:608688]















ATPase activity, coupled to transmembrane 
movement of ions, phosphorylative 
mechanism
hydrolase activity
hydrolase activity, acting on acid anhydrides, 





















ATPase activity, coupled to transmembrane 
movement of ions, phosphorylative 
mechanism
hydrolase activity
hydrolase activity, acting on acid 
anhydrases, catalyzing transmembrane 
movement of substances
magnesium ion binding






















ATP synthase, H+ transporting, 

















hydrogen-transporting ATP synthase activity, 
rotational mechanism
hydrogen-transporting ATPase activity, 
rotational mechanism
hydrolase activity
hydrolase activity, acting on acid anhydrides, 
catalyzing transmembrane movement 
ofsubstances
meta
2 32189394 NP_001677 ATP5B
ATP synthase, H+ transporting, 










synthase, catalytic core 
(sensu Eukaryota)
ATP synthesis coupled proton 
transport





hydrogen-exporting ATPase activity, 
phosphorylative mechanism
hydrogen-transporting ATP synthase activity, 
rotational mechanism















hydrogen-transporting ATP synthase activity, 
rotational mechanism






2 15011918 NP_005756 ATP6AP2 ATPase, H+ transporting, lysosomal access 1 5
integral to membrane
membrane not classified receptor activity

















hydrogen ion transporter 
activity Renal Tubular Acidosis, Distal, 
Autosomal Recessive [MIM:602722]









hydrogen-transporting ATP synthase activity, 
rotational mechanism













hydrogen-transporting ATP synthase activity, 
rotational mechanism




2 22749165 NP_689778 ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, 2 4
proton-transporting two-
sector ATPase complex
ATP synthesis coupled proton 
transport
hydrogen-transporting ATP synthase activity, 
rotational mechanism
hydrogen-transporting ATPase activity, 
rotation mechanism
2 19913424 NP_001681 ATP6V1A ATPase, H+ transporting, lysosomal 70kD, V22 49









hydrogen-transporting ATP synthase activity, 
rotational mechanism













ATP synthesis coupled proton 
transport





sensory perception of sound
ATP binding
hydrogen-exporting ATPase activity, 
phosphorylative mechanism
hydrogen-transporting ATP synthase activity, 
rotational mechanism





Renal Tubular Acidosis, Distal, with 
Progressive Deafness [MIM:267300]




ATP synthesis coupled proton 
transport






hydrogen-exporting ATPase activity, 
phosphorylative mechanism
hydrogen-transporting ATP synthase activity, 
rotational mechanism




2 4502315 NP_001686 ATP6V1C1 ATPase, H+ transporting, lysosomal 42kDa, 1 1
proton-transporting two-sec





hydrogen-transporting ATPase activity, 
rotational mechanism
hydrolase activity
hydrolase activity, acting on acid anhydrides, 






2 87159812 NP_001034451ATP6V1C2 vacuolar H+ ATPase C2 isoform a 1 1
proton-transporting two-secATP synthesis coupled proton tra
ATP binding
hydrolase activity, acting on acid anhydrides, 
catalyzing transmembrane movement of 
substances
2 7706757 NP_057078 ATP6V1D H(+)-transporting two-sector ATPase 2 3
proton-transporting two-sec




hydrogen-transporting ATP synthase activity, 
rotational mechanism












hydrogen-transporting ATP synthase activity, 
rotational mechanism














hydrogen-transporting ATP synthase activity, 
rotational mechanism














hydrogen-transporting ATP synthase activity, 
rotational mechanism













hydrogen-transporting ATP synthase activity, 
rotational mechanism









hydrogen ion transporter activity
hydrolase activity
metal ion binding
2 47717100 NP_998784 ATP6V1H ATPase, H+ transporting, lysosomal 50/57kD8 34
hydrogen-transporting 
ATPase V1 domain
peripheral to membrane 
of membrane fraction
ATP hydrolysis coupled proton 
transport










hydrogen-transporting ATP synthase activity, 
rotational mechanism














phosphotransferase activity, alcohol group 
as acceptor




2 21450861 NP_647537 ATRN attractin isoform 1 1 1
extracellular space







2 21450863 NP_647538 ATRN attractin isoform 2 1 1
extracellular space













defense response to Gram-
negative bacterium
glial cell migration











2 4757826 NP_004039 B2M beta-2-microglobulin precursor 1 1
extracellular region
antigen processing and 
presentation of endogenous 
antigen
antigen processing and 
presentation of endogenous 
peptide 
antigen via MHC class I
immune response




2 13929462 NP_001488 B4GALT1
UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase 1,













transferase activity, transferring glycosy
Congenital Disorder of Glycosylation 
Type Iid [MIM:607091]
1,2 9257197 NP_059344 BAIAP2 BAI1-associated protein 2 isoform 1 9 16 not classified not classified protein binding
2 9257199 NP_059345 BAIAP2 BAI1-associated protein 2 isoform 2 6 13 not classified not classified protein binding
1,2 32171238 NP_061330 BAIAP2L1 BAI1-associated protein 2-like 1 4 9 not classified not classified not classified
2 30795231 NP_006308 BASP1 brain abundant, membrane attached signal p6 20
cytoskeleton
plasma membrane not classified not classified
2 18375626 NP_542417 BAT2 HLA-B associated transcript-2 isoform a 1 14 nucleus not classified protein binding
2 14670390 NP_075381 BAZ1B bromodomain adjacent to zinc finger domain1 1
nucleus














oxidoreductase activity, acting on single 
donors with incorporation of molecular 
oxygen,incorporation of two atoms of oxygen
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2 31543106 NP_005572 BCAM basal cell adhesion molecule isoform 1 prec 1 1
cell surface







2 61742797 NP_001013275BCAM basal cell adhesion molecule isoform 2 prec 2 4
cell surface




signal transduction transmembrane receptor activity
2 20336332 NP_443074 BCL2L12 BCL2-like 12 isoform 2 1 1 not classified apoptosis not classified
2 82546843 NP_004318 BCR breakpoint cluster region isoform 1 2 2
intracellular
intracellular signaling cascade
protein amino acid 
phosphorylation





protein serine/threonine kinase activity
Rho guanyl-nucleotide exchange factor 
activity
transferase activity
2 82546845 NP_067585 BCR breakpoint cluster region isoform 2 2 3 intracellular
intracellular signaling cascade
protein amino acid 
phosphorylation





protein serine/threonine kinase activity
Rho guanyl-nucleotide exchange factor 
activity
transferase activity








2 4502403 NP_001702 BGN biglycan preproprotein 1 2




extracellular matrix structural constituent
transferase activity
2 39930463 NP_085142 BHLHB9 basic helix-loop-helix domain containing, cla 1 2 not classified not classified binding
Yes 1,2 4502407 NP_001704 BHMT betaine-homocysteine methyltransferase 12 37
not classified
protein amino acid methylation









2 13162290 NP_060084 BHMT2 betaine-homocysteine methyltransferase 2 1 1



















2 4502419 NP_000704 BLVRB biliverdin reductase B (flavin reductase (NAD4 4





2 4502447 NP_001716 BPI bactericidal/permeability-increasing protein p4 7
integral to plasma 
membrane
membrane






1,2 4757876 NP_004326 BST2 bone marrow stromal cell antigen 2 1 2







positive regulation of I-kappaB 
kinase/NF-kappaB cascade
defense response to bacterium
signal transducer activity
2 5802988 NP_006754 BTG2 B-cell translocation gene 2 1 3
not classified
DNA repair
negative regulation of cell 
proliferation




2 5802976 NP_006820 C10orf116 adipose specific 2 2 7 not classified not classified not classified
2 51468120 XP_374765 C10orf18 PREDICTED: similar to retinoblastoma-asso1 1 not classified not classified not classified
2 22749471 NP_689964 C10orf30 hypothetical protein LOC222389 1 1 not classified not classified not classified
2 42761479 NP_775860 C11orf47 hypothetical protein LOC283294 1 1 not classified not classified not classified
2 18087827 NP_542390 C11orf52 hypothetical protein LOC91894 1 1 not classified not classified not classified





1,2 8923579 NP_060377 C11orf59 hypothetical protein LOC55004 3 5 not classified not classified not classified
2 27902289 NP_776174 C12orf51 hypothetical protein LOC283450 1 1 not classified not classified not classified
2 23308507 NP_694567 C12orf59 hypothetical protein LOC120939 1 1 not classified not classified not classified
2 8392875 NP_037374 C16orf80 transcription factor IIB 1 1 not classified development not classified
2 22749499 NP_689979 C17orf61 hypothetical protein LOC254863 2 10 not classified not classified not classified
2 21361664 NP_060411 C17orf80 lung cancer-related protein 8 1 3 not classified not classified not classified
2 22748999 NP_689687 C19orf18 hypothetical protein LOC147685 1 1
integral to membrane
membrane not classified not classified
2 13027608 NP_076427 C1orf116 specifically androgen-regulated protein 4 6 not classified not classified not classified
2 28603818 NP_788954 C1orf179 hypothetical protein LOC338094 4 13 not classified not classified not classified
2 20149643 NP_060423 C1orf181 hypothetical protein LOC54680 1 1 not classified not classified not classified
2 68563515 NP_001020402C1orf45 keratinocyte expressed, proline-rich protein 1 1 not classified not classified not classified
1,2 21389601 NP_653296 C1orf58 hypothetical protein LOC148362 17 59 not classified not classified not classified
2 22748799 NP_689584 C1orf93 hypothetical protein LOC127281 1 1 not classified not classified not classified
2 71043622 NP_001012989C20orf106 hypothetical protein LOC200232 1 1 not classified not classified not classified
2 40807482 NP_149974 C20orf114 LPLUNC1 protein precursor 10 23 not classified not classified lipid binding
2 66773336 NP_542194 C20orf117 hypothetical protein LOC140710 isoform 1 1 1 not classified not classified catalytic activity
2 60685214 NP_115642 C2orf16 hypothetical protein LOC84226 1 1 not classified not classified not classified
2 31542711 NP_060347 C2orf18 hypothetical protein LOC54978 2 6
integral to membrane
membrane not classified not classified


















innate immune response endopeptidase inhibitor activity
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1,2 14165278 NP_115788 C5orf32 putative nuclear protein ORF1-FL49 2 28 nucleus not classified not classified
2 40354201 NP_954653 C6orf108 putative c-Myc-responsive isoform 2 1 1 nucleus cell proliferation not classified
1,2 21361741 NP_057569 C6orf55 (VTA1) hypothetical protein LOC51534 6 12 not classified not classified not classified
2 58219024 NP_001010905C6orf58 hypothetical protein LOC352999 1 1 not classified not classified not classified
2 13129018 NP_076956 C7orf24 hypothetical protein LOC79017 1 1 not classified not classified not classified
2 4502511 NP_001728 C9 complement component 9 1 1














1,2 11641247 NP_071738 C9orf19 chromosome 9 open reading frame 19 2 6
extracellular region
membrane not classified not classified
2 8923251 NP_060208 C9orf39 hypothetical protein LOC54875 1 1 membrane signal transduction two-component sensor activity
2 13899241 NP_113614 C9orf58 ionized calcium binding adapter molecule 2 2 3
actin cytoskeleton
focal adhesion not classified calcium ion binding
2 79750824 NP_001030611C9orf88 hypothetical protein LOC64855 isoform 2 2 3 not classified not classified not classified
1,2 4557395 NP_000058 CA2 carbonic anhydrase II 9 25





Autosomal recessive syndrome of 
osteopetrosis with renal tubular 
acidosis 
[MIM:259730]











Proximal renal tubular acidosis 
[MIM:114760]
1,2 7706481 NP_057373 CAB39 calcium binding protein 39 9 21 not classified not classified protein binding
2 72534734 NP_001026894CAB39L calcium binding protein 39-like 1 1 not classified not classified binding










dihydropyridine-sensitive calcium channel 
activity
receptor activity
voltage-gated ion channel activity
1,2 4826655 NP_004920 CALB1 calbindin 1 2 3




Yes 2 4502543 NP_001731 CALB2 calbindin 2 full length protein isoform 1 1 not classified not classified calcium ion binding
Yes 2 58218968 NP_005175 CALM3 calmodulin 3 1 1 not classified not classified calcium ion binding
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2 4885111 NP_005176 CALML3 calmodulin-like 3 1 1 not classified not classified calcium ion binding
2 4502557 NP_001735 CAMK4 calcium/calmodulin-dependent protein kinas 1 1
nucleus









protein serine/threonine kinase activity
transferase activity
2 39753970 NP_004336 CAMP cathelicidin antimicrobial peptide 1 3 extracellular region defense response to bacterium not classified
2 21361794 NP_060918 CAND1 TIP120 protein 1 2
nucleus
ubiquitin ligase complex
negative regulation of enzyme 
activity
protein ubiquitination








maintenance of cell polarity
signal transduction
actin binding
2 63252913 NP_001738 CAPG gelsolin-like capping protein 8 20
F-actin capping protein 
complex
nucleus




2 12408656 NP_005177 CAPN1 calpain 1, large subunit 15 26
intracellular





2 4502563 NP_001739 CAPN2 calpain 2, large subunit 1 1 intracellular proteolysis
calcium ion binding
calpain activity
2 37577157 NP_004046 CAPN5 calpain 5 10 20 intracellular
proteolysis
signal transduction calpain activity






2 5453597 NP_006126 CAPZA1 F-actin capping protein alpha-1 subunit 2 2
F-actin capping 
protein complex
actin cytoskeleton organization 
and biogenesis





2 5453599 NP_006127 CAPZA2 capping protein (actin filament) muscle Z-line1 1
F-actin capping 
protein complex
actin cytoskeleton organization 
and biogenesis





2 4826659 NP_004921 CAPZB F-actin capping protein beta subunit 2 3
F-actin capping 
protein complex
actin cytoskeleton organization 
and biogenesis








carbonyl reductase (NADPH) activity
oxidoreductase activity
prostaglandin-E2 9-reductase activity
Yes 2 4502601 NP_001227 CBR3 carbonyl reductase 3 2 5 cytosol metabolism




2 24431973 NP_060191 CC2D1A coiled-coil and C2 domain containing 1A 6 6
nucleus
positive regulation of I-kappaB 
kinase/NF-kappaB cascade





Mental Retardation Autosomal 
Recessive 3 [MIM:608443]
2 27735063 NP_775753 CCDC105 coiled-coil domain containing 105 2 2 not classified not classified not classified
2 5453603 NP_006422 CCT2 chaperonin containing TCP1, subunit 2 1 1
cytosol
protein folding














2 24307939 NP_036205 CCT5 chaperonin containing TCP1, subunit 5 (eps 3 8









































structural constituent of cytoskeleton
Focal Segmental Glomerulosclerosis 
FSGS3 [MIM:607832]









1,2 4502679 NP_001771 CD63 CD63 antigen isoform A 1 5
endosome membrane
integral to membrane




not classified not classified
2 91199546 NP_001035123CD63 CD63 antigen isoform B 2 50
endosome membrane
integral to membrane
integral to plasma 
membrane
lysosomal membrane
plasma membrane not classified not classified
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1,2 4757944 NP_004347 CD81 CD81 antigen 4 18
integral to plasma 
membrane
membrane
activation of MAPK activity




positive regulation of 
1-phosphatidylinositol 4-kinase 
activity
positive regulation of B cell 
proliferation
positive regulation of cel
protein binding
1,2 4502693 NP_001760 CD9 CD9 antigen 7 67
integral to membrane


















protein amino acid 
phosphorylation
regulation of progression 
through cell cycle
traversing start control point of 
mitotic cell cycle
ATP binding














maintenance of cell polarity
G1 phase
macrophage differentiation
negative regulation of protein 
complex assembly

















maintenance of cell polarity
G1 phase
macrophage differentiation
negative regulation of protein 
complex assembly



















maintenance of cell polarity
G1 phase
macrophase differentiation
negative regulation of protein 
complex assembly
positive regulation of 
pseudopodium formation
regulation of cell growth
regulation of progression 
through cell cycle












protein amino acid 
phosphorylation










protein serine/threonine kinase activity
small GTPase regulator activity
transferase activity
zinc ion binding






cytoskeleton organization and 
biogenesis
establishment and/or 
maintenance of cell polarity
intracellular signaling cascade
protein amino acid 
phosphorylation







protein serine/threonine kinase activity
small GTPase regulator activity
transferase activity
zinc ion binding
















positive regulation of neuron 
apoptosis
protein amino acid 
phosphorylation
striated muscle development
acetylcholine receptor activator activity
ATP binding
cyclin-dependent protein kinase activity
ErbB-2 class receptor binding









regulation of neuron 
differentiation
microtubule binding
neuronal Cdc2-like kinase binding
2 11386171 NP_004354 CEACAM5 carcinoembryonic antigen-related cell adhes 1 1
integral to membrane
integral to plasma 
membrane
membrane
not classified GPI anchor binding
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2 21735548 NP_009117 CEP250 centrosomal protein 2 isoform 1 1 1
centrosome
mitotic cell cycle
regulation of centriole-centriole 
cohesion
protein kinase binding






catalytic activitylipid binding Cholesterol Ester Transfer Protein 
Deficiency [MIM:607322]






complement factor D activity
peptidase activity
2 62739188 NP_001014975 CFH complement factor H isoform b precursor 1 1 extracellular space
complement activation, alternative 
pathway
innate immune response not classified
Hemolytic Uremic Syndrome, 
Atypical [MIM: 235400]
2 119392081 NP_000195 CFI complement factor I 1 1
extracellular region
membrane




complement factor I activity
peptidase activity
scavenger receptor activity
Complement Factor I Deficiency 
[MIM: 610984]





actin cytoskeleton organization 
and biogenesis
anti-apoptosis
Rho protein signal transduction
actin binding
protein binding













2 8923390 NP_060282 CHCHD3 coiled-coil-helix-coiled-coil-helix domain con 1 2 mitochondrion not classified protein binding













negative regulation of S phase 
of mitotic cell cycle
negative regulation of 
transcription by glucose




vesicle-mediated transport protein binding
1,2 31542306 NP_065145 CHMP1B chromatin modifying protein 1B 6 45 not classified protein transport not classified
1,2 7656922 NP_055268 CHMP2A chromatin modifying protein 2A 11 73 not classified protein transport not classified
1,2 40254866 NP_054762 CHMP2B chromatin modifying protein 2B 4 15




1,2 28827795 NP_789782 CHMP4B chromatin modifying protein 4B 2 6 not classified protein transport not classified
1,2 20127558 NP_057494 CHMP5 chromatin modifying protein 5 2 7 not classified protein transport not classified
2 31542673 NP_078867 CHMP6 chromatin modifying protein 6 2 3 membrane protein transport not classified
2 6005731 NP_009167 CHP calcium binding protein P22 1 1 not classified
potassium ion transport
small GTPase mediated signal 
transduction
calcium ion binding
potassium channel regulator activity
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2 19920317 NP_006816 CKAP4 cytoskeleton-associated protein 4 1 3
integral to membrane
membrane fraction not classified not classified
2 21536286 NP_001814 CKB brain creatine kinase 8 28 cytoplasm not classified creatine kinase activity
Yes 2 4502877 NP_001296 CLDN4 claudin 4 1 1























voltage-gated chloride channel activity









voltage-gated chloride channel activity














voltage-gated chloride channel activity










voltage-gated chloride channel activity




voltage-gated chloride channel activity
2 4758012 NP_004850 CLTC clathrin heavy chain 1 12 24




structural molecule activity Renal Cell Carcinoma [MIM:118955]
Yes 2 9257202 NP_009029 CLTCL1 clathrin, heavy polypeptide-like 1 4 6





















lipid metabolism not classified
2 20270371 NP_620164 CMBL carboxymethylenebutenolidase-like (Pseudo6 13 not classified not classified hydrolase activity
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2 41393057 NP_055742 CNKSR2 connector enhancer of kinase suppressor of 2 1
cytoplasm
membrane
regulation of signal 
transduction protein binding


















2 62821787 NP_055715 COBLL1 COBL-like 1 1 3 not classified not classified not classified
2 18641350 NP_001846 COL15A1 alpha 1 type XV collagen precursor 1 3
collagen type XV
cytoplasm












extracellular matrix (sensu 
Metazoa)
cell adhesion









zinc ion binding Knobloch Syndrome [MIM:267750]






extracellular matrix structural constituent
protein binding
Bethlem Myopathy [MIM:158810]
Ullrich Congenital Muscular 
Dystrophy, 
Autosomal Dominant [MIM:254090]
2 55743106 NP_476508 COL6A3 alpha 3 type VI collagen isoform 5 precursor 1 2
collagen type VI
cytoplasm






serine-type endopeptidase inhibitor activity
structural molecule activity
Ullrich Congenital Muscular 
Dystrophy [MIM: 254090]






















2 38027914 NP_937832 COPS8 COP9 signalosome subunit 8 isoform 2 1 1
nucleus
signalosome complex metabolism
racemase and epimerase activity, 
acting on amino acids and derivatives















copper ion transporter activity
ferroxidase activity
metal ion binding 
oxidoreductase activity Aceruloplasminemia [MIM:604290]












2 88971372 XP_947165 CPN2 PREDICTED: similar to Carboxypeptidase N2 1 not classified not classified not classified







Yes 2 30181236 NP_689940 CPNE2 copine II 1 1 not classified not classified not classified







protein serine/threonine kinase activity
transferase activity
transporter activity
1,2 25141323 NP_065990 CPNE5 copine V 3 5 not classified not classified not classified








Yes 1,2 25121972 NP_705898 CPNE8 copine VIII 16 37 not classified not classified not classified
Yes 2 88703066 NP_705899 CPNE9 copine-like protein 5 27 not classified not classified not classified
2 83641874 NP_112601 CPVL serine carboxypeptidase vitellogenic-like 6 12 not classified proteolysis
peptidase activity
serine carboxypeptidase activity
1,2 86793036 NP_000564 CR1 complement receptor 1 isoform F precursor 17 87






complement component C3b receptor 
activity
receptor activity
Yes 2 86793109 NP_000642 CR1 complement receptor 1 isoform S precursor 13 92






complement component C3b receptor 
activity
receptor activity
2 4503029 NP_001869 CRABP2 cellular retinoic acid binding protein 2 1 4
not classified
epidermis development






2 63054825 NP_775960 CRB2 crumbs homolog 2 1 2
integral to membrane
membrane response to stimulusvisual perccalcium ion binding
2 21040241 NP_631900 CRB3 crumbs 3 isoform a precursor 1 6
integral to membrane
membrane
tight junction not classified not classified
2 59938770 NP_878901 CREB5 cAMP responsive element binding protein 5 2 2
intracellular
nucleus
positive regulation of 
transcription, DNA-dependent
transcription









2 41327712 NP_058431 CRK v-crk sarcoma virus CT10 oncogene homolo1 1
cytoplasm
nucleus




regulation of transcription from 



















response to unfolded protein
calcium ion binding








2 32171215 NP_859066 CRTC2 transducer of regulated cAMP response elem1 1 not classified not classified not classified





transmembrane receptor protein 
tyrosine kinase signaling pathway
visual perception




2 7705744 NP_057058 CRYL1 lambda-crystallin 7 21 not classified fatty acid metabolism oxidoreductase activity
2 4503065 NP_001879 CRYM crystallin, mu isoform 1 1 3
not classified visual perception
ornithine cyclodeaminase 
activity
Autosomal Dominant Nonsyndromic 
Deafness [MIM:123740]
2 62241008 NP_001014444CRYM crystallin, mu isoform 2 1 3 not classified visual perception ornithine cyclodeaminase activity
2 13236495 NP_001880 CRYZ crystallin, zeta 4 7














importin-alpha export receptor activity
protein transporter activity




protein amino acid 
phosphorylation







Yes 2 98986450 NP_071331 CSNK1G1 casein kinase 1, gamma 1 1 1 not classified
protein amino acid 
phosphorylation




protein serine/threonine kinase activity
transferase activity
Yes 2 21314778 NP_001310 CSNK1G2 casein kinase 1, gamma 2 1 1
not classified
protein amino acid 
phosphorylation
signal transduction
Wnt receptor signaling 
pathway
ATP binding
casein kinase I activity
nucleotide binding
protein kinase activity
protein serine/threonine kinase activity
transferase activity





2 4503107 NP_000090 CST3 cystatin C precursor 1 3 not classified not classified




2 4503117 NP_000091 CSTB cystatin B 2 10
intracellular
nucleus
not classified cysteine protease inhibitor activity Myoclonic Epilepsy of Unverricht and 
Lundborg [MIM:254800]
2 56549681 NP_005799 CTDSPL small CTD phosphatase 3 isoform 2 1 3 nucleus not classified phosphoric monoester hydrolase activity
2 56549683 NP_001008393CTDSPL small CTD phosphatase 3 isoform 1 1 4 nucleus not classified phosphoric monoester hydrolase activity




lyase activity Cystathioniruria [MIM:219500]








proteolysis L-cystine transporter activity
Nephropathic Cystinosis [MIM: 
219800]









serine carboxypeptidase activity Galactosialidosis [MIM:256540]















Papillo-LeFevre Syndrome [MIM: 
245000]






Neuronal Ceroid Lipofuscinosis 
[MIM:610127]





1,2 4557503 NP_001072 CUBN cubilin 104 672
brush border membrane
















transporter activity Megaloblastic Anemia 1, Finnish Type 
[MIM:261100]
2 4503165 NP_003581 CUL3 cullin 3 1 1 nucleus
cell cycle
cell cycle arrest
G 1/S transition of mitotic cell 
cycle
induction of apoptosis by 
intracellular signals
positive regulation of cell 
proliferation
ubiquitin cycle protein binding




protein binding Cabezas Syndrome [MIM:300354]
Mental Retardation-Hypotonic Facies 
Syndrome [MIM:300639]
2 62198241 NP_001014433CUTA cutA divalent cation tolerance homolog isofo 1 1 membrane protein localization enzyme binding
2 62526026 NP_001014840CUTA cutA divalent cation tolerance homolog isofo 1 1 membrane protein localization enzyme binding
2 54792785 NP_056082 CUTL2 cut-like 2 2 2 nucleus regulation of transcription, DNA-d
sequence-specific DNA binding
transcription factor activity





Yes 2 74271907 NP_001028200CYFIP1 cytoplasmic FMR1 interacting protein 1 isofo4 5 not classified not classified not classified
Yes 2 24307969 NP_055423 CYFIP1 cytoplasmic FMR1 interacting protein 1 isofo1 1 not classified not classified not classified
2 82617630 NP_055191 CYFIP2 cytoplasmic FMR1 interacting protein 2 1 1
cytoplasm
synaptosome not classified not classified
2 20149621 NP_056348 DAK dihydroxyacetone kinase 2 15 37












activation of JNK activity
endocytosis
immune response




2 16751921 NP_444513 DCD dermcidin preproprotein 1 1 extracellular region
defense response to bacterium
defense response to fungus
xenobiotic metabolism manganese ion binding



















1,2 6912328 NP_036269 DDAH1 dimethylarginine dimethylaminohydrolase 1 1 5
not classified
arginine catabolism





zinc ion binding Hypertension [MIM: 604743]









2 148529014 NP_001914 DDB1 damage-specific DNA binding protein 1 1 1 nucleus
nucleotide-excision repair
ubiquitin cycle damaged DNA binding
2 4503281 NP_000781 DDC dopa decarboxylase (aromatic L-amino acid deca11 31
not classified







Aromatic L-Amino Acid 
Decarboxylase Deficiency 
[MIM:608643]
1,2 4503291 NP_001346 DDT D-dopachrome tautomerase 1 1 not classified melanin biosynthesis from tyrosi
dopachrome isomerase activity
lyase activity
2 62241024 NP_001014451DDX19B DEAD (Asp-Glu-Ala-As) box polypeptide 19 1 1
cytoplasm
nuclear pore


































Yes 1,2 4885179 NP_005208 DEFA3 defensin, alpha 3 preproprotein 2 14
extracellular region
defense response to bacterium




2 38158020 NP_919409 DHX34 DEAH (Asp-Glu-Ala-His) box polypeptide 34 1 1



















Yes 2 55749758 NP_775873 DIP2B DIP2 disco-interacting protein 2 homolog B 2 3 nucleus metabolism
catalytic activity
transcription factor binding
2 63055057 NP_001017992DKFZp686D0972 hypothetical protein LOC345651 2 2 not classified not classified protein binding








induction of bacterial 
agglutination
innate immune response
negative regulation of 
progression through cell cycle
calcium-dependent protein binding
pattern recognition receptor activity
scavenger receptor activity
Yes 2 17864092 NP_061720 DNAH7 axonemal dynein heavy chain 7 1 1 axonemal dynein complex ciliary or flagellar motility microtubule motor activity
1,2 15029526 NP_001362 DNAH8 dynein, axonemal, heavy polypeptide 8 1 1
axonemal dynein complex
dynein complex







2 4504511 NP_001530 DNAJA1 DnaJ (Hsp40) homolog, subfamily A, membe1 1
not classified protein folding
response to unfolded protein
heat shock protein binding




2 5031741 NP_005871 DNAJA2 DnaJ subfamily A member 2 1 1
membrane
G1 phase of mitotic cell cycle
positive regulation of cell 
proliferation
protein folding
regulation of progression 
through cell cycle






2 5453690 NP_006136 DNAJB1 DnaJ (Hsp40) homolog, subfamily B, membe2 2
nucleus
protein folding
response to unfolded protein
heat shock protein binding
unfolded protein binding
2 74047534 NP_056083 DNAJC13 DnaJ (Hsp40) homolog, subfamily C, memb 1 1 not classified protein folding
binding
heat shock protein binding
2 4507713 NP_003306 DNAJC7 DnaJ (Hsp40) homolog, subfamily C, memb 1 1 not classified protein folding heat shock protein binding





G2/M transition of mitotic cell 
cycle













Dominant Intermediate B 
[MIM:606482]





G2/M transition of mitotic cell 
cycle
positive regulation of apoptosis












Dominant Intermediate B [MIM: 
606482]





Golgi to endosome transport
not classified




























2 4503375 NP_001376 DPYS dihydropyrimidinase 5 6
not classified
nucleobase, nucleoside, nucleotide 













protein binding Arrhythmogenic right ventricular 
dysplasia-11 [MIM:610476]



















structural constituent of cytoskeleton
Keratosis Palmoplantaris Striata II 
Dilated Cardiomyopathy 
With Woolly Hair and Keratoderma 
[MIM:605676]








structural constituent of cytoskeleton
2 5802966 NP_006861 DSTN destrin isoform a 1 3 intracellular not classified actin binding
Yes 2 58530848 NP_001011546DSTN destrin isoform b 2 6 intracellular not classified actin binding
2 13128968 NP_076930 DUSP26 dual specificity phosphatase 26 1 1 not classified
































2 4503431 NP_003485 DYSF dysferlin 1 1
integral to membrane
plasma membrane muscle contraction not classified Miyoshi Myopathy [MIM: 254130]
2 4503443 NP_001388 ECE1 endothelin converting enzyme 1 1 1





endothelin-converting enzyme 1 activity
metal ion binding
neprilysin activity
zinc ion binding Hirschsprung Disease [MIM: 142623]








early endosome to late 
endosome transport

















translation elongation factor activity







translation elongation factor activity
2 4503483 NP_001952 EEF2 eukaryotic translation elongation factor 2 4 7
not classified protein biosynthesis
GTP binding
nucleotide binding
translation elongation factor activity
2 9665262 NP_004096 EFEMP1 EGF-containing fibulin-like extracellular matr1 1 extracellular matrix (sensu visual perception
calcium ion binding
protein binding
Doyne Honeycomb Retinal 
Dystrophy [MIM: 126600]
2 4758248 NP_004420 EFNB1 ephrin-B1 precursor 1 1


















activation of MAPK activity
chromosome organization and 
biogenesis (sensu Eukaryota)
DNA replication
epidermal growth factor 
receptor signaling pathway
positive regulation of cell 
proliferation
calcium ion binding




2 38093661 NP_938024 EGFL11 EGF-like-domain, multiple 11 1 2
integral to membrane
membrane not classified ATP binding
1,2 30240932 NP_006786 EHD1 EH-domain containing 1 14 34
































2 4503515 NP_003747 EIF3H eukaryotic translation initiation factor 3, subu1 5
eukaryotic translation 
initiation factor 3 complex
protein biosynthesis
regulation of translational 
initiation
translation initiation factor activity
not classified
Yes 2 83700235 NP_001958 EIF4A2 eukaryotic translation initiation factor 4A2 1 2
eukaryotic translation 
initiation factor 4F 
complex
protein biosynthesis









translation initiation factor activity






translation initiation factor activity




translation initiation factor activity
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negative regulation of chemokine 
biosynthesis
negative regulation of chemotaxis
negative regulation of 
inflammatory response
negative regulation of interleukin-8 
biosynthesis







2 34485720 NP_899243 EML5 echinoderm microtubule associated protein 1 1 not classified not classified lyase activity






















1,2 36951116 NP_001968 ENPEP glutamyl aminopeptidase (aminopeptidase A) 25 100








membrane alanyl aminopeptidase activity
metallopeptidase activity
zinc ion binding Hypertension [MIM:138297]
2 4826896 NP_005012 ENPP3 ectonucleotide pyrophosphatase/phosphodie2 2










2 7662358 NP_055751 ENPP4 ectonucleotide pyrophosphatase/phosphodie2 1 not classified nucleotide metabolism not classified




nucleotide metabolism hydrolase activity










oxygen and reactive oxygen 
species metabolism








2 8923678 NP_060427 EPN3 epsin 3 1 1 not classified not classified lipid binding
2 13876386 NP_112598 EPPK1 epiplakin 1 4 6 cytoskeleton not classified structural molecule activity
1,2 56682953 NP_004438 EPS8 epidermal growth factor receptor pathway su14 30
not classified
cell proliferation





2 21264608 NP_573441 EPS8L1
epidermal growth factor receptor pathway 
substrate 8-like protein 1 isoform a 6 8
not classified not classified not classified
2 148539855 NP_060199 EPS8L1 epidermal growth factor receptor pathway su4 7 not classified not classified hydrolase activity
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2 21264616 NP_073609 EPS8L2
epidermal growth factor receptor pathway 
substrate 8-like protein 2 11 18
not classified not classified not classified
Yes 2 4503595 NP_000493 EPX eosinophil peroxidase 1 1





2 33413400 NP_001975 ESD esterase D/formylglutathione hydrolase 1 1
cytoplasmic membrane-


















coagulation factor IXa activity
coagulation factor XIa activity
heparin binding
peptidase activity








1,2 4758328 NP_004093 FABP3 fatty acid binding protein 3 2 6
cytoplasm
soluble fraction





2 4557587 NP_000128 FAH fumarylacetoacetate hydrolase (fumarylacetoacet2 2
not classified








magnesium ion binding Tyrosinemia Type I [MIM:276700]
1,2 24308440 NP_612410 FAM125A hypothetical protein LOC93343 2 4 nucleus not classified not classified
2 58761488 NP_258257 FAM125B hypothetical protein LOC89853 isoform 1 1 1 not classified not classified not classified
2 116174742 NP_064608 FAM20C family with sequence similarity 20, member C1 1 not classified not classified not classified
2 56790935 NP_149079 FAM40A hypothetical protein LOC85369 1 1 not classified not classified not classified
2 42734438 NP_057707 FAM49B hypothetical protein LOC51571 1 2 not classified not classified not classified
2 39995080 NP_078795 FAM65A hypothetical protein LOC79567 2 2 not classified not classified
binding
DNA-directed RNA polymerase activity
2 41872631 NP_004095 FASN fatty acid synthase 20 38
not classified fatty acid biosynthesis
3-hydroxypalmitoyl-[acyl-carrier protein] 
dehydratase activity
3-oxoacyl-[acyl-carrier protein] reductase 
activity




enoyl-[acyl-carrier protein] reductase 
(NADPH, B-spec
2 66346693 NP_005236 FAT FAT tumor suppressor 1 precursor 1 1









2 12056465 NP_001427 FBL fibrillarin 1 1
nucleus




























phosphoric ester hydrolase activity
1,2 4503681 NP_003881 FCGBP Fc fragment of IgG binding protein 14 34 not classified not classified not classified
2 61744445 NP_004099 FCN2 ficolin 2 isoform a precursor 2 4
cytoplasm












muscle contraction not classified





muscle contraction calcium ion binding




















positive regulation of cell 
proliferation
not classified










2 70906439 NP_068656 FGG fibrinogen, gamma chain isoform gamma-B 1 3 fibrinogen complex
blood pressure regulation
platelet activation
positive regulation of cell 
proliferation
protein polymerization
signal transduction FK506 binding
2 5730075 NP_006673 FGL2 fibrinogen-like 2 precursor 4 7 fibrinogen complex not classified not classified



















peptidyl-prolyl cis-trans isomerase activity
protein binding
Yes 2 62990121 NP_001017421FKSG30 actin-like protein 6 135
actin filament not classified
ATP binding
protein binding
structural constituent of cytoskeleton














2 22749369 NP_689894 FLJ38482 hypothetical protein LOC201931 1 1 not classified not classified not classified
2 116063573 NP_001447 FLNA filamin A, alpha isoform 1 1 1 actin cytoskeleton
actin cytoskeleton organization 
and biogenesis
cell motility
cell surface receptor linked 
signal transduction
nervous system development






2 105990514 NP_001448 FLNB filamin B, beta (actin binding protein 278) 1 1
actin cytoskeleton
integral to membrane















not classified protein binding





















protein tyrosine kinase 
signaling pathway
collagen binding
extracellular matrix structural constituent
heparin binding
oxidoreductase activity
2 16933542 NP_002017 FN1 fibronectin 1 isoform 3 preproprotein 9 18
ER-Golgi intermediate 
compartment









protein tyrosine kinase 
signaling pathway
collagen binding





Yes 2 62548858 NP_001014986FOLH1 folate hydrolase 1 isoform 2 1 1














negative regulation of cell 
proliferation
protein amino acid 
phosphorylation
regulation of progression 
through cell cycle
ATP binding




2 11140815 NP_006648 FTCD formiminotransferase cyclodeaminase 6 6
cytoplasm






























Iron Overload, Autosomal Dominant 
[MIM:134770]

















hydrolase activity, acting on glycosyl bonds
Fucosidosis [MIM:230000]
2 20149693 NP_079405 FUZ fuzzy homolog 1 1 not classified not classified not classified













Hypomagnesemia 2, Renal 
[MIM:154020]








Nonspherocytic Hemolytic Anemia 
due to G6PD Deficiency 
[MIM:305900]
1,2 4503849 NP_000143 GAA acid alpha-glucosidase preproprotein 4 8
lysosome
carbohydrate metabolism





hydrolase activity, hydrolyzing O-glycosyl 
compounds Infantile-onset Glycogen Storage 
Disease Type II [MIM:232300]
2 119393895 NP_001073272GAA acid alpha-glucosidase preproprotein 5 8 lysosome
carbohydrate metabolism









2 12548785 NP_068711 GABRB2 gamma-aminobutyric acid (GABA) A recepto1 1













Yes 2 109948279 NP_001035972GAL7 galectin 7 1 4 not classified not classified not classified












Galactokinase Deficiency [MIM: 
230200]





2 38202257 NP_938148 GANAB alpha glucosidase II alpha subunit isoform 2 1 1
endoplasmic reticulum carbohydrate metabolism
hydrolase activity
hydrolase activity, hydrolyzing O-glycosyl 
compounds
protein binding
2 88900491 NP_938149 GANAB alpha glucosidase II alpha subunit isoform 3 1 1 endoplasmic reticulum carbohydrate metabolism
hydrolase activity, hydrolyzing O-glycosyl 
compounds
protein binding
hydrolase activity, acting on glycosyl bonds







Yes 2 7657116 NP_055179 GAPDHS glyceraldehyde-3-phosphate dehydrogenase1 5 not classified
glucose metabolism
glycolysis






2 4557619 NP_000149 GBE1 glucan (1,4-alpha-), branching enzyme 1 1 2
not classified
carbohydrate metabolism
generation of precursor metabolites 
and energy
glycogen biosynthesis
1,4-alpha-glucan branching enzyme activity
cation binding
hydrolase activity, hydrolyzing O-glycosyl 
compounds
transferase activity, transferrin glycosyl groups Type IV Glycogen Storage Disease 
[MIM:232500]
2 6912388 NP_036330 GCA grancalcin, EF-hand calcium binding protein 1 1
cytoplasm
plasma membrane membrane fusion calcium ion binding











Congenital Disorder of Glycosylation 
[MIM: 606056]





Yes 2 4503971 NP_001484 GDI1 GDP dissociation inhibitor 1 6 17
cytoplasm
protein transport
regulation of GTPase activity
signal transduction
GTPase activator activity
Rab GDP-dissociation inhibitor activity




regulation of GTPase activity
signal transduction
GTPase activator activity
Rab GDP-dissociation inhibitor activity
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2 146198640 NP_077283 GDPD3
glycerophosphodiester phosphodiesterase 
domain containing 3 1 2
not classified glycerol metabolism
glycerophosphodiester 
phosphodiesterase activity




































2 22035692 NP_665736 GFRA1 GDNF family receptor alpha 1 isoform b pre 1 1
extrinsic to membrane
membrane
cell surface receptor linked signa


















Yes 2 62079287 NP_002049 GGT2 (GGT1) gamma-glutamyltransferase 2 11 116 cellular component unknowglutathione biosynthesis
gamma-glutamyl
transferase activity
2 118200356 NP_055209 GHITM growth hormone inducible transmembrane p 1 1
integral to membrane
membrane
mitochondrion not classified protein binding


















2 41393579 NP_060125 GIPC2 PDZ domain protein GIPC2 1 1 not classified not classified protein binding










Glycerol Kinase Deficiency [MIM: 
307030]




















hydrolase activity, acting on glycosyl bonds Gangliosidosis GM1 [MIM:230500]








hydrolase activity, acting on glycosyl bonds










fibroblast growth factor binding
receptor binding







Yes 2 7705987 NP_057517 GLTP glycolipid transfer protein 1 1 membrane glycolipid transport
glycolipid binding
glycolipid transporter activity




regulation of neurotransmitter 
levels
glutamate-ammonia ligase activity
ligase activity Congenital Glutamine Deficiency 
[MIM:610015]







protein activity Gangliosidosis GM2 AB Variant 
Tay-Sachs Disease [MIM:272750]
1,2 4504037 NP_002058 GNA11 guanine nucleotide binding protein (G protei 7 20
cytoplasm
plasma membrane
G-protein coupled receptor 
protein signaling pathway







Yes 2 42476111 NP_031379 GNA12 guanine nucleotide binding protein (G protei 1 11 membrane
blood coagulation








Yes 2 24111250 NP_006563 GNA13 guanine nucleotide binding protein (G protei 9 20
membrane
cell motility







receptor signaling protein activity




G-protein coupled receptor 
protein signaling pathway







1,2 33946324 NP_002060 GNAI1
guanine nucleotide binding protein (G 
protein), 
alpha inhibiting activity polypeptide 1 8 16
plasma membrane









1,2 4504041 NP_002061 GNAI2
guanine nucleotide binding protein (G 
protein), 
alpha inhibiting activity polypeptide 2 8 21
not classified
G-protein coupled receptor 
protein signaling pathway








1,2 5729850 NP_006487 GNAI3
guanine nucleotide binding protein (G 
protein), 
alpha inhibiting activity polypeptide 3 8 16
not classified
G-protein coupled receptor 
protein signaling pathway








Yes 2 41281685 NP_620073 GNAO1 guanine nucleotide binding protein, alpha ac 2 4
not classified
axon guidance








receptor signaling protein activity






G-protein coupled receptor 
protein signaling pathway
phospholipase C activation













G-protein coupled receptor 
protein signaling pathway
















G-protein coupled receptor 
protein signaling pathway
















G-protein coupled receptor 
protein signaling pathway










Yes 2 20330805 NP_005263 GNAT2 guanine nucleotide binding protein, alpha tra1 3
heterotrimeric G-protein co










1,2 11321585 NP_002065 GNB1 guanine nucleotide-binding protein, beta-1 s 2 6 not classified signal transduction signal transducer activity
Yes 1,2 20357529 NP_005264 GNB2 guanine nucleotide-binding protein, beta-2 s 9 67 not classified signal transduction signal transducer activity
2 5174447 NP_006089 GNB2L1 guanine nucleotide binding protein (G protei 1 1 cytoplasm
protein kinase C activation
signal transduction




Yes 2 4504053 NP_002066 GNB3 guanine nucleotide-binding protein, beta-3 s 1 1 not classified
blood pressure regulation

























regulation of G-protein coupled 
















2 50541946 NP_001002296GOLGA7 golgi autoantigen, golgin subfamily a, 7 1 4 membrane not classified not classified




























isomerase activity Chronic Hemolytic Anemia Duet to 
GPI Deficiency [MIM:172400]
Yes 2 42476105 NP_963886 GPM6A glycoprotein M6A isoform 3 1 1
cell surface
integral to plasma 
membrane
membrane
not classified not classified
2 42476108 NP_963885 GPM6A glycoprotein M6A isoform 2 1 1
cell surface
integral to plasma 
membrane
membrane not classified glutathione peroxidase activity
















G-protein coupled receptor activity
receptor activity
Familial Febrile Seizures 
[MIM:604352]
Usher Syndrome Type IIC 
[MIM:605472]
1,2 4506403 NP_003970 GPRC5A G protein-coupled receptor, family C, group 1 4
integral to plasma 
membrane
membrane
G-protein coupled receptor 
protein signaling pathway
signal transduction





1,2 7706451 NP_057319 GPRC5B G protein-coupled receptor, family C, group 7 52
integral to membrane
membrane








2 40217833 NP_061123 GPRC5C G protein-coupled receptor family C, group 511 133
integral to plasma 
membrane
membrane
G-protein coupled receptor 
protein signaling pathway
signal transduction


































epidermal growth factor receptor binding
2 4504111 NP_002077 GRB2 growth factor receptor-bound protein 2 isofo 3 4
cytosol
cell-cell signaling
epidermal growth factor 
receptor signaling pathway
insulin receptor signaling 
pathway
intracellular signaling cascade
Ras protein signal transduction
epidermal growth factor receptor binding
insulin receptor substrate binding
SH3/SH2 adaptor activity
2 45359859 NP_987102 GRB2 growth factor receptor-bound protein 2 isofo 2 5 cytosol
cell-cell signaling
epidermal growth factor 
receptor signaling pathway
insulin receptor signaling 
pathway
intracellular signaling cascade
Ras protein signal transduction
insulin receptor substrate binding
SH3/SH2 adaptor activity
glycerate dehydrogenase activity









oxidoreductase activity, acting on the CH-OH 
group of donors, NAD or NADP as acceptor
protein binding
glutathione transferase activity
2 55770852 NP_060021 GRID1 glutamate receptor, ionotropic, delta 1 1 3
integral to membrane
membrane




glutamate-gated ion channel activity
ion channel activity
ionotropic glutamate receptor activity
receptor activity
transporter activity
































Glutathione Synthetase Deficiency 
[MIM:266130]





Yes 1,2 20149504 NP_000837 GSTA2 glutathione S-transferase A2 10 70 not classified metabolism
glutathione transferase activity
transferase activity





Yes 2 24308514 NP_714543 GSTA5 glutathione S-transferase A5 1 3 not classified metabolism
glutathione transferase activity
transferase activity
2 72534726 NP_001026890GSTCD glutathione S-transferase, C-terminal domai 1 1 not classified not classified
methyltransferase activity
transferase activity
Yes 2 23065544 NP_000552 GSTM1 glutathione S-transferase M1 isoform 1 1 2 cytoplasm metabolism
glutathione transferase activity
transferase activity
Yes 2 23065547 NP_666533 GSTM1 glutathione S-transferase M1 isoform 2 3 6 cytoplasm metabolism
glutathione transferase activity
transferase activity
2 4504175 NP_000839 GSTM2 glutathione S-transferase M2 1 1 not classified metabolism
glutathione transferase activity
transferase activity
Yes 1,2 23065552 NP_000840 GSTM3 glutathione S-transferase M3 9 28
not classified





2 4758484 NP_004823 GSTO1 glutathione-S-transferase omega 1 1 1
cytoplasm metabolism
glutathione transferase activity
monodehydroascorbate reductase (NADH) 
activity
transferase activity
2 38016131 NP_899062 GSTO2 glutathione S-transferase omega 2 1 1 cytoplasm metabolism
glutathione transferase activity
transferase activity
1,2 4504183 NP_000843 GSTP1 glutathione transferase 9 25
cytoplasm
anti-apoptosis

















2 24475863 NP_722575 H1FOO oocyte-specific histone H1 1 1
nucleosome
nucleus nucleosome assembly DNA binding























Yes 2 4504347 NP_000549 HBA1 alpha 1 globin 2 11





















Yes 2 4504351 NP_000510 HBD delta globin 1 5







Yes 2 28302131 NP_000550 HBG1 A-gamma globin 1 2













translation elongation factor activity
2 14149777 NP_115500 HDHD2 haloacid dehalogenase-like hydrolase doma 1 1 not classified metabolism metal ion binding
1,2 20336761 NP_057071 HEBP1 heme binding protein 1 6 8 not classified not classified not classified
2 7657603 NP_055135 HEBP2 heme binding protein 2 1 1 not classified not classified not classified
2 4504381 NP_000178 HGD homogentisate 1,2-dioxygenase 2 3















2 4885413 NP_005331 HINT1 histidine triad nucleotide binding protein 1 1 1
cytoskeleton
nucleus signal transduction
protein kinase C binding
zinc ion binding
nucleic acid binding










chromosome organization and 
biogenesis (sensu Eukaryota)
nucleosome assembly DNA binding
Yes 2 10800130 NP_066409 HIST1H2AD histone 1, H2ad 1 2 not classified not classified not classified
Yes 2 10645195 NP_066390 HIST1H2AE H2A histone family, member A 2 8
chromosome
nucleosome









chromosome organization and 
biogenesis (sensu Eukaryota)
defense response to bacterium
nucleosome assembly
DNA binding
Yes 2 4504295 NP_003527 HIST1H3H H3 histone family, member K 4 15 not classified not classified not classified
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Yes 2 4504315 NP_003536 HIST1H4E H4 histone family, member J 8 123 not classified not classified not classified












chromosome organization and 
biogenesis (sensu Eukaryota)
defense response to bacterium
nucleosome assembly DNA binding








Yes 2 77539758 NP_001029249HIST2H4B histone cluster 2, H4b 7 34 not classified not classified not classified




chromosome organization and 
biogenesis (sensu Eukaryota)
nucleosome assembly DNA binding
Yes 1,2 24797067 NP_002107 HLA-A major histocompatibility complex, class I, A p1 1
integral to membrane
integral to plasma 
membrane
membrane
MHC class I protein 
complex
antigen processing and 
presentation
antigen processing and 
presentation of endogenous 
antigen
antigen processing and 
presentation of endogenous 
peptide antigen
MHC class I receptor activity
protein binding
2 17986001 NP_005505 HLA-B major histocompatibility complex, class I, B 1 2
integral to membrane




MHC class I protein 
complex
antigen processing and 
presentation
antigen processing and 
presentation of endogenous 
antigen
antigen processing and 
presentation of endogenous 
peptide 
antigen via MHC class I
MHC class I 
receptor activity
2 52426774 NP_061984 HLA-DRA major histocompatibility complex, class II, D 1 1





antigen processing and 
presentation of exogenous 
antigen
antigen processing and 
presentation of exogenous 
peptide 
antigen via MHC class II
immune response
MHC class II 
receptor activity
Yes 2 17986005 NP_072049 HLA-DRB3 major histocompatibility complex, class II, D 1 1
integral to membrane
integral to plasma 
membrane
membrane
antigen processing and 
presentation of exogenous 
antigen
antigen processing and 
presentation of exogenous 
peptide 
antigen via MHC class II
immune response
signal transduction
MHC class II 
receptor activity
2 5901970 NP_008826 HNMT histamine N-methyltransferase isoform 1 1 1
















Yes 2 14110428 NP_112604 HNRPC heterogeneous nuclear ribonucleoprotein C 1 1
nucleus
spliceosome complex













Yes 2 19913446 NP_002134 HPCA hippocalcin 1 1 not classified not classified
actin binding
calcium ion binding
Yes 2 19913441 NP_002140 HPCAL1 hippocalcin-like 1 1 2 not classified not classified calcium ion binding
2 4504477 NP_002141 HPD 4-hydroxyphenylpyruvate dioxygenase 1 1
not classified







oxidoreductase activity Tyrosinemia Type III [MIM:276710]











transforming growth factor beta 
receptor signaling pathway




prostaglandin E receptor activity
protein homodimerization activity
Hypertension [MIM:601688]
Yes 2 45580723 NP_066275 HPR haptoglobin-related protein 1 2 extracellular region proteolysis
hemoglobin binding
serine-type endopeptidase activity




















regulation of progression 
through cell cycle






2 4504489 NP_000403 HRG histidine-rich glycoprotein precursor 2 5 extracellular region not classified
cysteine protease inhibitor activity
heparin binding





1,2 5032215 NP_005827 HRSP12 heat-responsive protein 12 2 4
cytoplasm





Yes 1,2 63029937 NP_001017963HSP90AA1 heat shock protein 90kDa alpha (cytosolic), 4 7
cytosol
mitochondrial transport




response to unfolded protein
signal transduction
ATP binding





Yes 2 92859630 NP_001035231HSP90AA2 heat shock 90kDa protein 1, alpha-like 3 4 10
not classified
protein folding
response to unfolded protein
ATP binding
unfolded protein binding
Yes 1,2 20149594 NP_031381 HSP90AB1 heat shock 90kDa protein 1, beta 4 4
cytoplasm
positive regulation of nitric 
oxide biosynthesis
protein folding
response to unfolded protein
ATP binding




Yes 2 62122861 NP_001014390HSP90AB2P heat shock protein HSP 90-beta 1 2
not classified
protein folding




2 62198220 NP_001014441HSP90AB6P heat shock protein 90Bf 1 1
not classified
protein folding
response to unfolded protein unfolded protein binding













sequestering of calcium ion
ATP binding
calcium ion binding




2 119874213 NP_079291 HSPA12A heat shock 70kDa protein 12A 1 1 not classified not classified
ATP binding
nucleotide binding
Yes 1,2 5123454 NP_005336 HSPA1A heat shock 70kDa protein 1A 19 53
not classified
protein folding




Yes 2 124256496 NP_005518 HSPA1L heat shock 70kDa protein 1-like 11 59 not classified
protein folding
response to unfolded protein
ATP binding
nucleotide binding






























Yes 1,2 34419635 NP_002146 HSPA6 heat shock 70kDa protein 6 (HSP70B') 6 31
not classified
protein folding
































regulation of translational initiation
response to unfolded protein
protein binding Charcot-Marie-Tooth Disease, Type 
2F [MIM:606595]
Distal Hereditary Motor Neuropathy 
IIB [MIM:608634]





protein import into 
mitochondrial matrix
regulation of apoptosis






2 62859979 NP_005520 HSPG2 heparan sulfate proteoglycan 2 18 41
basement membrane
extracellular space
cell adhesion not classified Schwartz-Jampel Syndrome Type 1 
[MIM: 255800]













2 4557878 NP_000192 ICAM1 intercellular adhesion molecule 1 precursor 1 1
integral to plasma membrane
plasma membrane cell-cell adhesion
transmembrane receptor activity
insulin-like growth factor receptor activity Graves Disease [MIM: 275000]











isocitrate dehydrogenase (NADP+) activity
oxidoreductase activity
oxidoreductase activity, acting on NADH or 
NADPH, NAD or NADP as acceptor








isocitrate dehydrogenase (NADP+) activity
oxidoreductase activity
oxidoreductase activity, acting on NADH or 
NADPH, NAD or NADP asacceptor




response to biotic stimulus protein binding




response to biotic stimulus not classified
2 119964726 NP_000867 IGF2R insulin-like growth factor 2 receptor precurso1 1
endosome




























interleukin-1 receptor antagonist activity






antagonist activity Gastic Cancer Risk [MIM:137215]
2 27894321 NP_776215 IL1RN interleukin 1 receptor antagonist isoform 4 1 1
extracellular region
extracellular space
intracellular inflammatory response calcium ion binding
Yes 2 28610147 NP_002175 IL6ST interleukin 6 signal transducer isoform 1 pre 1 2
integral to plasma 
membrane
plasma membrane






2 29029546 NP_795352 INADL InaD-like protein 7 11
membrane
tight junction not classified protein binding
2 14165288 NP_115639 IQCG IQ motif containing G 1 2 not classified not classified not classified




negative regulation of Ras 
protein signal transduction





Ras GTPase activator activity
2 5729887 NP_006624 IQGAP2 IQ motif containing GTPase activating prote 5 6
actin cytoskeleton
intracellular






Ras GTPase activator activity
2 5453700 NP_006138 IRF6 interferon regulatory factor 6 1 1
nucleus




Van der Woude Syndrome 
[MIM:119300]
Popliteal Pterygium Syndrom 
[MIM:119500]







































































translation initiation factor activity
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2 31542986 NP_060095 ITLN1 intelectin 4 7 membrane not classified
GPI anchor binding
sugar binding
1,2 11527402 NP_068839 ITM2B integral membrane protein 2B 5 21




sensory perception of sound
not classified
Familial Dementia [MIM:176500]




not classified not classified






regulation of Rho protein signal 
transduction calcium ion binding
Yes 2 47717123 NP_003015 ITSN1 intersectin 1 isoform ITSN-l 1 1
intracellular





Rho guanyl-nucleotide exchange factor 
activity
2 22325385 NP_006268 ITSN2 intersectin 2 isoform 1 1 1 intracellular
endocytosis
regulation of Rho protein signal 
transduction
protein binding


















protein amino acid 
phosphorylation







protein serine/threonine kinase activity
Rho guanyl-nucleotide exchange factor activity
transferase activity Coronary Heart Disease 
[MIM:608901]







regulation of heart contraction
delayed rectifier potassium channel activity
potassium ion binding
protein binding




transferase activity Essential Fructosuria [MIM:229800]





1,2 41281489 NP_055576 KIAA0174 putative MAPK activating protein PM28 19 229
ER-Golgi intermediate 
compartment not classified protein binding
2 14767307 XP_049237 KIAA0841 PREDICTED: similar to Protein KIAA0841 is 1 1 not classified not classified not classified
2 58331177 NP_001009959KIAA1189 hypothetical protein LOC57471 isoform a 1 1
cytoplasm
membrane not classified not classified
2 55741661 NP_065944 KIAA1529 hypothetical protein LOC57653 1 5 not classified not classified not classified
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2 113420564 XP_946410 KIAA1833 PREDICTED: similar to c11.1 CG12132-PA 2 1 not classified not classified ATP binding






































anterograde axon cargo 
transport




plus-end-directed microtubule motor activity
ATP binding















































2 4504875 NP_002248 KLK1 kallikrein 1 preproprotein 1 1 not classified proteolysis
peptidase activity
tissue kallikrein activity
Decreased Urinary Activity of 
Kallikrein [MIM:147910]






negative regulation of blood 
coagulation
negative regulation of cell 
adhesion
positive regulation of apoptosis
smooth muscle contraction
vasodilation








NLS-bearing substrate import 
into nucleus
protein import into nucleus, 
docking
protein import into nucleus, 
translocation
protein transport






Yes 2 15718761 NP_004976 KRAS c-K-ras2 protein isoform b 3 5
intracellular
membrane
regulation of progression 
through cell cycle
sensory perception of sound






Yes 2 15718763 NP_203524 KRAS c-K-ras2 protein isoform a 1 1
intracellular
regulation of progression 
through cell cycle
sensory perception of sound






2 21264602 NP_005551 LAMA5 laminin alpha 5 1 2
basal lamina






regulation of cell adhesion
regulation of cell migration










positive regulation of epithelial 
cell proliferation
protein complex assembly
extracellular matrix structural constituent
protein binding
1,2 7669501 NP_005552 LAMP1 lysosomal-associated membrane protein 1 3 25






not classified not classified






platelet dense granule 
membrane
not classified not classified
Danon Disease [MIM:300257]






























intracellular signaling cascade 
positive regulation of T cell 
activation 
positive regulation of T cell 
receptor signaling pathway
protein amino acid 
phosphorylation
Ras protein signal transduction
regulation of lymphocyte 
activation
regulation of progression 
through cell cycle 





























1,2 5031857 NP_005557 LDHA lactate dehydrogenase A 6 24
cytoplasmcytosol
anaerobic glycolysis





Yes 2 47059044 NP_659409 LDHAL6A lactate dehydrogenase A-like 6A 1 4
cytoplasm
anaerobic glycolysis




Yes 2 15082234 NP_149972 LDHAL6B lactate dehydrogenase A-like 6B 1 14
cytoplasm
anaerobic glycolysis




1,2 4557032 NP_002291 LDHB lactate dehydrogenase B 14 95
cytoplasm
anaerobic glycolysis




2 21361918 NP_071751 LEPRE1 leucine proline-enriched proteoglycan (lepre 1 2






oxidoreductase activity, acting on paired 
donors, with incorporation or reduction of 
molecular oxygen,each of oxygen into both 
donors
oxidoreductase activity, actin








Antigen 1 [MIM: 116920]
1,2 5031863 NP_005558 LGALS3BP galectin 3 binding protein 26 201













heterophilic cell adhesion sugar binding
155
Supplementary Table I
Yes 2 13324690 NP_077294 LILRA6
leukocyte immunoglobulin-like receptor, 
subfamily B 
(with TM and ITIM domains), member 6 1 1
not classified not classified not classified






protein transport calcium ion binding
sugar binding
2 21687060 NP_660295 LOC124220 hypothetical protein LOC124220 4 6 not classified not classified not classified
2 41107482 XP_060887 LOC128192 PREDICTED: similar to peptidylprolyl isome 1 2 not classified not classified not classified
2 88969090 XP_946711 LOC131691 PREDICTED: similar to peptidylprolyl isome 1 4 not classified not classified not classified
2 51474268 NP_001073912LOC146909 hypothetical protein LOC146909 1 3 not classified not classified not classified
2 32401447 NP_861450 LOC283537 hypothetical protein LOC283537 1 1 not classified not classified not classified
Yes 2 42661306 XP_375443 LOC284100
PREDICTED: similar to 14-3-3 protein 
epsilon (14-3-3E) 
(Mitochondrial import stimulation factor L 
subunit) (MSF L) 1 2
not classified not classified not classified
2 27500852 XP_209196 LOC284422 PREDICTED: hypothetical protein 1 2 not classified not classified not classified
2 47825361 NP_001001414LOC342897 similar to F-box only protein 2 2 2 not classified protein catabolism
protein binding
receptor activity
2 113417317 XP_946024 LOC345630 PREDICTED: similar to fibrillarin 2 1 not classified not classified not classified
Yes 2 51493085 XP_370729 LOC387934
PREDICTED: similar to Fatty acid-binding 
protein, epidermal (E-FABP) 
(Psoriasis-associated fatty acid-binding 
protein homolog) (PA-FABP) 2 4
not classified not classified not classified
2 51458856 XP_371330 LOC388720 PREDICTED: similar to ubiquitin and ribosom1 2 not classified not classified not classified
2 56847632 NP_001008741LOC388817 peptidylprolyl isomerase A 5 28 not classified protein folding not classified
2 113429505 XP_948564 LOC388849 PREDICTED: hypothetical protein 1 1 not classified not classified not classified
Yes 2 51466608 XP_372002 LOC389599
PREDICTED: similar to amyotrophic lateral 
sclerosis 2 
(juvenile) chromosome region, candidate 2 1 1
not classified not classified not classified
2 113423709 XP_945177 LOC390299 PREDICTED: similar to peptidylprolyl isome 1 1 not classified not classified not classified
2 89040598 XP_950835 LOC440335 PREDICTED: hypothetical protein isoform 4 1 1 not classified not classified not classified
Yes 2 122937516 NP_001074007LOC441282 hypothetical protein LOC441282 1 4 not classified not classified not classified
Yes 2 113419293 XP_941326 LOC642103 PREDICTED: similar to Maltase-glucoamyla 9 24 not classified not classified not classified
2 89042981 XP_951274 LOC643008 PREDICTED: hypothetical protein LOC6430 1 1 not classified not classified not classified
2 148233728 NP_001083064LOC643751 hypothetical protein LOC643751 1 4 not classified not classified not classified
2 148227764 NP_001083173LOC643752 hypothetical protein LOC643752 1 3 not classified not classified not classified
2 88951501 XP_942241 LOC646821 PREDICTED: similar to cytoplasmic beta-ac 1 1 not classified not classified not classified
2 89057283 XP_943300 LOC649125 PREDICTED: similar to actin-related protein 1 1 not classified not classified not classified
2 89062025 XP_945805 LOC651536 PREDICTED: similar to immunoglobulin iota 1 1 not classified not classified transferase activity
Yes 2 89037862 XP_945963 LOC651665 PREDICTED: similar to retrotransposon-like 1 1 not classified not classified not classified
2 51472697 XP_290660 LOC654259
PREDICTED: similar to Programmed cell 
death 6-interacting protein 
(ALG-2-interacting protein X) (ALG-2-
interacting protein 1) (E2F1-inducible 
protein) (Eig2) 6 33
not classified not classified not classified
Yes 2 113412128 XP_001134257LOC732165 PREDICTED: similar to Triosephosphate iso1 1 not classified not classified not classified


















2 18677767 NP_570843 LRRC15 leucine rich repeat containing 15 1 1
integral to membrane
membrane not classified transferase activity
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2 23397554 NP_694992 LRRC57 leucine rich repeat containing 57 1 1 not classified not classified protein binding
2 83722282 NP_940980 LRRK2 leucine-rich repeat kinase 2 4 5
not classified
protein amino acid 
phosphorylation







protein serine/threonine kinase activity
transferase activity Parkinson Disease [MIM:607060]

















Yes 2 54607120 NP_002334 LTF lactotransferrin 1 3
extracellular region
extracellular space









2 9966764 NP_009191 LYPLA2 lysophospholipase II 1 1 not classified
fatty acid metabolism
lipid metabolism hydrolase activity




defense response to bacterium 
metabolism
hydrolase activity, acting on glycosyl bonds
lysozyme activity Familal Visceral Amyloidosis  
[MIM:105200]







2 16418397 NP_443118 MAL2 MAL2 proteolipid protein 1 1
integral to membrane
membrane not classified ferric iron binding








protein amino acid 
glycosylation
calcium ion binding















hydrolase activity, acting on glycosyl bonds
mannosyl-oligosaccharide 1,3-1,6-alpha-
mannosidase activity
2 11496277 NP_068805 MAP2K1IP1 mitogen-activated protein kinase kinase 1 in 1 1 membrane not classified not classified













protein serine/threonine kinase activity
transferase activity
2 11125772 NP_002347 MARCKS myristoylated alanine-rich protein kinase C s4 6
actin cytoskeleton





1,2 21264363 NP_006601 MASP2 mannan-binding lectin serine protease 2 isof12 124
extracellular region








2 38202209 NP_060798 MBD5 methyl-CpG binding domain protein 5 1 1 nucleus not classified DNA binding
























2 5174557 NP_005919 MFGE8 milk fat globule-EGF factor 8 protein 2 2 lipid particle
cell adhesion
fertilization (sensu Metazoa) protein binding
2 5174559 NP_005920 MFI2 melanoma-associated antigen p97 isoform 12 3
extracellular region










2 16163666 NP_201573 MFI2 melanoma-associated antigen p97 isoform 21 3
extracellular region


















hydrolase activity, hydrolyzing O-glycosyl 
compounds
Yes 2 113419289 XP_001130164MGAM PREDICTED: similar to Maltase-glucoamyla 1 3 not classified not classified not classified











transferase activity, transferring glycosyl 
groups 
2 31543193 NP_689672 MGC45438 hypothetical protein LOC146556 1 1 not classified not classified not classified
Yes 2 113427454 XP_943120 MGC57346 PREDICTED: similar to ADP-ribosylation fac1 4 not classified not classified not classified
2 39752687 NP_945352 MGC59937 hypothetical protein LOC375791 1 1 not classified not classified not classified
2 44917608 NP_056061 MGRN1 mahogunin, ring finger 1 1 2


















cell surface receptor linked signal 
transduction
inflammatory response
negative regulation of apoptosis
prostaglandin biosynthesis





ATP binding Rheumatoid Arthritis [MIM: 604302]
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2 68161546 NP_001020108MINK1 misshapen/NIK-related kinase isoform 4 2 3 not classified
development
JNK cascade





protein serine/threonine kinase activity
small GTPase regulator activity
transferase activity
metal ion binding
1,2 20270349 NP_620153 MITD1 MIT, microtubule interacting and transport, d9 19 not classified not classified not classified
2 4758720 NP_004520 MLLT3
myeloid/lymphoid or mixed-lineage 
leukemia (trithorax homolog, Drosophila); 
translocated to, 3 1 1
nucleus




2 5174575 NP_005927 MLLT4
myeloid/lymphoid or mixed-lineage 
leukemia (trithorax homolog, Drosophila); 









1,2 6042202 NP_009219 MME membrane metallo-endopeptidase 48 311









Important cell surface marker in the 
diagnostic of 
human acute lymphocytic leukemia 
[MIM:120520]
2 5729929 NP_006681 MMP24 matrix metalloproteinase 24 preproprotein 1 2
extracellular matrix (sensu 
Metazoa)









2 13027809 NP_073209 MMP25 matrix metalloproteinase 25 preproprotein 1 1
cell surface










1,2 13376091 NP_079032 MMRN2 multimerin 2 1 1 extracellular matrix (sensu not classified not classified
2 4505227 NP_002423 MNDA myeloid cell nuclear differentiation antigen 1 3 nucleus
cellular defense response
regulaion of transcription, DNA-
dependent
transcription 3-mercaptopyruvate sulfurtransferase activity

















not classified protein binding








Yes 2 15809016 NP_291024 MRLC2 myosin regulatory light chain MRCL2 3 5 not classified not classified calcium ion binding







structural constituent of cytoskeleton





response to oxidative stress
oxidoreductase activity
protein-methionine-S-oxide reductase activity
2 47132622 NP_002442 MTAP 5'-methylthioadenosine phosphorylase 1 1 not classified
nucleobase, nucleoside, 









2 13699868 NP_005947 MTHFD1 methylenetetrahydrofolate dehydrogenase 1 4 5
mitochondrion
amino acid biosynthesis














oxidoreductase activity Spina Bifida [MIM:601634]




integral to plasma 
membrane
membrane
not classified actin binding
hormone activity








extracellular matrix structural constituent
Yes 2 116284392 NP_002448 MUC2 mucin 2 precursor 1 2
extracellular region
extracellular space not classified extracellular matrix structural constituent
Yes 2 153945878 NP_002449 MUC5B mucin 5, subtype B, tracheobronchial 4 8
extracellular matrix (sensu 
Metazoa)
extracellular region cell adhesion
extracellular matrix structural constituent
protein binding









2 24432077 NP_689636 MUM1L1 melanoma associated antigen (mutated) 1-li 2 6 not classified not classified not classified












response to drug not classified
2 18390319 NP_056234 MXRA5 adlican 1 1
not classified protein amino acid phosphorylati
ATP binding
transferase activity
vascular endothelial growth factor receptor 
activity
1,2 14150145 NP_115724 MXRA8 matrix-remodelling associated 8 7 28 not classified not classified not classified
Yes 2 41406064 NP_005955 MYH10 myosin, heavy polypeptide 10, non-muscle 4 10
myosin cytokinesis







2 11321579 NP_003793 MYH13 myosin, heavy polypeptide 13, skeletal musc1 1
muscle myosin
myosin










2 33563340 NP_079005 MYH14 myosin, heavy chain 14 isoform 2 8 17
myosin
regulation of cell shape






Autosomal Dominant nonsyndromic 
sensorineural hearing loss 
[MIM:600652]
2 116284396 NP_001070654 MYH14 myosin, heavy chain 14 isoform 1 1 1 myosin
regulation of cell shape






Autosomal Dominant Nonsyndromic 
Sensorineural Deafness [MIM: 
600652]
2 11342672 NP_002461 MYH3 myosin, heavy chain 3, skeletal muscle, embryon1 1
myosin












1,2 12667788 NP_002464 MYH9 myosin, heavy polypeptide 9, non-muscle 19 51
myosin
regulation of cell shape














structural constituent of muscle





structural constituent of muscle
2 22547229 NP_057323 MYO15A myosin XV 1 3
cytoskeleton
myosin







Recessive Congenital Deafness 
[MIM:600316]
























































2 50582540 NP_004990 MYO6 myosin VI 7 21
unconventional myosin
actin filament-based movement









structural constituent of muscle
Autosomal Recessive Congenital 
Sensorineural Deafness 
[MIM:607821]
Autosomal Dominant Nonsyndromic 
Sensorineural Deafness 
[MIM:606346]

















hydrolase activity, acting on glycosyl bonds Mucopolysaccharidosis Type IIIB 
[MIM:252920]
2 47933379 NP_003818 NAPA N-ethylmaleimide-sensitive factor attachmen1 2
endoplasmic reticulum
Golgi apparatus









Yes 2 44917606 NP_071363 NAPB N-ethylmaleimide-sensitive factor attachmen1 2
endoplasmic reticulum
Golgi apparatus





2 48675830 NP_945341 NAPE-PLD N-acyl-phosphatidylethanolamine-hydrolyzin1 1 not classified not classified hydrolase activity















2 40255089 NP_660202 NAPRT1 nicotinate phosphoribosyltransferase domain2 2
not classified pyridine nucleotide biosynthesis
nicotinate phosphoribosyltransferase activity
transferase activity, transferring glycosyl 
groups










N-terminal protein amino acid 
acetylation






















2 13376735 NP_079422 NAT13 N-acetyltransferase 13 1 1 cytoplasm





Yes 2 98985795 NP_001035720NCALD neurocalcin delta 1 3












central nervous system 
development
protein binding




central nervous system 
development calcium ion binding
2 24638433 NP_056146 NCSTN nicastrin precursor 2 2
endoplasmic reticulum
Golgi apparatus
integral to plasma 
membrane
membrane
amyloid precursor protein 
catabolism
membrane protein ectodomain 
proteolysis
Notch receptor processing




2 37655183 NP_006087 NDRG1 N-myc downstream regulated gene 1 2 5 nucleus
cell differentiation
response to metal ion
not classified
Charcot-Marie-Tooth Disease Type 
4D [MIM:601455]
2 32130514 NP_071922 NDRG3 N-myc downstream-regulated gene 3 isoform1 1
cytoplasm
cell differentiation




2 4758794 NP_004534 NEB nebulin 2 4
actin cytoskeleton
striated muscle thin filament
Z disc




structural constituent of muscle Nemaline Myopathy [MIM:256030]
2 5453758 NP_006384 NEBL nebulette sarcomeric isoform 1 1
actin cytoskeleton regulation of actin filament length
actin binding
structural constituent of muscle
zinc ion binding





extracellular matrix structural constituent
protein binding
hedgehog receptor activity
2 47578107 NP_056199 NIPBL delangin isoform B 1 1 nucleus cell cycle binding
2 9910460 NP_064587 NIT2 nitrilase family, member 2 1 1 not classified
nitrogen compound 
metabolism
hydrolase activity, acting on carbon-
nitrogen (but not peptide) bonds
















negative regulation of cell 
proliferation
negative regulation of 











nucleoside diphosphate kinase activity
nucleotide binding
transferase activity








negative regulation of cell 
proliferation
negative regulation of 


























nucleotide and nucleic acid 
metabolism
purine-nucleoside phosphorylase activity




























1,2 7657615 NP_055440 NPHS2 podocin 6 9
integral to plasma membrane
membrane




2 4505417 NP_000895 NQO2 NAD(P)H dehydrogenase, quinone 2 1 2
not classified electron transport
electron carrier activity
metal ion binding
NAD(P)H dehydrogenase (quinone) activity
NADPH dehydrogenase (quinone) activity
zinc ion binding
Yes 2 4505451 NP_002515 NRAS neuroblastoma RAS viral (v-ras) oncogene h5 10
intracellular
membrane
regulation of progression 
through cell cycle





2 93141039 NP_001035199NRF1 nuclear respiratory factor 1 1 4 nucleus
generation of precursor 
metabolites and energy
regulation of transcription from 
RNA polymerase II promoter






































Yes 2 5031985 NP_005787 NUTF2 nuclear transport factor 2 1 1 intracellular protein transport protein binding
1,2 32313593 NP_006409 OLFM4 olfactomedin 4 precursor 19 63 membrane not classified latrotoxin receptor activity
2 50080203 NP_001001959OR11L1 olfactory receptor, family 11, subfamily L, me1 1
integral to membrane
membrane
G-protein coupled receptor 
protein signaling pathway
response to stimulus




Yes 2 52317120 NP_001004738OR5L1 olfactory receptor, family 5, subfamily L, mem1 1
integral to membrane
membrane
G-protein coupled receptor 
protein signaling pathway
response to stimulus











2 109148508 NP_060140 OTUB1 otubain 1 2 5 not classified
immune response
ubiquitin cycle protein binding
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2 4826878 NP_005100 OXSR1 oxidative-stress responsive 1 2 2
not classified
protein amino acid 
phosphorylation
protein kinase cascade





protein serine/threonine kinase activity
transferase activity
1,2 28416927 NP_002551 P2RX4 purinergic receptor P2X4 2 2
integral to membrane






ATP-gated cation channel activity
ion channel activity
receptor activity
2 6005826 NP_009160 PACSIN2 protein kinase C and casein kinase substrate4 9
cytoplasm





1,2 19224660 NP_057307 PACSIN3 protein kinase C and casein kinase substrate4 8
cytoplasm
endocytosis




2 15042937 NP_031391 PADI2 peptidyl arginine deiminase, type II 1 1




























2 4505585 NP_002563 PAFAH1B2 platelet-activating factor acetylhydrolase, iso1 2
not classified lipid catabolism
1-alkyl-2-acetylglycerophosphocholine 
esterase activity
hydrolase activity, acting on ester bonds







maintenance of cell polarity
intercellular junction assembly
regulation of cell migration not classified




Ras protein signal transduction catalytic activity
Parkison Disease 7, Autosomal 
Recessive [MIM: 606324]














transferase activity, transferring glycosyl 
groups
2 62177133 NP_071412 PBLD MAWD binding protein isoform a 4 6 not classified biosynthesis
catalytic activity
isomerase activity





2 4557831 NP_000272 PCBD1 pterin-4 alpha-carbinolamine dehydratase precur 1 1





















phosphoenolpyruvate carboxykinase (GTP) 
activity
















2 20127517 NP_009148 PDCD10 programmed cell death 10 2 3 not classified apoptosis not classified
Cerebral Cavernous Malformations 
[MIM:603285]








1,2 7019485 NP_037364 PDCD6 programmed cell death 6 11 41
not classified
apoptosis
induction of apoptosis by 
extracellular signals
calcium ion binding
1,2 22027538 NP_037506 PDCD6IP programmed cell death 6 interacting protein 42 183 cytosol
apoptosis
protein transport signal transducer activity
2 32699045 NP_872418 PDDC1 Parkinson disease 7 domain containing 1 1 1 not classified not classified not classified
2 47132537 NP_775656 PDE8A phosphodiesterase 8A isoform 2 1 1 not classified
cyclic nucleotide metabolism








two-component response regulator activity
6-phosphofructokinase activity
2 4505701 NP_003672 PDXK pyridoxal kinase 1 3







2 21361142 NP_002605 PDZK1 PDZ domain containing 1 16 35 not classified drug transport
PDZ domain binding
protein C-terminus binding




not classified not classified
1,2 4505621 NP_002558 PEBP1 prostatic binding protein 8 21





serine-type endopeptidase inhibitor activity














2 7656971 NP_055702 PFAAP5 phosphonoformate immuno-associated prote1 1 not classified not classified not classified









































1,2 4826898 NP_005013 PFN1 profilin 1 5 23
actin cytoskeleton
actin cytoskeleton organization 
and biogenesis
cytoskeleton organization and 
biogenesis
actin monomer binding
1,2 16753215 NP_444252 PFN2 profilin 2 isoform a 1 2
actin cytoskeleton
actin cytoskeleton organization 
and biogenesis
cytoskeleton organization and 
biogenesis

















































2 4827036 NP_005082 PGLYRP1 peptidoglycan recognition protein 1 1 1
extracellular region




















2 40556370 NP_056103 PHF15 PHD finger protein 15 1 2














oxidoreductase activity, acting on the CH-OH 
group of donors, NAD or NADP as acceptor
phosphoglycerate dehydrogenase activity
transporter activity Phosphoglycerate Dehydrogenase 
Deficiency [MIM:601815]






1,2 31377806 NP_002635 PIGR polymeric immunoglobulin receptor 17 32
integral to plasma 
membrane
membrane
protein secretion protein transporter activity














2 4505821 NP_002643 PIP prolactin-induced protein 2 2 extracellular region not classified actin binding
2 21322230 NP_079055 PIP4K2C phosphatidylinositol-5-phosphate 4-kinase, t 1 3 not classified not classified
kinase activity
magnesium ion binding
1,2 58331146 NP_001009944 PKD1 polycystin 1 isoform 1 precursor 1 1
extracellular matrix (sensu 
Metazoa)
integral to membrane









Polycystic Kidney Disease, adult, type 
I [MIM:601313]





















voltage-gated chloride channel activity
voltage-gated sodium channel activity




2 25777667 NP_733842 PKHD1 polyductin isoform 2 6 9








negative regulation of cell motility
protein binding
receptor activity
Autosomal Recessive Polycystic 
Kidney Disease [MIM:263200]
2 10835121 NP_000289 PKLR pyruvate kinase, liver and RBC isoform 1 1 1 not classified glycolysis
magnesium ion binding
pyruvate kinase activity
Pyruvate Kinase Deficiency 
[MIM:266200]
2 32967597 NP_870986 PKLR pyruvate kinase, liver and RBC isoform 2 1 1 not classified glycolysis
pyruvate kinase activity
magnesium ion binding






















phosphoinositide phospholipase C activity
signal transducer activity
2 72534684 NP_001026866PLD3 phospholipase D3 isoform 1 1 1 membrane metabolism catalytic activity
2 50234893 NP_001001974PLEKHA1
pleckstrin homology domain containing, 
family A 
(phosphoinositide binding specific) 
member 1 1 1
membrane
nucleus
not classified phospholipid binding
2 48675827 NP_778228 PLEKHA7 pleckstrin homology domain containing, fam 1 1 not classified not classified not classified














Ehlers-Danlos Syndrome, Type VIA 
[MIM:225400]









oxidoreductase activity, acting on single 
donors with incorporation of molecular 
oxygen, incorporation of two atoms of oxygen
procollagen-lysine 5-dioxygenase activity
prot
2 4505897 NP_002661 PLS1 plastin 1 1 2
actin cytoskeleton
brush border not classified
actin filament binding
calcium ion binding
structural constituent of cytoskeleton
Yes 2 7549809 NP_005023 PLS3 plastin 3 9 21
























Yes 1,2 66277202 NP_001018121PODXL podocalyxin-like precursor isoform 1 9 52
integral to plasma 
membrane
membrane
not classified not classified
2 33598950 NP_005388 PODXL podocalyxin-like precursor isoform 2 8 57
integral to plasma 
membrane
membrane
not classified not classified
2 29171738 NP_795714 PPAP2A phosphatidic acid phosphatase type 2A isofo2 3




androgen receptor signaling 
pathway
germ cell migration




protein kinase C activation
regulation of lipid metabolism
hydrolase activity
phosphatidate phosphatase activity
2 29171755 NP_003616 PPFIA2 PTPRF interacting protein alpha 2 1 1 cytoplasm cell-matrix adhesion protein binding
2 10863927 NP_066953 PPIA peptidylprolyl isomerase A 5 17
not classified
protein folding




peptidyl-prolyl cis-trans isomerase activity
unfolded protein binding
virion binding
Yes 2 30102944 NP_839944 PPIAL4 peptidylprolyl isomerase A (cyclophilin A)-lik 2 3
not classified protein folding
isomerase activity
peptidyl-prolyl cis-trans isomerase activity







peptidyl-prolyl cis-trans isomerase activity
unfolded protein binding
2 45439327 NP_002696 PPL periplakin 18 28 cytoskeleton keratinization
protein binding
structural constituent of cytoskeleton






































inactivation of MAPK activity
induction of apoptosis
negative regulation of cell 
growth
negative regulation of tyrosine 
phosphorylation of Stat3 
protein
protein amino acid 
dephosphorylation
protein complex assembly





protein phosphatase type 2A regulator 
activity
Yes 2 4506019 NP_002708 PPP2R2A alpha isoform of regulatory subunit B55, pro 1 3 protein phosphatase type 2




protein phosphatase type 2A activity
protein phosphatase type 2A regulator 
activity
Yes 2 32307117 NP_858062 PPP2R2B beta isoform of regulatory subunit B55, prote1 2 protein phosphatase type 2 signal transduction
protein phosphatase 
type 2A regulator activity
2 40805841 NP_955450 PRCP prolylcarboxypeptidase isoform 2 preproprot 1 4
lysosome proteolysis
serine-type peptidase activity
serine-type Pro-X carboxypeptidase activity


























response to oxidative stress
oxidoreductase activity
peroxiredoxin activity




response to oxidative stress
oxidoreductase activity
peroxiredoxin activity




response to oxidative stress
peroxiredoxin activity
ATP binding










Yes 2 154800441 NP_006241 PRH1 proline-rich protein HaeIII subfamily 1 1 1 integral to membrane G-protein coupled receptor prote rhodopsin-like receptor activity















2 4506067 NP_002728 PRKCA protein kinase C, alpha 1 1
membrane fraction
cell surface receptor linked 
signal transduction
induction of apoptosis by 
extracellular signals
intracellular signaling cascade
protein amino acid 
phosphorylation






















protein kinase C activity
transferase activity
zinc ion binding

















protein serine/threonine kinase activity
2 28557781 NP_006246 PRKCH protein kinase C, eta 1 2
not classified
intracellular signaling cascade






protein kinase C activity
transferase activity
zinc ion binding Cerebral Infarction [MIM:601367]




cytoskeleton organization and 
biogenesis
establishment and/or 
maintenance of epithelial cell 
polarity
intercellular junction assembly 
and maintenance
intracellular signaling cascade
membrane organization and 
biogenesis










protein serine/threonine kinase activity
transferase activity
zinc ion binding






protein amino acid 
phosphorylation
ATP binding





protein serine/threonine kinase activity
transferase activity
zinc ion binding






protein amino acid 
phosphorylation









2 13375901 NP_078929 PRKRIP1 PRKR interacting protein 1 (IL11 inducible) 1 1 not classified not classified not classified
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response to oxidative stress
copper ion binding
GPI anchor binding
microtubule binding Creutzfeldt-Jakob Disease [MIM: 
123400]
1,2 5174387 NP_006008 PROM1 prominin 1 23 174




not classified Autosomal Recessive Retinal 
Degeneration [MIM:604365]
2 21389623 NP_653308 PROM2 prominin 2 18 92 integral to membrane not classified not classified













proteolysis serine-type endopeptidase 
activity
2 71361688 NP_002768 PRTN3
proteinase 3 (serine proteinase, neutrophil, 
Wegener granulomatosis autoantigen) 1 1
not classified
collagen catabolism
























Due to SAP1 Deficiency 
[MIM:249900]
Gaucher Disease, Atypical 
Due to SAP2 Deficiency 
[MIM:610539]





























1,2 5031995 NP_005663 PSCA prostate stem cell antigen preproprotein 1 7 plasma membrane not classified GPI anchor binding




proteasome core complex 
(sensu Eukaryota)
ubiquitin-dependent protein 
catabolism threonine endopeptidase activity
2 4506181 NP_002778 PSMA2 proteasome alpha 2 subunit 2 3
cytosol
proteasome core complex 
(sensu Eukaryota)








proteasome core complex 
(sensu Eukaryota)
ubiquitin-dependent protein cata protein binding
threonine endopeptidase activity
2 4506185 NP_002780 PSMA4 proteasome alpha 4 subunit 1 2
cytosol
proteasome core complex 
(sensu Eukaryota)
ubiquitin-dependent protein cata threonine endopeptidase activity
2 23110942 NP_002781 PSMA5 proteasome alpha 5 subunit 2 4
cytosol
proteasome core complex 
(sensu Eukaryota)
ubiquitin-dependent protein 
catabolism hydrolase activity, acting on ester bonds
Yes 2 23110944 NP_002782 PSMA6 proteasome alpha 6 subunit 1 1
cytosol






Yes 2 68303565 NP_001020268PSMA8 proteasome (prosome, macropain) subunit, 1 1
cytosol
proteasome core complex 
(sensu Eukaryota) ubiquitin-dependent protein cata threonine endopeptidase activity
2 4506193 NP_002784 PSMB1 proteasome beta 1 subunit 1 1
cytosol






2 4506195 NP_002785 PSMB2 proteasome beta 2 subunit 1 4
cytosol
nucleus






1,2 22538465 NP_002786 PSMB3 proteasome beta 3 subunit 4 6
cytosol
nucleus






2 4506201 NP_002788 PSMB5 proteasome beta 5 subunit 3 6
cytosol






2 23110925 NP_002789 PSMB6 proteasome beta 6 subunit 1 1
cytosol












negative regulation of 
programmed cell death









thyrotropin-releasing hormone receptor 
binding
transcription factor binding





















not classified not classified












immune response proteasome activator 
activity
2 20070186 NP_109589 PTER phosphotriesterase related 2 4
not classified catabolism
hydrolase activity, acting on ester bonds
metal ion binding
zinc ion binding
Yes 2 18104971 NP_536316 PTP4A2 protein tyrosine phosphatase type IVA, mem2 3
membrane protein amino acid dephosphory
hydrolase activity
prenylated protein tyrosine phosphatase 
activity
2 18104973 NP_536317 PTP4A2 protein tyrosine phosphatase type IVA, mem1 1 membrane
protein amino acid 
dephosphorylation
prenylated protein tyrosine phosphatase 
activity
hydrolase activity
2 18375650 NP_542416 PTPN13 protein tyrosine phosphatase, non-receptor t9 14
cytoplasm
cytoskeleton
protein amino acid 
dephosphorylation
hydrolase activity




2 24308073 NP_056281 PTPN23 protein tyrosine phosphatase, non-receptor t4 5 not classified
protein amino acid 
dephosphorylation
hydrolase activity
protein tyrosine phosphatase activity




G-protein coupled receptor 
protein signaling pathway
intracellular signaling cascade
negative regulation of cell 
proliferation




protein tyrosine phosphatase activity
1,2 18860900 NP_002834 PTPRJ protein tyrosine phosphatase, receptor type, J pre1 1
integral to plasma membrane
cell-cell signaling
protein amino acid 
dephosphorylation
transmembrane receptor protein 
tyrosine kinase signaling pathway
hydrolase activity
transmembrane receptor protein tyrosine 
phosphatase activity
Somatic Colon Cancer [MIM:114500]
2 13677220 NP_109595 PTPRO receptor-type protein tyrosine phosphatase O2 2
integral to membrane
integral to plasma 
membrane
membrane
protein amino acid 
dephosphorylation
hydrolase activity
protein tyrosine phosphatase activity
receptor activity
transmembrane receptor protein tyrosine 
phosphatase activity
2 13677222 NP_109596 PTPRO receptor-type protein tyrosine phosphatase O2 6
integral to membrane
integral to plasma 
membrane
membrane
protein amino acid 
dephosphorylation
protein tyrosine phosphatase activity
receptor activity
transmembrane receptor protein tyrosine 
phosphatase activity
not classified 






protein import into nucleus GTP binding
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1,2 33695095 NP_057215 RAB10 ras-related GTP-binding protein RAB10 10 23
membrane
protein transport




Yes 1,2 4758984 NP_004654 RAB11A Ras-related protein Rab-11A 1 4
Golgi trans face
plasma membrane to 
endosome transport
protein transport








Yes 1,2 4758986 NP_004209 RAB11B RAB11B, member RAS oncogene family 7 33
membrane
protein transport





Yes 2 50363228 NP_079427 RAB11FIP1 Rab coupling protein isoform 1 1 1 not classified protein transport not classified





regulation of transcription, DNA-
dependent



































2 38371739 NP_941959 RAB15 RAB15, member RAS onocogene family 1 3 membrane
protein transport

















regulation of transcription, DNA-
dependent

















ER to Golgi vesicle-mediated 
transport
protein transport
regulation of transcription, DNA-
dependent











regulation of transcription, DNA-
dependent






1,2 4506365 NP_002856 RAB2 RAB2, member RAS oncogene family 6 12
endoplasmic reticulum
ER to Golgi vesicle-mediated 
transport
protein transport




1,2 7661922 NP_055814 RAB21 RAB21, member RAS oncogene family 2 3
endosome
protein transport








endosome organization and 
biogenesis
protein transport






2 9966861 NP_065120 RAB25 RAB25 1 2
membrane
protein transport




2 19923264 NP_004571 RAB27A Ras-related protein Rab-27A 1 1
not classified
protein transport





Yes 1,2 5729997 NP_004154 RAB27B RAB27B, member RAS oncogene family 2 2
not classified
protein transport





Yes 2 33589861 NP_006859 RAB31 RAB31, member RAS oncogene family 1 1
membrane
protein transport





Yes 2 5803133 NP_006825 RAB32 RAB32, member RAS oncogene family 1 1
mitochondrion
protein transport




2 31543537 NP_114140 RAB34 RAB39 1 1 membrane
protein transport




1,2 5803135 NP_006852 RAB35 RAB35, member RAS oncogene family 4 8
membrane
protein transport





Yes 2 11641237 NP_071732 RAB38 RAB38 1 5 membrane
protein transport

















1,2 19923750 NP_002858 RAB3B RAB3B, member RAS oncogene family 2 5
membrane
protein transport







Yes 2 19923985 NP_612462 RAB3C RAB3C, member RAS oncogene family 2 4 membrane
protein transport




1,2 4759000 NP_004274 RAB3D RAB3D, member RAS oncogene family 1 1
membrane
exocytosis
hemocyte development (sensu 
Arthropoda)
protein transport






2 55743118 NP_036365 RAB3GAP1 RAB3 GTPase-activating protein 1 1 soluble fraction regulation of GTPase activity
Rab GTPase binding
GTP binding
Warburg Micro Syndrome [MIM: 
600118]




























2 41393614 NP_958842 RAB5C RAB5C, member RAS oncogene family isofo5 57
not classified
protein transport





Yes 2 96975097 NP_057661 RAB6B RAB6B, member RAS oncogene family 1 3 Golgi apparatus




transport, Golgi to ER















2 4506375 NP_003920 RAB7L1 RAB7, member RAS oncogene family-like 1 4 5
membrane
protein transport






1,2 16933567 NP_005361 RAB8A mel transforming oncogene 5 24
membrane
protein transport








regulation of transcription, DNA-
dependent























negative regulation of receptor 
mediated endocytosis
positive regulation of Rho 
protein signal transduction
ruffle organization and 
biogenesis






Yes 2 38505165 NP_942126 RAC1 ras-related C3 botulinum toxin substrate 1 is 6 21 intracellular
actin filament polymerization
lamellipodium biogenesis
negative regulation of receptor 
mediated endocytosis
positive regulation of Rho 
protein signal transduction
ruffle organization and 
biogenesis






Yes 2 4506381 NP_002863 RAC2 ras-related C3 botulinum toxin substrate 2 1 3 intracellular
signal transduction





































mitotic spindle organization 
and biogenesis
positive regulation of 
transcription, DNA-dependent
protein export from nucleus













negative regulation of 
progression through cell cycle









negative regulation of 
progression through cell cycle







Yes 2 58219792 NP_001010942RAP1B RAP1B, member of RAS oncogene family 2 3
intracellular
membrane small GTPase mediated signal tr
GTP binding
nucleotide binding
2 20070314 NP_066982 RAP1GDS1 RAP1, GTP-GDP dissociation stimulator 1 1 3 not classified not classified
binding
GTPase activator activity









2 38201690 NP_002877 RAP2B RAP2B, member of RAS oncogene family 1 1
intracellular
membrane small GTPase mediated signal tr
GTP binding
nucleotide binding
2 32129209 NP_067006 RAP2C RAP2C, member of RAS oncogene family 1 1
intracellular
membrane










protein amino acid 
phosphorylation
regulation of small GTPase 
mediated signal transduction
cAMP binding
cAMP-dependent protein kinase regulator 
activity
guanyl-nucleotide exchange factor activity
nucleotide binding









2 21361292 NP_005602 RBL2 retinoblastoma-like 2 (p130) 1 1
nucleus
cell cycle
negative regulation of 
progression through cell cycle
regulation of lipid kinase 
activity















Retinol-Binding Protein Deficiency 
[MIM:180250]














Autosomal Recessive Deafness 24 
[MIM:611022]
2 4506477 NP_002901 RENBP renin binding protein 1 1






2 32528306 NP_002904 RFC1 replication factor C large subunit 1 1






regulation of transcription, DNA-
dependent


















1,2 7706683 NP_057405 RHCG Rhesus blood group, C glycoprotein 5 8
apical plasma membrane























actin cytoskeleton organization 
and biogenesis
positive regulation of I-kappaB 
kinase/NF-kappaB cascade
positive regulation of NF-
kappaB import into nucleus
Rho protein signal transduction

















endosome to lysosome 
transport
negative regulation of 
progression through cell cycle
positive regulation of 
angiogenesis
protein transport






2 28395033 NP_786886 RHOC ras homolog gene family, member C precurs1 1
intracellular
membrane
positive regulation of I-kappaB 
kinase/NF-kappaB cascade
















1,2 46249393 NP_001656 RHOG ras homolog gene family, member G 5 11
intracellular
membrane
positive regulation of cell 
proliferation
regulation of progression 
through cell cycle





Yes 2 50263042 NP_036381 RHOQ ras-like protein TC10 1 2
intracellular
plasma membrane





1,2 7657520 NP_055187 RNF11 ring finger protein 11 1 6


























membrane alanyl aminopeptidase activity
metal ion binding
zinc ion binding









positive regulation of axonogenesis
ureteric bud development
axon guidance receptor activity
identical protein binding
Vesicoureteral Reflux 2 [MIM:610878]









nucleoside diphosphate kinase activity
unfolded protein binding X-Linked Retinitis Pigmentosa 2 
[MIM:312600]
Yes 2 4506597 NP_000967 RPL12 ribosomal protein L12 1 1





structural constituent of ribosome
Yes 2 4506613 NP_000974 RPL22 ribosomal protein L22 proprotein 1 1






structural constituent of ribosome
Yes 2 4506679 NP_001005 RPS10 ribosomal protein S10 1 1
cytosolic small ribosomal 
subunit (sensu Eukaryota)
ribonucleoprotein complex protein biosynthesis
RNA binding
structural constituent of ribosome
2 4506681 NP_001006 RPS11 ribosomal protein S11 1 1




protein biosynthesis rRNA binding
structural constituent of ribosome
Yes 2 4506691 NP_001011 RPS16 ribosomal protein S16 1 1
cytosolic small ribosomal 
subunit (sensu Eukaryota)
intracellular
ribosome protein biosynthesis structural constituent of ribosome
2 11968182 NP_072045 RPS18 ribosomal protein S18 2 2
cytosolic small ribosomal 
subunit (sensu Eukaryota)
intracellular
protein biosynthesis rRNA binding
structural constituent of ribosome
Yes 2 15011936 NP_001020 RPS26 ribosomal protein S26 1 1




protein biosynthesis RNA binding
structural constituent of ribosome
2 5454028 NP_006261 RRAS related RAS viral (r-ras) oncogene homolog 4 11
intracellular







1,2 21361416 NP_036382 RRAS2 related RAS viral (r-ras) oncogene homolog 4 10
intracellular
membrane











Ras protein signal transduction
regulation of transcription, DNA-
dependent
transcription







2 55741719 NP_055621 RUSC2 RUN and SH3 domain containing 2 1 1 not classified not classified not classified
2 10863871 NP_000531 RYR1 skeletal muscle ryanodine receptor isoform 11 1

















Central Core Disease [MIM:117000]
Minicore Myopathy with External 
Ophthalmoplegia [MIM:255320]
2 4506761 NP_002957 S100A10 S100 calcium binding protein A10 1 1 not classified not classified calcium ion binding




negative regulation of cell 
proliferation







2 10190712 NP_065723 S100A14 S100 calcium binding protein A14 2 3 not classified not classified calcium ion binding
1,2 17933772 NP_525127 S100A16 S100 calcium binding protein A16 1 5 not classified not classified calcium ion binding
2 4506765 NP_002952 S100A4 S100 calcium-binding protein A4 1 1 not classified not classified calcium ion binding









positive regulation of fibroblast 
proliferation








2 21614544 NP_002955 S100A8 S100 calcium-binding protein A8 6 28 extracellular space inflammatory response calcium ion binding





1,2 5174663 NP_005971 S100P S100 calcium binding protein P 1 11
cytoplasm









not classified not classified





2 5031631 NP_005497 SCARB2 scavenger receptor class B, member 2 9 18





cell adhesion receptor activity





















negative regulation of cell 
proliferation
positive regulation of apoptosis



















voltage-gated calcium channel activity
voltage-gated sodium channel activity









voltage-gated sodium channel activity
dipeptidase activity
2 11055992 NP_067639 SCPEP1 serine carboxypeptidase 1 precursor protein 1 1 not classified proteolysis
peptidase activity
serine carboxypeptidase activity
2 24308406 NP_612364 SCRN2 secernin 2 1 1 not classified proteolysis cytoskeletal protein binding
2 29568086 NP_002988 SDC1 syndecan 1 precursor 1 2
integral to plasma 
membrane
membrane
not classified cytoskeletal protein binding












protein targeting to membrane






















protein targeting to membrane




















2 34335134 NP_899195 SEC13L1 SEC13 protein 1 1 not classified intracellular protein transport not classified









2 16306550 NP_003935 SELENBP1 selenium binding protein 1 5 7 not classified not classified selenium binding
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2 71834872 NP_849196 SERINC2 tumor differentially expressed 2-like 1 1
membrane
phosphatidylserine metabolism
positive regulation of 
transferase activity
not classified
2 30172548 NP_840060 SERINC5 developmentally regulated protein TPO1 1 1 membrane
phosphatidylserine metabolism
positive regulation of 
transferase activity protein binding
2 50363219 NP_001002236SERPINA1
serine (or cysteine) proteinase inhibitor, 
clade A 
(alpha-1 antiproteinase, antitrypsin), 
member 1 4 15
extracellular region
extracellular space
acute-phase response protein binding
serine-type endopeptidase inhibitor activity
1,2 50659080 NP_001076 SERPINA3
serpin peptidase inhibitor, clade A, 









2 21361302 NP_006206 SERPINA4
serine (or cysteine) proteinase inhibitor, 
clade A 
(alpha-1 antiproteinase, antitrypsin), 
member 4 2 3
not classified not classified protein binding
serine-type endopeptidase inhibitor activity
1,2 21361195 NP_000615 SERPINA5
serine (or cysteine) proteinase inhibitor, 
clade A 
(alpha-1 antiproteinase, antitrypsin), 









serine-type endopeptidase inhibitor activity
2 4507377 NP_000345 SERPINA7 serine (or cysteine) proteinase inhibitor, clad1 1
extracellular region
extracellular space not classified
binding
serine-type endopeptidase inhibitor activity
2 13489087 NP_109591 SERPINB1 serine (or cysteine) proteinase inhibitor, clad7 9 cytoplasm not classified
serine-type endopeptidase 
inhibitor activity
2 8393956 NP_036529 SERPINB13 serine (or cysteine) proteinase inhibitor, clad1 3 not classified
regulation of proteolysis
response to UV serine-type endopeptidase inhibitor activity
2 5902072 NP_008850 SERPINB3 serine (or cysteine) proteinase inhibitor, clad3 7 not classified not classified
serine-type endopeptidase 
inhibitor activity





2 41152086 NP_004559 SERPINB6 serine (or cysteine) proteinase inhibitor, clad2 6
cytosol not classified
protein binding
serine-type endopeptidase inhibitor activity
2 39725934 NP_002606 SERPINF1
serine (or cysteine) proteinase inhibitor, 
clade F 
(alpha-2 antiplasmin, pigment epithelium 




negative regulation of 
angiogenesis












inhibitor activity Hereditary Angioedema Type I 
[MIM:106100]
Yes 2 5453886 NP_006208 SERPINI2 serpin peptidase inhibitor, clade I (pancpin), 1 2 not classified cell motility
serine-type endopeptidase 
inhibitor activity




negative regulation of protein 
kinase activity





2 40786408 NP_955376 SFT2D2 SFT2 domain containing 2 1 1
integral to membrane
membrane protein transport SH3/SH2 adaptor activity
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2 4506925 NP_003013 SH3BGRL SH3 domain binding glutamic acid-rich prote1 3 nucleus not classified glycine hydroxymethyltransferase activity
2 13775198 NP_112576 SH3BGRL3 SH3 domain binding glutamic acid-rich prote1 2 nucleus not classified not classified
2 7657562 NP_055336 SH3BP4 SH3-domain binding protein 4 1 1 nucleus
cell cycle
endocytosis signal transducer activity
Yes 2 32261324 NP_003020 SHC1
SHC (Src homology 2 domain containing) 
transforming protein 1 isoform p52Shc 1 1
plasma membrane
activation of MAPK activity
intracellular signaling cascade
positive regulation of cell 
proliferation
positive regulation of mitosis
regulation of cell growth
regulation of epidermal growth 
factor receptor activity
insulin receptor binding
insulin-like growth factor receptor binding
phospholipid binding
protein binding
transmembrane receptor protein tyrosine 
kinase adaptor protein activity
















2 4502175 NP_001640 SHROOM2 apical protein of Xenopus-like 1 1
not classified not classified
amiloride-sensitive sodium channel activity
protein binding















2 91105767 NP_001035112SIRPA signal-regulatory protein alpha precursor 1 1
integral to membrane
plasma membrane cell adhesion sodium ion binding














Bartter Syndrome, Antenatal, Type 1 
[MIM:601678]
1,2 4506977 NP_000330 SLC12A3 solute carrier family 12 (sodium/chloride transpo28 102









transporter activity Gitelman Syndrome [MIM:263800]





2 4506979 NP_003975 SLC13A2
solute carrier family 13 (sodium-dependent 
dicarboxylate transporter), 
member 2 5 10



























2 31543624 NP_066568 SLC15A2 solute carrier family 15 (H+/peptide transpor 1 1










organic cation transporter activity
1,2 66773030 NP_004161 SLC1A1 solute carrier family 1, member 1 3 6











2 8923870 NP_060954 SLC22A11 solute carrier family 22 member 11 2 9




sodium-independent organic anion 
transporter activity
transporter activity











urate transporter activity Renal Hypouricemia [MIM:220150]
2 4758852 NP_004247 SLC22A13 organic cation transporter like 3 1 1






2 4507001 NP_003049 SLC22A2 solute carrier family 22 member 2 isoform a 2 3
integral to membrane






























2 20070188 NP_004781 SLC22A6 solute carrier family 22 member 6 isoform a 1 3
integral to membrane











organic anion transporter activity
sodium ion binding
symporter activity
2 24497480 NP_695010 SLC22A6 solute carrier family 22 member 6 isoform d 1 1
integral to membrane














2 24497499 NP_004245 SLC22A8 solute carrier family 22 member 8 1 2
integral to membrane













2 44680143 NP_689898 SLC23A1 solute carrier family 23 (nucleobase transpo 6 10
















2 44680145 NP_005838 SLC23A1 solute carrier family 23 (nucleobase transpo 4 6

























2 47132595 NP_998776 SLC25A3 solute carrier family 25 member 3 isoform b prec1 5










symporter activity Mitochondrial Phosphate Carrier 
Deficiency [MIM:610773]
Yes 2 55749577 NP_001142 SLC25A4
solute carrier family 25 (mitochondrial 
carrier; 
adenine nucleotide translocator), member 
4 1 1
integral to membrane















Yes 2 156071459 NP_001143 SLC25A5 solute carrier family 25, member 5 2 1


























2 85540447 NP_775897 SLC26A11 solute carrier family 26, member 11 1 1 integral to membrane transport transporter activity
2 4505697 NP_000432 SLC26A4 pendrin 2 4
integral to membrane
membrane









Deafness, Autosomal Recessive 4 
[MIM:600791]


























2 32401453 NP_861441 SLC36A2 solute carrier family 36 (proton/amino acid s 7 15 not classified not classified not classified










2 4507019 NP_000332 SLC3A1 solute carrier family 3, member 1 14 25













solute carrier family 3 (activators of dibasic 
and neutral amino acid transport), 


























2 18034692 NP_536856 SLC44A1 CDW92 antigen 1 1
integral to membrane
membrane transport transporter activity
1,2 31377727 NP_065161 SLC44A2 CTL2 protein 18 70
integral to membrane
membrane




1,2 13376868 NP_079533 SLC44A4 NG22 protein isoform 1 6 59
integral to membrane
membrane
not classified not classified Sialidosis 1 [MIM:606107]
2 4507021 NP_000333 SLC4A1 solute carrier family 4, anion exchanger, member2 2
cortical cytoskeleton





inorganic anion exchanger activity
protein binding
Defective kidney acid secretion 
leading 
to distal renal tubular acidosis 
[MIM:179800]





inorganic anion exchanger activity
sodium ion binding
symporter activity
Renal Tubular Acidosis, Proximal, 
With Ocular Abnormalities 
[MIM:604278]
Yes 2 90568034 NP_004849 SLC4A8 solute carrier family 4, sodium bicarbonate c 1 1
integral to membrane
membrane anion transport inorganic anion exchanger activity
2 4507031 NP_000334 SLC5A1 solute carrier family 5 (sodium/glucose cotranspo2 3
















sodium ion transport transporter activity




sodium ion trasnport transporter activity

















transporter activity Renal Glucosuria [MIM:233100]




sodium ion transport transporter activity




sodium ion trasnport protein binding
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2 21361581 NP_057699 SLC6A13 solute carrier family 6 (neurotransmitter tran 1 1








2 51468073 NP_001003841 SLC6A19 solute carrier family 6, member 19 4 8




amino acid transporter activity
neurotransmitter:sodium symporter activity
symporter activity Hartnup Disorder [MIM:234500]










1,2 4759140 NP_004243 SLC9A3R1 solute carrier family 9 (sodium/hydrogen exc4 9
actin cytoskeleton
protein complex assembly
Wnt receptor signaling 
pathway
beta-2 adrenergic receptor binding
protein binding
sodium:hydrogen antiporter regulator activity




protein complex assembly ATP binding
2 38679890 NP_851322 SLCO4C1 solute carrier organic anion transporter fami 2 2
integral to membrane
membrane transport transporter activity






G-protein coupled receptor 
protein signaling pathway
glial cell migration






positive regulation of axonogen
calcium ion binding
follicle-stimulating hormone receptor activity
receptor binding
transferase activity










protein serine/threonine kinase activity
transferase activity






















G-protein coupled receptor 
protein signaling pathway
G-protein coupled receptor activity
non-G-protein coupled 7TM receptor activity
protein binding
receptor activity
1,2 57242798 NP_055289 SMPDL3B acid sphingomyelinase-like phosphodiestera1 2 not classified metabolism








negative regulation of BMP 
signaling pathway























1,2 4507113 NP_003078 SNCG synuclein, gamma (breast cancer-specific pr 9 20 cytoplasm not classified not classified
2 21361380 NP_009172 SNF8 EAP30 subunit of ELL complex 1 1
nucleus
protein transport























1,2 4507149 NP_000445 SOD1 superoxide dismutase 1, soluble 2 4
cytoplasm
nervous system development








2 4507155 NP_003095 SORD sorbitol dehydrogenase 3 11






2 4507157 NP_003096 SORL1 sortilin-related receptor containing LDLR cla 1 1












2 27436920 NP_003962 SPAG9 sperm associated antigen 9 isoform 1 2 2 not classified not classified not classified





2 14790190 NP_055816 SPEN spen homolog, transcriptional regulator 2 2
nucleus
Notch signaling pathway








2 6912682 NP_036577 SPON2 spondin 2, extracellular matrix protein 1 1






immune response actin binding










Dystonia, Dopa-Responsive, Due To 
Sepiapterin Reductase Deficiency 
[MIM:251120]


















Yes 2 83582817 NP_001019380SPRR2E small proline-rich protein 2E 1 4 not classified not classified not classified












barbed-end actin filament cappin
actin binding
calmodulin binding
structural constituent of cytoskeleton




barbed-end actin filament 
capping
calmodulin binding
structural constituent of cytoskeleton
calcium channel regulator activity








positive regulation of transcription 
from RNA polymerase II promoter
protein localization









Paget Disease of Bone [MIM:602080]
2 4885609 NP_005408 SRC proto-oncogene tyrosine-protein kinase SRC1 1
integral to membrane
membrane













1,2 4507207 NP_003121 SRI sorcin isoform a 4 10
cytoplasm
heart development
intracellular sequestering of 
iron ion
muscle development
regulation of action potential
regulation of heart contraction




calcium channel regulator activity
calcium ion binding
receptor binding
2 38679884 NP_944490 SRI sorcin isoform b 3 8 cytoplasm
heart development
intracellular sequestering of 
iron ion
muscle development
regulation of action potential 
regulation of heart contraction







2 19923193 NP_003923 ST13 heat shock 70kD protein binding protein 2 3 cytoplasm protein folding
protein binding, bridging
metal ion binding












2 4507271 NP_000446 STK11 serine/threonine protein kinase 11 1 1




protein serine/threonine kinase activity
transferase activity
2 73808092 NP_001027467STK24 serine/threonine kinase 24 (STE20 homolog 5 12
not classified






protein serine/threonine kinase activity
protein-tyrosine kinase activity
transferase activity
Yes 2 21361358 NP_006365 STK25 serine/threonine kinase 25 1 2
not classified
protein amino acid 
phosphorylation






protein serine/threonine kinase activity
transferase activity
1,2 38016911 NP_004090 STOM stomatin isoform a 13 76
cytoskeleton
integral to plasma 
membrane
membrane
not classified not classified
2 4759184 NP_004168 STX3 syntaxin 3A 2 5
integral to membranemem
intracellular protein transport
neurotransmitter transport protein transporter activity
2 73760415 NP_001027392STXBP1 syntaxin binding protein 1 isoform b 1 1 not classified
protein transport
vesicle docking during 
exocytosis
vesicle-mediated transport calcium ion binding
194
Supplementary Table I
2 5902128 NP_008880 STXBP2 syntaxin binding protein 2 10 22
not classified
intracellular protein transport





2 63999048 NP_848604 STXBP4 syntaxin binding protein 4 1 1 not classified not classified
protein binding
ATP binding






succinate-CoA ligase (ADP-forming) activity
G-protein coupled receptor activity, unknown 
ligand
Mitochondrial DNA Depletion 
Syndrome [MIM: 609560]
2 47271392 NP_149039 SUCNR1 succinate receptor 1 1 1
integral to membrane
membrane
G-protein coupled receptor 
protein signaling pathway
signal transduction





2 10092665 NP_062547 SUSD2 sushi domain containing 2 5 10 not classified not classified not classified
2 33239443 NP_874384 SYPL1 synaptophysin-like 1 isoform b 1 12







2 4505059 NP_002345 TACSTD1 tumor-associated calcium signal transducer 1 1
integral to membrane
plasma membrane not classified ATP binding
2 4507357 NP_003555 TAGLN2 transgelin 2 4 6
nuclear membrane
plasma membrane muscle development not classified
2 45439370 NP_065842 TAOK1 TAO kinase 1 1 1
not classified protein amino acid phosphorylati
ATP binding
nucleotide binding
protein serine/threonine kinase activity
transferase activity
Yes 2 19923464 NP_057365 TAOK3 TAO kinase 3 1 1
not classified
MAPKKK cascade
negative regulation of JNK 
cascade
positive regulation of JNK 
cascade




protein serine/threonine kinase activity
transferase activity







negative regulation of Wnt 
receptor signaling pathway
Rho protein signal transduction






2 13994322 NP_114143 TBC1D10A TBC1 domain family, member 10A 4 5 microvillus not classified
PDZ domain binding
protein binding
2 23503283 NP_699187 TBC1D21 TBC1 domain family, member 21 1 1 not classified not classified GTPase activator activity













2 4885627 NP_005413 TECTA tectorin alpha precursor 1 1





sensory perception of sound
extracellular matrix structural constituent
GPI anchor binding
Autosomal Dominant nonsyndromic 




2 13994250 NP_114104 TEKT3 tektin 3 1 1 microtubule
microtubule cytoskeleton 
organization and biogenesis glycosaminoglycan binding







metal ion binding Alzheimer Disease [MIM:104300]









2 39777599 NP_945189 TGM2 transglutaminase 2 isoform b 1 1
cytosol
extracellular matrix (sensu 
Metazoa)
membrane
G-protein coupled receptor 
protein signaling pathway
peptide cross-linking








2 4507479 NP_003232 TGM4 transglutaminase 4 (prostate) 5 6
not classified
peptide cross-linking




















2 55770864 NP_005773 THOC4 THO complex 4 1 1
nucleus
spliceosome complex
mRNA export from nucleus







1,2 19923362 NP_006279 THY1 Thy-1 cell surface antigen 3 20
cytosol
endoplasmic reticulum
external side of plasma 
membrane
growth cone










negative regulation of 
apoptosis
negative regulation of 
axonogenesis
negative regulation of cell 
migration




Rho GTPase activator activity
2 58331189 NP_001010927TIAM2 T-cell lymphoma invasion and metastasis 2 1 2
intracellular
intracellular signaling cascade
regulation of Rho protein signal 
transduction
protein binding
receptor signaling protein activity
Rho guanyl-nucleotide exchange factor 
activity
2 4507521 NP_001055 TKT transketolase 1 1





















1,2 7706575 NP_057635 TM7SF3 transmembrane 7 superfamily member 3 3 8
integral to membrane
membrane not classified not classified
1,2 50593008 NP_071435 TMBIM1 transmembrane BAX inhibitor motif containin1 7
integral to membrane
membrane not classified not classified
2 22748685 NP_689524 TMEM12 transmembrane protein 12 1 1 integral to membrane not classified not classified
2 70778895 NP_001020527TMEM16F transmembrane protein 16F 6 10
integral to membrane
membrane not classified not classified
2 7019555 NP_037522 TMEM2 transmembrane protein 2 1 1 integral to membrane not classified not classified
2 15042969 NP_065716 TMEM27 transmembrane protein 27 2 3
integral to membrane
membrane not classified not classified
2 13129060 NP_076979 TMEM38A transmembrane protein 38A 1 1 integral to membrane not classified serine-type endopeptidase inhibitor activity
2 20070191 NP_004863 TMEM59 thymic dendritic cell-derived factor 1 1 1 integral to membrane not classified peptidase activity
2 7662308 NP_055513 TMEM63A transmembrane protein 63A 2 3
integral to membrane
membrane not classified nucleotide binding
2 4758508 NP_004253 TMPRSS11D transmembrane protease, serine 11D 1 1
extracellular region







1,2 14602459 NP_005647 TMPRSS2 transmembrane protease, serine 2 2 2































2 75677323 NP_653279 TOM1L2 target of myb1-like 2 isoform 2 1 1 intracellular
intracellular 
protein transport not classified
2 75677327 NP_001028723TOM1L2 target of myb1-like 2 isoform 1 1 3 intracellular intracellular protein transport protein binding
















tripeptidyl-peptidase  I activity
Ceroid Lipofuscinosis Neuronal 2 
[MIM:204500]
2 6005914 NP_009111 TREH trehalase 4 7








hydrolase activity, acting on glycosyl bonds
2 11342676 NP_004231 TRIP10 thyroid hormone receptor interactor 10 1 1 cytoplasm
actin cytoskeleton organization 
and biogenesis
signal transduction alpha-actinin binding
Yes 2 17505200 NP_062815 TRPV5 transient receptor potential cation channel, s1 1













Yes 2 21314682 NP_061116 TRPV6 transient receptor potential cation channel, s1 3












1,2 5454140 NP_006283 TSG101 tumor susceptibility gene 101 17 66
membrane
protein transport





ubiquitin-protein ligase activity Breast Cancer [MIM:176960]











cell proliferation not classified




positive regulation of I-kappaB 
kinase/NF-kappaB cascade
signal transducer activity











2 4507709 NP_003304 TSTA3 tissue specific transplantation antigen P35B 1 1
cytoplasm













2 40255087 NP_660153 TTC18 tetratricopeptide repeat domain 18 1 1 not classified not classified binding












protein amino acid 
autophosphorylation
protein amino acid 
phosphorylation








protein serine/threonine kinase activity
protein-tyrosine kinase activity
structural constituent of cell wall
transferase Cardiomyopathy [MIM:188840]












protein amino acid 
autophosphorylation
protein amino acid 
phosphorylation







protein serine/threoninen kinase activity
protein-tyrosine kinase activity
structural constituent of cell wall
transferase activity
GTP binding
1,2 51100978 NP_079526 TTYH3 tweety 3 1 7 not classified not classified not classified


































































MHC class I protein binding
nucleotide binding
structural molecule activity










structural constituent of cytoskeleton











































structural constituent of cytoskeleton
structural molecule activity











































protein disulfide oxidoreductase activity
thiol-disulfide exchange intermediate activity




protein disulfide oxidoreductase activity
2 14249348 NP_116120 TXNL5 thioredoxin-like 5 2 2 not classified not classified
electron carrier activity
protein disulfide oxidoreductase activity
2 59850762 NP_060473 UACA uveal autoantigen with coiled-coil domains a 1 1
cytoskeleton
extracelluar region
nucleus viral life cycle ATP binding







ubiquitin activating enzyme activity
ligase activity








long-term strengthening of 
neuromuscular junction




regulation of synaptic plasticity
protein binding
structural constituent of ribosome
transcription regulator activity
2 55770884 NP_057256 UBADC1 ubiquitin associated domain containing 1 1 1 not classified not classified not classified
Yes 1,2 67191208 NP_066289 UBC ubiquitin C 7 198 not classified protein modification not classified
2 23510338 NP_003325 UBE1 ubiquitin-activating enzyme E1 2 4







ubiquitin activating enzyme activity




2 13489085 NP_003333 UBE2G1 ubiquitin-conjugating enzyme E2G 1 1 1 not classified ubiquitin cycle
ubiquitin-protein ligase activity
not classified




activation of NF-kappaB 
transcription factor
positive regulation of DNA 
repair















activation of NF-kappaB 
transcription factor
cell differentiation
positive regulation of I-kappaB 
kinase/NF-kappaB cascade
protein polyubiquitination
regulation of DNA repair
regulation of progression 
through cell cycle




ubiquitin conjugating enzyme activity
ubiquitin-protein ligase activity





activation of NF-kappaB 
transcription factor
cell differentiation
positive regulation of I-kappaB 
kinase/NF-kappaB cascade
protein polyubiquitination
regulation of DNA repair
regulation of progression 
through cell cycle





ubiquitin conjugating enzyme activity
ubiquitin-protein ligase activity
2 6005928 NP_009037 UBL3 ubiquitin-like 3 2 8
intracellular
membrane protein modification L-lactate dehydrogenase activity
Yes 2 109659841 NP_689490 UBTD2 dendritic cell-derived ubiquitin-like protein 1 1 not classified protein modification not classified
2 13376854 NP_079517 UBXD1 UBX domain containing 1 1 1 not classified not classified not classified










2 103472011 NP_001035787UEVLD ubiquitin-conjugating enzyme E2-like isoform4 10 not classified
glycolysis
protein transport






2 156416000 NP_057490 UFC1 ubiquitin-fold modifier conjugating enzyme 1 1 1 not classified ubiquitin cycle kinase activity













UTP: glucose-1-phosphate uridylyltransfease 
activity
ATP binding
1,2 39930361 NP_056333 ULK3 unc-51-like kinase 3 4 12
not classified protein amino acid phosphorylati
ATP binding
nucleotide binding














Medullary cystic kidney disease-2 
(MCKD2) [MIM:603860] 
Familial juvenile hyperuricemic 
nephropathy (FJHN) [MIM:16200]
2 7706509 NP_057411 UPB1 beta-ureidopropionase 1 1 not classified
nitrogen compound 
metabolism
hydrolase activity, acting on carbon-nitrogen 
(but not peptide) bonds
metal ion binding 
zinc ion binding
protein binding















physiological process structural molecule activity
1,2 5803215 NP_006751 UPK2 uroplakin 2 4 27
endoplasmic reticulum
integral to endoplasmic 
reticulum membrane





membrane organization and 
biogenesis
not classified








Yes 2 32698815 NP_872294 USP12 ubiquitin-specific protease 12-like 1 1 1 not classified ubiquitin-dependent protein cata
cysteine-type endopeptidase activity
ubiquitin thiolesterase activity
Yes 2 148727247 NP_003472 USP5 ubiquitin specific peptidase 5 isoform 2 1 1
lysosome
proteasome complex 




ubiquitin-specific protease 5 activity
zinc ion binding
















vesicle-mediated transport not classified





vesicle docking during exocytosis
vesicle-mediated transport actin binding
Beta-Ureidopropionase Deficiency 
[MIM: 606673]











2 39930521 NP_612449 VASN slit-like 2 1 2
integral to membrane
membrane not classified transferase activity
2 4507869 NP_003361 VASP vasodilator-stimulated phosphoprotein 1 1 actin cytoskeleton cell motility actin binding














































Cardiomyopathy, Dilated [MIM: 
611407]






















Inclusion Body Myopathy with Early 
Onset 
Paget Disease and Frontotemporal 
Dementia 
[MIM:167320]









apoptogenic cytochrome c release channel 
activity
voltage-gated anion channel porin activity
voltage-gated ion-selective channel activity






outer membrane anion transport
voltage-gated anion channel porin activity
voltage-gated ion-selective channel activity
2 25188179 NP_005653 VDAC3 voltage-dependent anion channel 3 1 1









voltage-gated anion channel porin activity
voltage-gated ion-selective channel activity
2 6005944 NP_009058 VIL1 villin 1 2 3
cytoskeleton
F-actin capping protein 
complex
actin filament bundle formation
actin filament severing
barbed-end actin filament 
capping












actin filament bundle formation
cytoskeletal anchoring







2 32698964 NP_872372 VMO1 secretory protein LOC284013 4 7 not classified not classified not classified
2 66348091 NP_060550 VPS13C vacuolar protein sorting 13C protein isoform 1 1 not classified protein localization not classified
2 54607139 NP_056193 VPS13D vacuolar protein sorting 13D isoform 1 1 1 not classified protein localization not classified
2 7706353 NP_057163 VPS24 vacuolar protein sorting 24 isoform 1 1 3 membrane protein transport not classified
2 54144646 NP_001005753VPS24 vacuolar protein sorting 24 isoform 2 1 4 membrane protein transport protein binding
2 14150155 NP_115729 VPS25 vacuolar protein sorting 25 6 20
nucleus
protein transport




1,2 7705885 NP_057292 VPS28 vacuolar protein sorting 28 isoform 1 7 13 cytosolendosome protein transport protein binding
2 34452693 NP_898880 VPS28 vacuolar protein sorting 28 isoform 2 2 8
cytosol
endosome protein transport protease binding





retrograde transport, endosome 
to Golgi
protein binding
2 71051598 NP_057159 VPS36 vacuolar protein sorting 36 5 8
nucleus
protein transport




2 13375926 NP_078943 VPS37B vacuolar protein sorting 37B 5 11 not classified not classified not classified
2 57863314 NP_060436 VPS37C vacuolar protein sorting 37C 1 1 not classified not classified not classified
2 51466316 NP_001071089VPS37D vacuolar protein sorting 37D 5 19 not classified not classified not classified

















peroxisome organization and 
biogenesis













2 89191868 NP_000543 VWF von Willebrand factor preproprotein 1 4








Von Willebrand Disease [MIM: 
193400]
2 51702526 NP_003932 WASL Wiskott-Aldrich syndrome gene-like protein 1 1
actin cytoskeleton
nucleus








small GTPase regulator activity
2 9257257 NP_059830 WDR1 WD repeat-containing protein 1 isoform 1 10 18 cytoskeleton sensory perception of sound
actin binding
protein binding
2 53729352 NP_005103 WDR1 WD repeat-containing protein 1 isoform 2 4 9 cytoskeleton sensory perception of sound
protein binding
metal ion binding






Yes 2 12711660 NP_061852 WNK1 WNK lysine deficient protein kinase 1 11 67
cytoplasm
ion transport
protein amino acid 
phosphorylation
protein kinase cascade




protein kinase inhibitor activity




Yes 2 50845416 NP_001002838WNK3 WNK lysine deficient protein kinase 3 isoform8 17
not classified






protein serine/threonine kinase activity
transferase activity
Yes 2 50845418 NP_065973 WNK3 WNK lysine deficient protein kinase 3 isoform5 12 not classified






protein serine/threonine kinase activity
transferasae activity
Yes 2 34365793 NP_115763 WNK4 WNK lysine deficient protein kinase 4 4 11 tight junction
ion transport
protein amino acid 
phosphorylation
protein kinase cascade
regulation of cellular process
ATP binding
nucleotide binding
protein serine/threonine kinase activity
transferase activity
2 14249180 NP_116031 WNT5B wingless-type MMTV integration site family, 2 2 extracellular region
development
frizzled-2 signaling pathway signal transducer activity







Yes 2 4885661 NP_005424 YES1 viral oncogene yes-1 homolog 1 6 13
not classified
intracellular signaling cascade







Yes 2 21328448 NP_647539 YWHAB
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase 
activation protein, beta polypeptide 7 22
cytoplasm
perinuclear region not classified
monooxygenase activity
protein domain specific binding
1,2 5803225 NP_006752 YWHAE
tyrosine 3/tryptophan 5 -monooxygenase 
activation protein, epsilon polypeptide 4 13
not classified not classified
enzyme binding
protein domain specific binding
1,2 21464101 NP_036611 YWHAG
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase 
activation protein, gamma polypeptide 2 4
cytoplasm
cytoskeleton organization and 
biogenesis
negative regulation of 
apoptosis
negative regulation of protein 
kinase activity
regulation of mitosis
regulation of neuron 
differentiation
regulation of signal 
transduction
regulation of synaptic plasticity
actin binding
insulin-like growth factor receptor binding
protein domain specific binding
protein homodimerization activity
protein kinase C binding
protein kinase C inhibitor activity
205
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2 4507951 NP_003396 YWHAH tyrosine 3/tryptophan 5 -monooxygenase ac 1 1
cytoplasm






negative regulation of 
apoptosis
negative regulation of dendrite 
morphogenesis




insulin-like growth factor receptor binding
protein domain specific binding
protein kinase C inhibitor activity
transcriptional activator activity
1,2 5803227 NP_006817 YWHAQ
tyrosine 3/tryptophan 5 -monooxygenase 
activation protein, 
theta polypeptide 1 2
not classified
exocytosis
regulation of progression 
through cell cycle
protein domain specific binding
protein kinase C inhibitor activity
1,2 4507953 NP_003397 YWHAZ
tyrosine 3/tryptophan 5 -monooxygenase 
activation protein, 
zeta polypeptide 8 28
not classified not classified
protein domain specific binding
transcription factor binding
Yes 2 21735625 NP_663723 YWHAZ tyrosine 3/tryptophan 5 -monooxygenase ac 7 29 not classified not classified
protein domain specific binding
transcription factor binding
2 57863248 NP_001009881ZCCHC11 zinc finger, CCHC domain containing 11 isof1 5























Madibuloacral Dysplasia [MIM: 
608612]
2 23957700 NP_705836 ZNF114 zinc finger protein 114 1 1
intracellular
nucleus





2 150170665 NP_443084 ZNF486 zinc finger protein 486 1 1
intracellular
nucleus
regulation of transcription, DNA-
dependent
transcription
metal ion binding
zinc ion binding
206
